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Abstract 
RUNX1, also known as CBFα, is a master regulator of haematopoiesis.  In 
Acute Myeloid Leukaemia (AML) it is frequently disrupted by translocations to 
different epigenetic regulators, resulting in the expression of core-binding factor 
fusion proteins. 
We compared the chromatin landscape of t(8;21) and t(3;21) AML which 
express RUNX1-ETO and RUNX1-EVI1, respectively. We found that the 
diverse clinical outcomes of patients with these two forms of AML are reflected 
in fundamental differences in gene expression and chromatin landscape.  
Despite both fusion proteins sharing a RUNT DNA binding domain, we show 
that RUNX1-EVI-1 targets a more immature stem cell-related gene expression 
program of genes as compared to RUNX1-ETO. 
Despite the differences in the epigenomic landscape of t(3;21) and t(8;21) 
leukaemia, knockdown of either core-binding factor fusion protein activates a 
common myeloid differentiation program involving up regulation of C/EBPα.   By 
blocking C/EBPα DNA binding through a dominant negative partner, we showed 
that this factor is required for the downstream effects of RUNX1-EVI-1 
knockdown.  
Even in the continued presence of RUNX1-EVI-1, ectopic expression of C/EBPα 
is sufficient to initiate myeloid differentiation in t(3;21) cells.  Overall, this 
suggests that deregulation of C/EBPα is a common pathway in the development 
of both t(8;21) and t(3;21) AML. 
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Chapter 1. Introduction 
1.1 Haematopoiesis  
Haematopoiesis is the process by which cells of the blood system develop.  
Haematopoietic stem cells (HSCs) are largely quiescent, dividing infrequently, 
but have self-renewal mechanisms that allow them to persist over the lifetime of 
an organism to replenish more rapidly dividing pools of downstream progenitors 
(Wilson et al., 2008, Sun et al., 2014, Busch et al., 2015).  This process is 
carefully regulated by homeostatic mechanisms to allow the organism to 
respond to stresses such as infection and bleeding but rarely result in 
uncontrolled proliferation (Essers et al., 2009, Baldridge et al., 2010).  HSCs are 
also multi-potent which allows differentiation into all the lineages of the 
haematopoietic system (Spangrude et al., 1988).  This section will detail how 
the haematopoietic system emerges and is subsequently regulated. 
1.1.1 The emergence of haematopoietic stem cells 
HSCs emerge from the haemogenic endothelium that lines the surface of the 
major arteries, principally, in the aorto-gonadal mesonephros (AGM), before 
maturing in the fetal liver and finally, implanting in the bone marrow.  These 
definitive HSCs are capable of maintaining an adult haematopoietic system. In 
contrast, prior to this time, cells from the yolk sac provide early haematopoietic 
precursors to sustain the developing embryo, but are unable to survive in the 
adult haematopoietic system (Cumano et al., 1996, Cumano et al., 2001).  The 
AGM was shown to be the site where definitive HSCs emerge by transplanting 
tissue from this region into lethally irradiated mice where long-term 
haematopoiesis was successfully reconstituted (Medvinsky and Dzierzak, 1996, 
Medvinsky et al., 1993, Muller et al., 1994).  Later, the sites of HSC emergence 
in situ were identified through gene-labelling experiments (Zovein et al., 2008) 
and visualised through confocal imaging of dissected murine embryos (Boisset 
et al., 2010).  After this emergence at day 10.5 in mice, HSCs migrate through 
the circulatory system to develop further in the foetal liver, to finally reside in the 
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bone marrow (Gekas et al., 2005, Christensen et al., 2004, Morrison et al., 
1995). 
1.1.2 Hierarchical relationship of blood cell development 
HSC differentiate into intermediate progenitors which display increasingly 
restricted lineage potential (figure1-1).  This developmental process has been 
delineated through the use of labelling cell surface markers by antibody 
staining. Bone marrow subpopulations were isolated by magnetic beads or 
fluorescent activated cell sorting (FACS), and their function subsequently 
identified by transplantation into lethally irradiated mice. Initial work identified a 
population of HSCs (Spangrude et al., 1988, Muller-Sieburg et al., 1986) 
capable of differentiating into all lineages.  Common lymphocyte progenitors 
(CLP) which only produce lymphocytes (Kondo et al., 1997) and the existence 
of common myeloid progenitors (CMP) capable of producing granulocyte-
monocyte progenitors (GMP) and megakaryocyte-erythrocyte progenitors 
(MEP) were later identified (Akashi et al., 2000). 
The precise fate of CMPs and the origins of GMPs have been challenged.  For 
example, some groups have shown that MEPs come direct from short-term 
HSCs, and not from CMPs, suggesting the existence of a separate lymphoid 
primed multi-potential progenitor (LMPP).  LMPPs, expressing FLT3, were 
shown to be precursors to both the lymphoid (CLP) and myeloid (GMP) 
populations (Adolfsson et al., 2005).  This version of the haematopoietic 
hierarchy was subsequently debated by further studies (Pronk et al., 2007, 
Arinobu et al., 2007) using other cell surface markers.  The development of 
indexed FACS coupled with single-cell RNA-seq technology will likely result in 
improved understanding of the functional heterogeneity that resides in the early 
progenitor compartments (Paul et al., 2015).  In the following parts of this 
section we will discuss the ways in which these developmental trajectories can 
be regulated. 
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Figure 1-1 The haematopoietic hierarchy.  
The development of haematopoietic cells from HSC to terminally differentiated 
effector cells.  Dashed lines represent alternative differentiation pathway in the 
model proposed by Adolffsson et al., 2005, based on the presence of LMPPs. 
 
1.1.3 Regulation of differentiation in haematopoietic cells 
Regulation of haematopoiesis by signalling from microenvironment 
A paradigm suggests that cytokines have a “permissive” role in haematopoiesis.  
In this paradigm, cytokine signalling only drives cell proliferation and survival, 
implying that differentiation to different cell fates is determined intrinsically by 
the expression of lineage specific transcription factors.  A classical experiment 
in support of this view was conducted by Lagasse and Weissman in 1997.  Mice 
were engineered that lacked the cytokine M-CSF and had low numbers of 
monocytes.  Monocyte and neutrophil counts could be restored by permitting 
their survival through the transgenic expression of human BCL2, through the 
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endogenous mrp8 promoter, a gene which is expressed from early myeloid 
progenitors onwards (Lagasse and Weissman 1997).   
Another paradigm suggests that cytokines can be instructive in determining cell 
fate (Rieger et al., 2009).  For example, the receptors for GM-CSF and M-CSF 
are expressed at low levels on primitive HSC but are down regulated upon 
differentiation to CLP.  Human IL-2Rβ (hIL-2Rβ) can couple with mouse γc 
chain to form a receptor that exclusively responds to human IL-2 cytokine.  A 
transgenic mouse model which expresses hIL-2Rβ constitutively was 
developed.  Normal CLP do not express the IL-2 receptor.  Unlike normal CLP, 
CLP expressing hIL2Rβ trans-differentiate into granulocytes and monocytes 
when exposed to hIL-2, through upregulation of GM-CSF and M-CSF receptors 
(Kondo, Scherer et al. 2000).   
However, in contrast to knock out of transcription factors, knock out of 
components of signalling transduction pathway often results in an incompletely 
penetrant phenotype, arguing against the cytokine-instructive paradigm.  For 
example, although death and severe anaemia results in erythropoietin receptor 
deficient mice, early erythroid progenitors still exist in their bone marrow and 
erythropoiesis can be detected in the yolk sac (Kieran, Perkins et al. 1996). In 
part this may be due to the compensatory effects of thrombopoietin (TPO) 
through the receptor c-MPL, as in vitro, burst forming unit erythroid (BFU-E) 
colonies can be formed when liver and yolk sac extracted cells were cultured 
with recombinant TPO.   
Taken together, this suggests a pleotropic role for cytokine signalling in 
haematopoiesis with the ability for cytokines to deliver an instructive signal for 
differentiation in specific developmental contexts. 
Regulation of haematopoiesis by transcription factors 
The importance of transcription factors in the regulation of haematopoiesis was 
established early on, through the identification of transcription factors which are 
essential for the normal development of the haematopoietic hierarchy (Mercer 
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et al., 2011).  This later led to the identification of the mechanisms by which 
transcription factors may regulate each other, thereby acting as a switch 
between lineages.  Finally, this paradigm has been further refined. Instead of 
emphasising individual key transcription factors, recent work suggests that 
transcription factors act as part of a network, specific for different stages of 
differentiation (Gottgens, 2015). 
Transcription factors roles are dependent on the stage of haematopoiesis 
Transcription factors may have a specific role in differentiation into particular 
lineages but this role may subsequently differ at other stages of 
haematopoiesis.  For example, it was shown that mice which develop from a 
chimeric mix of Scl+/+, Scl+/- and Scl-/-  ES cells show a failure of Scl knockout 
cells to contribute to haematopoiesis as HSCs fail to develop in the absence of 
Scl  (Porcher et al., 1996).  However conditional knockout of Scl after embryonic 
development show that lymphopoiesis and myelopoiesis is possible but 
erythroid and megakaryocyte differentiation remain compromised (Mikkola et 
al., 2003). 
Despite the lineage defining roles of transcription factors they also play an 
important role at multiple stages of differentiation.  Cebpa is absolutely required 
for the development of eosinophils and neutrophils (Zhang et al., 1997a).  
However, the Cebpa knockout also uncovered a role of this factor in adult HSC 
function (Ye et al., 2013).  The inducible knockout of Cebpa in mice resulted in 
a pronounced increase in HSC numbers due to an increase in proliferation, with 
a transcriptional program that was more similar to foetal HSCs. 
Transcription factors repress alternate lineage fates to enable lineage 
commitment 
One route by which transcription factors may impart lineage specificity is 
through repression of alternative cell fates.  One example is that of Pax5.  In 
Pax5-/- mice pro-B cells fail to develop into mature B cells.  This capacity is 
rescued by retroviral expression of Pax5.  Pax5-/- pro B cells remain capable of 
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differentiating into granulocytes, neutrophils and other lineages when exposed 
to appropriate cytokines, because they aberrantly express genes from other 
non-lymphoid lineages (Nutt et al., 1999).  Therefore, it appears that PAX5 is 
required to repress myeloid specific genes whilst the subsequent expression of 
other transcription factors such as E2A and EBF can then drive expression of B 
cell specific genes in the B lineage committed cell. 
GMPs develop into either granulocytic neutrophils or monocytes/macrophages.  
This decision rests in part with Gfi-1.  This transcription factor is important for 
the development of terminally differentiated neutrophils:  rescue of GFI1 in 
atypical Gfi-1-/- progenitors result in differentiation of neutrophils, presumably 
through suppression of the alternative monocytic fate (Hock et al., 2003).  In 
contrast, Pu.1-/- haematopoietic progenitors could be rescued through retroviral 
expression of Pu.1, which results in macrophage but not neutrophil 
development (DeKoter and Singh, 2000).  Furthermore, Pu.1 haploinsufficiency 
results in preferential development of GMP into neutrophils at the expense of 
monocytic differentiation (Dahl et al., 2003).  Mechanistically, there appears to 
be a direct physical association between Gfi-1 and PU.1 that prevents PU.1 
mediated activation of target genes (Dahl et al., 2006), thereby affecting the 
balance between neutrophil versus monocyte development. 
Lineage re-programming properties of transcription factors 
One of the most potent lines of evidence that transcription factors are lineage 
instructive is their ability after ectopic expression to trans-differentiate cells and 
enable lineage switching.  For example, ectopic expression of GATA-1 in CLPs 
enforces their development into megakaryocytes and erythrocytes.  However, 
the effect of GATA-1 still depends on which cell type it is expressed in: when 
GATA-1 was transduced into pro-B cells and GMP, it appeared to induce 
apoptosis (Iwasaki et al., 2003). 
C/EBP transcription factors are capable of trans-differentiating lymphoid cells 
into myeloid cells (Xie et al., 2004, Laiosa et al., 2006, van Oevelen et al., 
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2015). Xie et al showed that primary B cell precursors are capable of 
conversion into macrophages after the retroviral expression of C/EBPα (Xie et 
al., 2004).  Although fully mature B cells could also undergo trans-
differentiation, the conversion rate was lower.  This conversion process lasted 
3-4 days, with an intermediate stage whereby both lymphoid and myeloid 
surface markers were expressed.  The efficiency of reprogramming was 
proportional to the level of transcription factor expression.  These mature 
macrophages were capable of phagocytosis, but retained evidence of 
immunoglobulin gene rearrangement. C/EBPβ was also capable of 
reprogramming but differed from C/EBPα in the longevity of re-programmed 
cells.  Although C/EBPα and PU.1 acted synergistically in the ability to 
reprogram lymphocytes, PU.1 alone was incapable of reprogramming 
lymphocytes, but is required for the upregulation of Mac-1 by C/EBPα. 
Typically, these trans-differentiation experiments involve the use of CLP as 
targets suggesting that this cell type has a particularly plastic epigenome: 
interestingly, the ability for transcription factors to switch myeloid progenitors to 
a lymphoid lineage has not been shown (Iwasaki and Akashi, 2007). 
Transcription factors act in complexes which include chromatin re-modellers 
Transcription factors form complexes with other transcription factors.  This 
allows greater potential controlling different stages of development, by 
increasing the range of regulatory elements that can be bound.  For example, 
Tal1 knockout mice have demonstrated an important role for SCL/TAL1 in HSC 
and megakaryocyte/erythrocyte development.  However, HSC development 
remains preserved even when SCL/TAL1 DNA binding capacity is lost, but 
SCL/TAL1 DNA binding capacity remains critical for megakaryocyte/erythrocyte 
development (Porcher et al., 1999).  This suggest that in HSC development the 
predominant role of SCL is in stabilising a transcription factor complex, without 
necessarily binding DNA, whilst in megakaryocyte/erythrocytes regulatory 
elements that are directly bound by SCL/TAL1 are essential (Tijssen et al., 
2011). 
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Transcription factors may also have synergistic effects with other co-operating 
partners in a complex.  ChIP-seq of ten transcription factors in the HPC-7 cell 
line revealed novel interactions and transcription factor complexes. One 
example was a previously uncharacterised interaction between RUNX1 and 
GATA2/SCL.  This was suggested by computational analyses showing 
clustering of ChIP-seq binding sites and their physical interaction was confirmed 
by co-immunoprecipitation of the transcription factors.  Furthermore, although 
single heterozygous Runx1 or Gata2 +/- mice were viable, compound 
heterozygous mice were not (Wilson et al., 2010).  The authors suggested that 
this may be due to the fact that both GATA2/SCL and RUNX1 have a role in 
regulating the proliferative capacity of HSCs: Runx1 knockout in adult mice 
reduced the number of long-term HSC and increased numbers of immature 
progenitors (Growney et al., 2005) whilst high Gata2 levels increase quiescence 
in HSCs (Tipping et al., 2009). 
Finally, transcription factor complexes include other co-activators, repressors 
and chromatin modifiers to directly affect transcriptional activity.  One example 
is the interaction between EKLF and BRG-1.  Gene targeting studies in mice 
revealed that EKLF is required for definitive haematopoiesis.  EKLF forms an 
interaction with BRG1 which is part of the SWI/SNF complex (Brown et al., 
2002).  SWI/SNF complexes have nucleosome remodelling function and have 
the capacity to increase chromatin accessibility to allow gene transcription.  
Brg1 mutants, which are unable to remodel chromatin result in the same 
phenotype as seen in EKLF knockout mice (Bultman et al., 2005). 
Identification of transcription factor networks which regulate haematopoiesis 
As described above, much of the early work in studying the importance of 
transcription factors in haematopoiesis has focused on the effects of the 
knockout of single genes.  In more recent years, there has been an emphasis 
on how these transcription factors interact with each other, as this ultimately is 
responsible for the cellular identity.  One way of understanding such a gene 
regulatory network is through the identification of cis-regulatory modules that 
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control the transcriptional activity of neighbouring genes.  These cis-regulatory 
modules comprise of promoters/enhancers/insulators, which are bound by 
different sets of transcription factors.  These sub circuits can then interact with 
each other through their output to build up a larger gene regulatory network 
(Pimanda and Gottgens, 2010).   A cis-regulatory module that has been 
identified in HSCs consists of Gata2-3, Fli1+12, and Scl+19 enhancers.  They 
are active in HSCs and are bound by these transcription factors themselves, 
forming an auto-regulatory sub circuit (Pimanda et al., 2007).  A key paper in 
this field (Novershtern et al., 2011) used gene expression analysis of 38 distinct 
cell populations of the adult haematopoietic hierarchy.  Using the principle that 
co-regulated genes form part of the same sub-circuit, the authors combined this 
gene expression data with motif analyses from cis-regulatory modules to 
identify novel transcriptional networks for different haematopoietic lineages. 
They validated this data through ChIP-seq of four transcription factors in HSC 
and by shRNA against predicted members of these transcription factor networks 
in in vitro erythroid and myeloid differentiation of primary CD34+ cells.   
Using this paradigm, ChIP-seq data from 16 transcription factors at different 
stages of an in vitro ES cell differentiation has been used to construct gene 
regulatory networks that define cellular identify at different stages of 
haematopoietic development (Goode et al., 2016) .  The association of different 
transcription factor networks with different stages of differentiation provides 
strong evidence of its importance in regulating this developmental pathway. 
1.2 Transcriptional regulation in eukaryotic cells 
1.2.1 RNA polymerase and core transcriptional machinery 
Central to the transcriptional process is the binding of RNA polymerase II 
(RNAPII) to the core promoter and subsequent initiation and production of the 
RNA transcript.  The initial assembly pre-initiation complex requires the 
recruitment of RNAPII with general transcription factors.  Promoter clearance 
takes place as the complex begins the process of RNA transcription and results 
in RNAPII phosphorylation.  RNA elongation requires separation from the 
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general transcription factor and recruitment of other proteins involved in RNA 
processing.  Elongation continues until the whole of the gene is transcribed.  
Finally, termination of the process releases the elongation complex to allow the 
components to bind the promoter again to repeat the process (Jonkers and Lis, 
2015). 
The process of transcription encounters many obstacles, including other 
components of the DNA replication and damage response pathways.  The 
RNAPII complex also has to traverse through nucleosome bound DNA 
(Bondarenko et al., 2006, Kireeva et al., 2005).  A number of models have been 
posited, to explain how this takes place.  It has been suggested that 
nucleosomes encountered by RNAPII may be displaced and retained by 
chaperones until the RNAPII complex has traversed through (Belotserkovskaya 
et al., 2003, Kireeva et al., 2002). Another model suggests that histone 
acetylases increase chromatin accessibility as RNAPII progresses (Guermah et 
al., 2006, Carey et al., 2006).  When the elongation process has completed, 
deacetylases return the histone to its former state (Selth et al., 2010) .  
1.2.2 Structure and modification of nucleosomes 
The nucleosome is the core subunit of chromatin and forms the basis of the 
chromatin fibre (figure 1-2).  The nucleosome itself is a DNA and histone 
complex.  It is comprised of a core formed from a pair of H3 and H4 histones 
contacting a 70bp coil of DNA. A pair of H2A and H2B is formed above and 
below this, each conjoined to a further 40bp of DNA, thus the basic histone 
octamer comprises of 147bp DNA (Luger et al., 1997).  After separation by 
further linker regions these nucleosomes are spaced 200bp apart.  Secondary 
structures of 30nM fibres are then formed.  There is evidence that 
subsequently, these secondary structures can be folded into much higher levels 
of compaction, with subsequent de-compaction upon gene activation in the 
region (Hu et al., 2009, Janicki et al., 2004). 
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Figure 1-2 Histones and DNA interact to form nucleosomes.   
A tetramer formed of two pairs of H3/H4 histones are paired with 70bp coil of 
DNA.  This is subsequently joined by two pairs of H2A/H2B histones each with 
40bp DNA to form the basic nucleosome octameric structure (Figure 
reproduced from publication (Cockerill, 2011))   
 
Post-translational histone modifications 
The resolution of the crystal structure of the nucleosome demonstrated that the 
N-terminal of histone tails protruded out of the core octamer subunit (Luger et 
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al., 1997) (figure 1-2).  The majority of post-translational histone modifications 
have been characterised on these tails, but they have also been found in the 
histone globular core.  Histone acetylation and methylation were the original 
modifications to be identified and were recognised to be post translational 
modifications with the capacity to influence RNA synthesis (Allfrey et al., 1964). 
The acetylation of histone lysines are accomplished by histone acetylases 
(HATs), and subsequently removed by histone deacetylases (HDACs).  These 
histone modifiers often have little specificity in themselves, and act in 
complexes with other enzymes and transcription factors.  Other than lysines, a 
number of other residues that can be modified have been characterised, 
including serine and arginine.  Furthermore, an increasing number of 
modifications have been discovered, including phosphorylation, ubiquitination 
and sumolyation (Bannister and Kouzarides, 2011). 
Function of histone modifications 
A number of hypotheses have been suggested as to the mechanism by which 
histone modifications can affect RNA transcription.  It has been postulated that 
the neutralisation of the positive charge in the histone N terminal weakens the 
interaction between the histone and the bound DNA, thereby making it easier to 
displace them (Bannister and Kouzarides, 2011).  Consistent with this 
hypothesis, is that histones are acetylated prior to displacement at active 
promoter regions (Reinke and Hörz, 2003). Histone modifications may also 
affect the higher order structure of chromatin.  One example is the acetylation of 
H4 at lysine 16 (H4K16).  The incorporation of a chemically ligated H4K16ac 
into a nucleosome array prevented the formation of the 30nM chromatin fibre 
and inhibited interaction between fibres (Shogren-Knaak et al., 2006). 
Histone modifications can also be read by other proteins, through which 
complexes with other functions can be recruited.  As such it has been 
suggested that combinations of histone modifications act as a “code” and can 
be “read” by other proteins to result in a range of downstream effects (Turner, 
2002, Turner, 2012, Strahl and Allis, 2000).  For example, acetylated lysines 
can be bound by bromodomains whilst methylated lysines can be bound by 
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chromodomains or PHD regions (Li et al., 2007).  Proteins with the same 
domain can recognise different residues despite the presence of the same 
modification.   For example, heterochromatin gene repression is dependent on 
HP1.  Although HP1 has a chromodomain, it specifically recognises tri-
methylated H3 lysine 9 but not tri-methylated H3 lysine 4 (Bannister et al., 
2001). 
Transcription factors and chromatin remodellers modify nucleosome 
structure 
“Pioneer factors” describe proteins that bind to DNA through compact chromatin 
(Zaret et al., 2016). Their binding precedes the subsequent binding of other 
larger protein complexes.  Therefore pioneer factors have to have the ability to 
decondense chromatin and thereby increase its accessibility (Zaret and Carroll, 
2011). One possible mechanism by which this may occur is illustrated by the 
FOXA transcription factors which possess DNA sequence specific binding 
domains but also has another domain that can contact neighbouring core 
histones and is necessary for the chromatin modifying capacity of the 
transcription factor (Cirillo et al., 2002).  It is suggested that this ability to bind 
both core histones and the neighbouring DNA disrupts the nucleosomal 
structure.   
Chromatin remodellers are a class of ATP dependent enzymes that can 
persistently displace nucleosomes (Owen-Hughes et al., 1996).  A number of 
mechanisms have been suggested to explain the disruption of nucleosomes 
from the DNA, but the key requirement is for the hydrolysis of ATP to provide 
the energy required for this reaction to occur.  These remodelling complexes do 
not work alone, and will interact with other DNA binding proteins such as 
transcription factor complexes and RNAPII.  They also require histone 
chaperones to bind evicted histones and prevent their subsequent re-assembly 
(Schwabish and Struhl, 2006).   
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1.2.3 DNaseI hypersensitive sites 
The observation that active genes have increased sensitivity to nucleases, such 
as DNaseI, was made by noting that β globin gene fragments could be isolated 
through the nuclease treatment of nuclei from erythrocytes but not from 
fibroblasts (Weintraub and Groudine, 1976). It was further observed that sites 
postulated to be involved in the regulation of the adjacent gene encoding heat 
shock protein in Drosophila was DNaseI sensitive (Wu, 1980).  DNaseI 
hypersensitivity sites (DHSs) can represent tissue specific enhancers, 
consistent with their importance in the specific control of gene expression 
(Cockerill et al., 1999).   Fox example, DHS mapping has been use to locate the 
regulatory elements that control globin gene loci.  By using a “mini-locus” that 
contain the human β-globin gene and the flanking DHSs, investigators have 
been able to stably reproduce, in transgenic mice, the expression of the gene at 
levels observed in humans (Grosveld et al., 1987).  DHS can also represent 
other elements that include promoters, insulators, and locus control regions 
(Cockerill, 2011) .   
DNaseI hypersensitive sites from DNase-seq and their association with 
other epigenetic features 
DHSs have been mapped genome wide through the use of tiling arrays and 
subsequently by massively paralleled sequencing technology (Boyle et al., 
2008).  By coupling DNaseI digestion to next generation sequencing (NGS) 
(e.g. Illumina platform) authors were able to produce base pair resolution 
mapping of DHSs in CD4+ T cells. They showed that vast majority of DHSs are 
distal to the promoters of genes.  From their data nearly all highly expressed 
genes have a DHS, but a presence of a DHS did not necessarily mean that the 
proximal gene is expressed.   
The analysis of DHSs with corresponding histone modifications from ChIP-seq 
confirms that the DHS peak correspond to a depletion of nucleosomes.  
However, histone modification enrichment was largely dependent on whether 
the nearest gene was transcribed.  For example, average profiles for tri-
methylated H3 lysine 4 showed that it was generally present at DHS but the 
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level of enrichment was dependent on the transcriptional activity of the gene 
nearest to the DHS.  In contrast, trimethyl H3 lysine 9 and H3 lysine 27, as 
expected from their role in gene repression, were absent from DHS profiles.  In 
comparison to predictions based on histone modifications alone, using 
ENCODE data, DHSs outperformed histone modification states in predicting 
enhancer activity (Kwasnieski et al., 2014), however not all DHSs are 
enhancers (Dogan et al., 2015).   
Across a number of cell lines increased CpG methylation is almost uniformly 
associated with a lack of DHS (Thurman et al., 2012). However, when looking at 
all CpG containing DHS, a simple linear regression showed that only 20% of 
these sites had a significant association between methylation and accessibility.   
Analysis of sequences from distal DHS in CD4+ T cells (Boyle et al., 2008) 
showed that motifs relevant to the cell type could be recognised.  Nearly all 
(94.4%) transcription factor binding sites catalogued through ChIP-seq, by the 
ENCODE project, reside in DHSs (Thurman et al., 2012).  The small percentage 
of transcription factors that do not, are associated with heterochromatin 
maintenance, such as SETDB1. 
DNaseI footprinting identified regions occupied by transcription factors 
DNaseI footprinting is based on the observation that DNA is protected from 
cleavage by nucleases by the presence of DNA-bound proteins that interact 
with the bases in the DNA such as transcription factors (Dynan and Tjian, 
1983).  This principle can be used to map transcription factor binding across the 
genome, although this may not be possible for highly dynamic transcription 
factor-DNA interactions (Vierstra and Stamatoyannopoulos, 2016, Sung et al., 
2016).  The use of this principle at a genome wide level critically depends on 
the density of nuclease cleavages at these DHSs.  For the purpose of genome 
wide DNaseI footprinting, in the ENCODE project, an average of 273 million 
reads per cell type were sequenced (Neph et al., 2012).  In this paper, they 
showed that the probability of detecting a footprint was proportional to the ChIP-
seq signal for that transcription factor.   They also showed that heterozygous 
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single nucleotide variants (SNVs) in binding motifs can result in the loss of a 
transcription factor footprint.  Differences in chromatin accessibility between 
alleles of DNA were dependent on the presence or absence of these SNVs.   
Unsurprisingly, they were also able to show that DNaseI footprinting between 
different cell types were able to identify different patterns of transcription factor 
footprints. 
DNA cleavage pattern around a footprinted protein and the adjacent 
nucleosome can be used to optimise footprinting analysis pathways.  A recent 
algorithm takes advantage of this to improve transcription factor footprinting 
predictions from high read depth DNase-seq data (Piper et al., 2013).  DNaseI 
cleavages within a footprinted location can be compared with the number of 
DNaseI cleavages within the surrounding DHS.  DNA bound transcription 
factors lying adjacent to nucleosomes offer protection to the DNA from the 
nucleases.   This results in longer DNA fragments than is otherwise found within 
the DHS (figure 1.3).  There is a reduced probability of identifying a fragment 
that aligns downstream from the transcription factor complex because the 
second cut will then have to occur outside the DHS in the nucleosome region.  
Information from each strand is assessed independently by making use of the 
sequencing from both the positive and negative strands (figure 1-3).  
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Figure 1-3 DNaseI Hypersensitivity site mapping and transcription factor 
footprinting.   
DNaseI preferentially cleaves DNA at nucleosome free regions.  Transcription 
factor binding sites are protected from DNAseI cleavage relative to the 
surrounding DHS.  Fragments upstream of transcription factor binding sites 
aligning to the + strand (red), whilst fragments downstream of these binding 
sites align to the - strand (green) (From Piper et al 2013). 
 
1.2.4 Regulation of transcription through DNA modifications 
The best characterised DNA modification is methylation at position 5 of cytosine 
(5mC) and this is accomplished by DNMT3a and DNMT3b (Okano et al., 1999).  
5mC is a highly conserved modification found in many animal, plant and fungi 
(Wu and Zhang, 2014).  This modification can be subsequently maintained by 
DNMT1 and its partner UHRF1.  DNMT1 recognises methylated CpG islands on 
one strand and subsequently methylate the cytosine on the newly replicated 
strand (Fatemi et al., 2001, Hermann et al., 2004, Bostick et al., 2007).  This 
ability to maintain 5mC allows the transmission of epigenetic information to 
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daughter cells and is crucial for normal development of many cell types.  
Correct maintenance of 5mC is also important for genomic stability: knockout of 
DNMT1 in cell lines result in mitotic catastrophe (Chen et al., 2007). 
5mC like other epigenetic marks can be reversed.  Two major routes of 
removing 5mC have been found, both of which converge on DNA damage 
pathways of repair.  The two routes of 5mC removal differ from whether there is 
involvement of the TET family of proteins.  The TET enzymes catalyse the 
progressive oxidation of 5mC into subsequent forms such as 5-
hydroxymethylcytosine, 5 formylcytosine and 5-carboxylcytosine.  These latter 
two species can be subsequently removed by base-excision repair.  α-
ketoglutarate is used as a co-factor in the oxidation of 5mC and is produced  
through the tricarboxylic acid cycle (TCA) by  the enzyme Isocitrate 
dehydrogenase (IDH) 1 and 2 (Wu and Zhang, 2014).    Both TET1/2 and 
IDH1/2 can be affected by mutations seen in acute myeloid leukaemia (AML). 
Like other epigenetic modifications, 5mC can be read by other enzymes and 
thus can interact with other epigenetic pathways (Zhu et al., 2016).  For 
example the enzyme MeCP2 is part of a family of proteins with a methyl-
cytosine binding domain.  MeCP2 acts as a transcriptional repressor and binds 
highly methylated promoters (Nan et al., 1997).  This transcriptional repression 
is in part due to the recruitment of histone deacetylates by MeCP2 to these 
methylated CpG (Nan et al., 1998). 
1.3 . Deregulation of transcriptional regulation in acute myeloid 
leukaemia 
AML is a disease defined by the presence of at least 20% myeloid blasts, which 
represent early myeloid progenitor cells which are blocked in their differentiation 
pathway, in the peripheral blood or bone marrow aspirate.  There is a worldwide 
incidence of approximately 3 cases per 100000 population per year (Swerdlow, 
2008). 
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AML is the most common acute leukaemia in adults and despite improvements 
in supportive care, outcomes for these patients remains poor.  Less than 60% of 
younger adults achieve longer term survival (Burnett et al., 2015) whilst those 
aged over 60, unfit for intensive chemotherapy one-year survival are less than 
30% (Dennis et al., 2015).  
1.3.1 Mutations found in acute myeloid leukaemia 
A striking feature of AML is the clinical heterogeneity that underlies this 
diagnosis.  This can be explained by the presence of different recurrent 
mutations that are associated with AML.  For example, a patient with an AML 
expressing the fusion gene CBFB–MYH11 as a result of inv(16) translocation 
has over 60% chance of overall survival, in comparison to patients with 
monosomy 5 cytogenetic abnormalities who have a less than 10% chance of 
overall survival (Grimwade et al., 2010).  This can be subsequently refined by 
new discoveries of driver mutations and re-classification by subgroups based on 
these findings (Papaemmanuil et al., 2016, Cancer Genome Atlas Research, 
2013).  Some of these findings are summarised in table 1-1.  Newly discovered 
patterns of cooperativity and exclusivity may provide new avenues of research 
underlying the mechanisms behind the mutations.  For example, the co-
occurrence between NPM1c and FLT3-ITD mutations has been recognised for 
a long time and has been reproduced in a mouse model (Mupo et al., 2013).  
DNMT3a mutations and FLT3-ITD have been also more recently characterised 
(Meyer et al., 2016, Yang et al., 2016).  However, the newly characterised 
group of patients with NPM1c-DNMT3a-FLT3-ITD mutations, which confers a 
particularly poor prognosis, (Papaemmanuil et al., 2016) has yet to be studied.  
An example of exclusivity, suggesting that mutations work in the same pathway 
is that of the TET and IDH mutations (Weissmann et al., 2012, Figueroa et al., 
2010a).  Here TET and IDH mutations are mutually exclusive.  IDH mutations 
result in an overproduction of 2-hydroxygluatarate, depleting 2-ketoglutarate 
which is normally required for the oxidative capacity of TET enzymes.  TET loss 
of function mutations thereby mimics gain of function mutations in IDH. 
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Table 1-1 Mutations in acute myeloid leukaemia 
Class of mutations Examples 
Transcription factor RUNX1; C/EBPα; CBFB-MYH11; RUNX1-RUNX1T1; 
WT1;  translocations involving MECOM e.g. inv(3) 
DNA methylation TET2; IDH1/2, DNMT3A  
Epigenetic modifiers MLL; ASXL1; EZH2 
Cohesin RAD21, SMC3, SMC1A, and STAG2 
Spliceosome SRSF2; U2AF1; SF3B1 
Signalling FLT3; KIT; NRAS; KRAS 
Others  Complex karyotypes; monosomy 5 and 7; NPM1 
 
Even in newly discovered classes of mutations, where there are other functions 
of the mutated protein, the pathological effect of the mutation is that of 
transcriptional dysregulation.  For example the spliceosome mutations affect 
mRNA splicing in the target cell, however, through overexpression and rescue 
experiments, the block in differentiation seen in these cells can be shown to be 
a result of the polycomb protein EZH2 downregulation (Kim et al., 2015).  Whilst 
mutations in cohesin complex, involved in many cellular processes including 
DNA damage response, principally results in changes in chromatin accessibility 
for transcription factors such as ERG and GATA2 (Mazumdar et al., 2015). 
Finally, the ability to describe prognostic gene expression and methylation 
profiles based on these classifiers confirm the view that these diseases are 
distinct biological entities driven by deregulated transcriptional profiles (Cancer 
Genome Atlas Research, 2013, Valk et al., 2004, Figueroa et al., 2010b). 
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Pre leukaemic clones and clonal heterogeneity in acute myeloid 
leukaemia 
Cancers have long been defined by the uncontrolled growth of a clonal 
population of cells.  However, recent use of NGS has increased sensitivity of 
mutation detection and through the use of variant allele frequency, has allowed 
detection of the prevalence of these mutations across the bulk population of 
cells that have been sequenced.  These studies suggest that a significant 
proportion of AML consist of 2 or more subclones (Cancer Genome Atlas 
Research, 2013).  One significance of this is the discovery that leukaemia 
relapse can occur through the accumulation of further mutations in a subclone 
(Ding et al., 2012). 
This model also suggests the possibility of the existence of pre-leukaemic 
clones, of which one eventually dominants haematopoiesis through the 
acquisition of further mutations.  One study showed that the accumulation of 
mutations in HSCs from otherwise healthy individuals are a function of age 
(Welch et al., 2012), which is in keeping with the predominance of AML in older 
adults.  Subsequently, a number of targeted sequencing projects in large 
cohorts have identified recurrent mutations in DNMT3A¸ ASXL1 and TET2 in 
otherwise healthy individuals (Jaiswal  et al., 2014, Genovese  et al., 2014).  
This is in keeping with the increased self-renewal of DNMT3A knockout murine 
HSC (Challen et al., 2012) which confers upon these HSCs a selective 
advantage.  This is also seen in engraftment of human pre-leukaemic DNMT3A 
mutant HSC, from patients in remission from AML, in xenotransplantation 
models, where they have a repopulating advantage over HSC without a 
mutation in DNMT3A (Shlush et al., 2014).  The presence of mutations in HSCs 
is not a new idea as this has been previously demonstrated for both BCR-ABL 
and RUNX1-RUNX1T1, with the detection of these transcripts in both myeloid 
and lymphoid cells in patients in remission from their disease (Miyamoto et al., 
2000, Passegue et al., 2003). 
Understanding the subclonal architecture has many implications.  One is the 
possibility that therapies affecting a clone with one mutation may result in the 
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outgrowth of a subclone with another mutation unaffected by this therapy (Wong 
et al., 2015) (Greaves and Maley, 2012).  A second is the concern that minimal 
residual disease monitoring of a secondary mutation, e.g. NPM1c, may miss a 
relapse from another mutation in a pre-leukaemic clone.  However, this has not 
been borne out in clinical studies (Ivey et al., 2016) which suggests that 
although pre-leukaemic clones are present, the path to the development of a full 
AML is stereotyped, due to cooperativity required between mutations.       
Leukaemic stem cells in acute myeloid leukaemia 
The concept of leukaemic stem cells (LSC) (or leukaemia initiating cell) in AML 
proposes that only a subpopulation of cells within the bulk leukaemic blast 
population has leukaemia initiating potential, which is defined as the capacity to 
initiate leukaemia in a xenotransplantation model. According to this model, to 
prevent relapse after remission induction therapy, it is vital to eradicate this 
population of cells.  A pioneering study showed that the frequency of these cells 
were approximately 1 in 1x106 CD34+CD38- AML cells, and was defined as 
leukaemia initiating through their ability to transplant a leukaemia into an 
immunodeficient (SCID) mice (Lapidot et al., 1994).  Subsequent further 
characterisation by the group demonstrated that a single LSC had the potential 
to generate millions of “differentiated” blasts of various immunophenotypes, and 
could serially repopulate irradiated mice confirming they had self-renewal 
capacity (Bonnet and Dick, 1997).  From this the authors proposed that that the 
normal CD34+CD38- HSCs are the target for transformation in AML. 
However, subsequent studies have sought to further refine characteristics of 
LSC to enable their separation from normal HSC, through identification of cell 
surface markers.  These have included CD47, TIM3 (Kikushige et al., 2011) and 
CD32/CD25 (Saito et al., 2010).  CD47 expression transiently expressed on 
normal HSC is constitutively expressed on LSC to prevent phagocytosis from 
circulating macrophages (Jaiswal et al., 2009).  Furthermore, studies also 
discovered that some LIC were not CD34+, but resided in a CD34- population, 
typically these are NPM1 mutant AML (Taussig et al., 2010, Quek et al., 2016).  
Taken together, this suggests that the immunophenotype of LSC may be 
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heterogeneous (perhaps a reflection of the underlying genetic heterogeneity) 
and is dependent on the target cell of transformation but may also reflect the 
inherent differences between models of immunodeficient mice used which may 
display differences in engraftment potential.  Given that the “gold-standard” for 
LSC remain that of engraftment in mice, the lack of a suitable mouse recipient 
has hindered research into LSCs in certain leukaemia such as t(15;17) or 
t(8;21). 
Although the evidence suggests that HSCs are cells in which mutations can 
occur, further studies are now more consistent with the model that the LSC 
arises from a more committed progenitor.  This include evidence from CML 
where the GMP population were expanded in patients in blast crisis and these 
cells have evidence of increased self-renewal properties (Jamieson et al., 2004) 
and in AML where the CD34+ LSC is more in keeping with LMPP expression 
profile (Goardon et al., 2011) and the CD34- LSC more in keeping with the 
GMP profile (Quek et al., 2016).  This suggests that committed progenitors may 
aberrantly acquire stem cell characteristics such as self-renewal as part of 
leukaemic transformation.  The proof-of-principle came from studies of MLL 
fusion leukaemias where investigators showed the ability to transform 
committed GMPs into LSC through overexpression of MLL-AF9 (Krivtsov et al., 
2006).  
To understand the mechanism behind the self-renewal properties of LSCs 
investigators have used gene expression profiling of HSCs and compared them 
to LSCs to identify an aberrant transcriptional profile (Eppert et al., 2011) and in 
keeping with another study (Gentles et al., 2010) were able to show that this 
LSC gene expression pattern can be seen in patients and had prognostic 
significance. This lends credence to the LSC hypothesis, suggesting that this 
model is not only an artefact of xenotransplantation.  However, the degree of 
overlap in genes identified by these studies was small and although in vivo 
testing for LSC were performed, the frequency of true leukaemia initiating cells 
in the population identified as “LSC” used for gene expression profiling was 
extremely low (Eppert et al., 2011).  
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1.3.2  Targeting transcriptional deregulation in acute myeloid 
leukaemia 
The standard treatment for AML has been a combination of anthracycline and 
cytarabine for many decades.  This course of treatment is intensive and 
restricted to patients fit enough to withstand the side effects.  Even, in this 
setting relapse or treatment refractory disease remains the most common cause 
for treatment failure.  Therefore, targeted therapy (table 1-2) holds promise in 
providing novel, more tolerable clinical options (Shafer and Grant, 2016).   The 
practical considerations of this strategy are many fold and include rapid turn-
around of mutational analyses in a clinical setting in order to identify patients 
who might benefit from these drugs.  Furthermore, even if proved successful the 
expense of funding novel agents, even in affluent healthcare systems, may 
prove prohibitive to many patients.    
Table 1-2 Examples of novel targeted epigenetic therapies in clinical trials 
(CR= complete remission, CRi= complete remission with incomplete count 
recovery) 
Name of agent Target Clinical 
responses 
Clinical trial 
identifier 
AG221 Mutant IDH2  11/32 CR or CRi Phase III 
(NCT02577406) 
OTX015 BRD2/3/4  2/33 CR or CRi-
ongoing study 
Phase I 
(NCT01713582) 
GSK2879552 LSD1 No results 
available 
Phase I 
(NCT02177812) 
EPZ-5676 DOT1L 1/28 CR-ongoing 
study 
Phase I 
(NCT01684150) 
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Targeting regulators of DNA methylation  
Azacitidine and decitabine are cytosine analogues that can be incorporated into 
DNA and can inhibit DNMT1 leading to widespread hypomethylation (Kelly et 
al., 2010, Klco et al., 2013, Yan et al., 2012).  It has been approved for the 
treatment of higher risk myelodysplastic syndrome through a Phase III clinical 
trial in this setting (Fenaux et al., 2009).  Although there is evidence of a 
conventional cytotoxic effect at higher doses, another mechanism may be re-
activation of endogenous retroviral elements through demethylation of 5mC, 
leading to stimulation of the host immune system (Roulois et al., 2015, 
Chiappinelli et al., 2015).   
As discussed above, IDH gain of function mutations are seen in AML. Oral 
inhibitors of mutant IDH have seen good tolerability and impressive responses.  
Furthermore investigators have been able to use the aberrantly produced 
metabolite α-HG as a biomarker of response (Stein et al., 2014). 
Targeting epigenetic readers and modifiers 
Bromodomains confer the ability to bind to acetylated histones to the BET family 
of proteins such as BRD2/3/4, thus acting as an adaptor for the recruitment of 
members of the transcriptional elongation machinery.  In AML cells with MLL 
translocation, knockdown of BRD4 by shRNA or inhibition by small molecules 
resulted in cell death (Zuber et al., 2011, Dawson et al., 2011).  The effects of 
BET inhibition include the reduction in transcription of genes such as MYC and 
BCL2. BET bromodomain inhibition may also function through inhibiting the 
recruitment of key transcription factors, to the regulation of important 
downstream genes (Roe et al., 2015). 
LSD1 also known as KDM1A is a histone lysine demethylase of both 
dimethylated histone 3 lysine 9 (thereby activating target genes) and also 
dimethylated histone 3 lysine 4 (thereby repressing target genes).  It appears to 
have a crucial role in maintaining the leukaemic stem cell phenotype of MLL 
leukaemia models (Harris et al., 2012).  An oral inhibitor of LSD1, GSK2879552, 
is currently undergoing trials in treatment of relapsed refractory AML. 
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The histone methyltransferase DOT1L is a binding partner of MLL fusion 
proteins and methylates histone 3 lysine 79, increasing gene expression of 
targets such as MEIS1 and the HOXA cluster.  Inhibition of DOT1L in a 
conditional knockout system resulted in differentiation of AML cells expressing 
MLL-AF9 (Bernt et al., 2011).  A DOT1L inhibitor, EPZ-5676, reproduced these 
findings in a pre-clinical model (Daigle et al., 2013) and preliminary results from 
a Phase I clinical trial shows some signs of clinical activity. 
Targeting transcription factor complexes 
A recent, example of targeting transcription factor interactions is the use of a 
small molecule inhibitor to bind disrupt the interaction between RUNX1 and the 
fusion protein CBFβ-SMMHC, a product of the chromosomal translocation 
inv(16).   AI-10-46 specifically affected AML cells that had the inv(16) 
abnormality.  By disrupting the association between CBFβ-SMMHC to RUNX1, 
normal RUNX1 binding to native CBFβ was restored.  This allowed RUNX1 to 
bind DNA normally, and activate its target genes (Illendula et al., 2015). 
1.4 Role of RUNX1 in normal haematopoiesis 
RUNX1 is a master regulator of haematopoiesis and is essential for both early 
development and emergence of haematopoietic stem cells as well as 
subsequent myeloid lineages and lymphopoeisis (Speck and Gilliland, 2002). 
RUNX1 is a member of the core-binding factor transcription factor family and 
forms a heterodimer with core-binding factor Beta (CBFβ), which is important for 
RUNX1 activity.  Tissue specific expression of Runx1, Runx2 and Runx3 in 
mice suggests a role in developmental regulation.  DNA interaction is mediated 
by the evolutionarily conserved Runt domain (Daga et al., 1992) which can bind 
to the consensus DNA sequence TGTGGT (Thornell et al., 1988, Speck and 
Baltimore, 1987).  
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1.4.1 Role of Runx1 at the onset of haematopoiesis 
Runx1 is essential for development of definitive HSCs in the AGM.  When 
Runx1 is knocked out in mice by homologous recombination, they exhibit 
embryonic lethality at E12.5 due to a failure of fetal liver haematopoiesis (Okuda 
et al., 1996).  The embryos are anaemic, although primitive erythrocytes are 
present and death is a result of haemorrhage secondary to severe 
thrombocytopaenia.  Transplant of Runx1-/- embryonic stem cells into Runx1 +/- 
blastocysts created chimeric mice, Runx1-/- cells failed to develop into 
haematopoietic tissue confirming that the defect resides in the mutant cells and 
not due to a defect with the HSC niche.  
A  Runx1-lacZ knock in embryo has been generated with exons 7 and 8 of 
Runx1 replaced with lacZ sequences.   The resultant fusion protein is non-
functional as a Runx1 allele. Thus, in a mouse hemizygous for a normal/Runx1-
lacZ RUNX1 gene, haploinsufficient Runx1 expressing cells can be isolated.  It 
can be shown that all HSC express Runx1 and that the prevalence of HSCs and 
their distribution in different compartments is sensitive to Runx1 dosage (North 
et al., 2002). Through transplantation assays it can be demonstrated that all 
developing HSCs, found in the AGM, fetal liver and the vitelline uterine artery 
are Runx1 positive.  RUNX1 can be detected as early as E7.5 in mesenchymal 
cells located in the yolk sac.       
1.4.2 Role of Runx1 in Adult Haematopoiesis  
Given the embryonic lethality of mice with full Runx1 knock-out alleles, a 
conditional knock out of Runx1 was generated to examine the role of RUNX1 in 
adult haematopoiesis (Ichikawa et al., 2004, Growney et al., 2005, Putz et al., 
2006).  Mice, where exon 5 of the Runx1 gene was flanked by loxP sites, were 
crossed with Mx-cre mice (Ichikawa et al., 2004).  Homozygous Runx1 deleted 
mice could be generated by injection of polyinosinic-polycytidylic acid.  Although 
these mice produced mature lymphocytes, the proportion of lymphocytes with 
biallelic deletions in thymocytes and B cells were only 9% and 57%, 
respectively, suggesting their development was impaired.  Erythrocytes and 
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neutrophil counts were unaltered, but platelet counts dropped substantially to up 
to a sixth of the initial numbers.  A striking result was the presence of biallelic 
deleted Runx1 HSC that were able to repopulate mice in a competitive 
repopulation assay.  Thus, although Runx1 is essential for their development, it 
is not required for the maintenance of HSCs.  Although definitive lymphocyte 
development was absent, immature T cell precursors accumulated in the 
thymus.  Again, normal myeloid precursors and morphologically normal 
neutrophils were present in expected numbers.  Others were in agreement with 
this phenotype except, in addition, some have noted a mild myeloproliferative 
phenotype in adult mice with knockout of Runx1 (Growney et al., 2005).    
Due to the disrupted lymphopoiesis in adult mice with conditional Runx1 knock 
out, the role of Runx1 in lymphocyte development has been examined further.  
To specifically target early T cell progenitors, Runx1-loxP flanked homozygous 
mice were crossed with Lck-Cre mice (Taniuchi et al., 2002).  T lymphocyte 
development involves the transition of double negative (DN) CD4-CD8- cell to 
double positive CD4+CD8+ cells, and finally to mature single positive (SP) 
CD4+ or CD8+ cells.  Although analysis of thymocytes from these mice 
revealed 95% population of cells had the genotype Runx1-/-, substantial 
numbers of SP CD4+ (23%) or CD8+ (59%) cells were Runx1+/+, suggesting 
Runx1 may have a role in thymic selection.  However, given that a significant 
number of mature SP cells retained the Runx1-/- genotype, RUNX1 is not 
essential in maintaining CD4 or CD8 silencing.  Runx1 is also involved in later 
lineage decisions between Th1 and Th2 cells.  Gata3 is required for the 
differentiation of T lymphocytes into Th2 phenotype cells.  Runx1 
overexpressing cells showed a skew to Th1 cells with the mechanism being an 
inhibition of Gata3 expression.  Indeed, the Th2 phenotype could be rescued 
through forced Gata3 expression(Komine et al., 2003). 
In humans, families have been identified that carry a Familial Platelet disorder 
gene with predisposition to acute myelogeneous leukaemia (FPD/AML).  These 
pedigrees show an autosomal dominant pattern of inheritance.  Patients with 
FPD/AML are thromobocytopaenic, with dysfunctional platelets and have an 
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increased risk of developing AML (Song et al., 1999).  Linkage disequilibrium 
studies using genetic markers defined a 3.2Mb genetic region of interest on 
chromosome 21.  Sanger sequencing of the candidate gene Runx1 identified a 
number of mutations, all of which resulted in the loss of the transactivation 
domain, and/or point mutations resulting in a truncated form of the protein or 
disruption to the RUNT DNA binding domain.  Bone marrow specimens from 
affected patients were used in megakaryocyte colony forming assays, which 
confirmed the presence of defective megakaryopoiesis.  Although there was no 
evidence of the inappropriate expansion and maturation arrest of myeloid cells 
subsequent analysis of leukaemic cells from these patients showed retention of 
the wild-type allele in cells showing clonal chromosomal abnormalities.   
In summary, Runx1 is essential for the development but not the maintenance of 
HSC.  It has a clear role in the development and further differentiation of T 
lymphocytes.  Although B lymphocytes numbers were reduced in adult mice 
with conditional knock out of Runx1 the mechanism of Runx1 function in B 
lymphopoiesis is not fully elucidated.  Patients with FPD/AML demonstrate 
impaired megakaryopoiesis: a phenotype which is reproduced in the murine 
conditional Runx1 knockout model or mice with the same mutations as those 
seen in patients with FPD/AML (Matheny et al., 2007, Sun and Downing, 2004). 
1.4.3 RUNX1 as a transcription factor 
RUNX1, and the drosophila homologue Runt, binds a murine retrovirus 
enhancer element in a sequence specific manner (Thornell et al., 1988, Speck 
and Baltimore, 1987).  RUNX1, also known as core-binding factor alpha 
(CBFα), functions as a heterodimer with core binding factor beta (CBFβ), which 
increases its DNA binding affinity by up to tenfold (Wang et al., 1996). CBFβ 
does not interact directly with DNA, but restricts the mobile regions of the Runt 
domain of RUNX1, resulting in a more stable conformation with DNA (Tahirov et 
al., 2001).  Mice with homozygous deletions of CBFβ die from widespread 
haemorrhage with an identical phenotype to Runx1 knock out counterparts 
(Wang et al., 1996). 
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Transcription factors cooperate with other partners to increase tissue specific 
DNA binding activity.  RUNX1 in mammalian cells tends to associate with other 
haematopoietic activators such as the C/EBP or ETS family transcription 
factors, through adjacent motifs localised in enhancer regions of genes 
encoding markers of monocytic differentiation such as cytokine receptors 
(Zhang et al., 1994, Petrovick et al., 1998).  For example, the tyrosine kinase 
receptor CSF-1R, is encoded by a gene whose expression is restricted to 
monocytes, and is essential for their proliferation and survival (Dai et al., 2002).  
A short -87 to-29 bp region in the promoter region encodes a binding sequence 
for PU.1 (a member of the ETS family of transcription factors), as well as 
RUNX1 and C/EBPα.  Furthermore, there is direct physical interaction between 
C/EBPα, and RUNX1, as demonstrated by co-immunoprecipitation (Co-IP) and 
by a reduction in luciferase promoter activity when a construct is generated that 
increases the distance between these binding motifs.  In these reporter assays 
basal levels of transcription generated by the heterodimer RUNX1 and CBFβ is 
80 fold increased by the addition of C/EBPα.   A further intronic regulatory 
element (FIRE) in this gene has also been identified (Himes et al., 2001).  Here, 
an Ets/Runx1 site co-exists and through ChIP direct occupancy of RUNX1 can 
be demonstrated (Tagoh et al., 2002).  RUNX1 binding sites often co-localise 
with ETS transcription factor binding sites (Gunther and Graves, 1994): the 
presence of ETS family transcription factors  improves DNA binding ability of 
RUNX1 (Gu et al., 2000).  Recent ChIP seq data have confirmed the co-
localisation of ETS motifs with RUNX1 binding sites (Ptasinska et al., 2012, 
Ben-Ami et al., 2013). 
Transcriptional co-activators that do not bind DNA directly act in complex with 
RUNX1 to modify histones to increase accessibility and recruit transcription 
initiating complexes.  Two well-characterised co-activators are p300 and CREB 
binding protein (CBP).  These are multifunctional adaptor proteins that bind a 
variety of transcription factors including AP-1 (Arias et al., 1994, Kamei et al., 
1996) and c-Myb (Zor et al., 2002, Dai et al., 1996).  P300 and CBP can interact 
with the basal transcription factor TFIIB (Kwok et al., 1994) and can acetylate 
histone H3 independently (Oelgeschlager et al., 1996) and via a partner protein, 
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P/CAF (Yang et al., 1996) to increase chromatin accessibility for other factors.  
A C-terminal region of RUNX1, lost in CBF fusion proteins, is essential for the 
physical interaction of p300 and CBP to RUNX1 (Kitabayashi et al., 1998).  
Luciferase activity reporter assays with the Myeloperoxidase (MPO) promoter, a 
gene important for neutrophil function, suggests both p300 and RUNX1 are 
required for its transcriptional activation. Other co-activating partners such as 
ALY and YAP function in similar cooperative fashion. 
Outside of the myeloid system, RUNX1 has been shown to act in the context of 
transcriptional repression.  As described above RUNX1 plays an important role 
in lymphocyte differentiation, in particular in silencing CD4 gene expression.  
Although direct evidence is lacking this may be due to the recruitment of the 
BAF chromatin remodelling complex (Chi et al., 2002).  In the context of p21 
gene regulation RUNX1 is also able to interact with the repressive chromatin 
modifiers, mSin3A and mSin3B, which exists in complexes associated with 
histone de-acetylases (Lutterbach and Hiebert, 2000). 
 
1.5 Role of EVI-1 in normal haematopoiesis 
EVI-1 (also known as MECOM or PRDM3) is found on chromosome 3q26 and 
is a dual domain zinc finger transcription factor (seven at the N-terminal and 
three at the C-terminal).  Evi-1 in itself is an essential regulator of self-renewal 
in haematopoietic stem cells (Goyama et al., 2008).   
1.5.1 Role of EVI-1 in fetal haematopoiesis 
Expression of EVI-1 in the haematopoietic system is limited to CD34+ precursor 
cells (Gerhardt et al., 1997, Privitera et al., 1997), including HSCs (Phillips et 
al., 2000) and becomes down-regulated in maturing cells (Russell et al., 1994).  
However, EVI-1 is likely to have an important role outside of the haematopoietic 
system.  Widespread abnormalities are seen in mice with lack of Evi-1: the lack 
of Evi-1 is lethal at day 11 of embryonic development with widespread 
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abnormalities seen in the cranial system, somites and peripheral nervous 
system (Hoyt et al., 1997).   
 
In murine Evi-1 -/- embryos, the defect in haematopoiesis is seen in cells of the 
para-aortic-splanchno-pleural (P-Sp) which in wild-type embryos have a high 
Evi-1 expression and show a decrease in frequency of HSCs isolated in the 
knock-out. In vitro stromal co-culture studies of these isolated cells demonstrate 
a reduced proliferative capacity and after adoptive transfer into a myeloablated 
murine host, these cells are incapable of establishing haematopoiesis at all 
(Yuasa et al., 2005).  Gene expression analyses suggest that Evi-1 knockout 
results in a substantial decrease in Gata-1 and Gata-2 mRNA levels (Yuasa et 
al., 2005).  Evi-1 knockout P-Sp HSCs transfected with a retrovirus that 
enforced the expression of Evi-1 or Gata-2 were able to rescue the function of 
these Evi-1 deficient HSCs. Gata-2 expression is regulated through the use of 
two promoters: haematopoietic cells employ the IS promoter, whilst a 3’ 
proximal IG promoter is used in other tissues (Pan et al., 2000).  Yuasa et al 
(Yuasa et al., 2005) suggest that a region between 6-7kb upstream of this 
promoter contains a DNA binding motif for the first of the two zinc finger 
domains of EVI-1 located towards the N-terminus.  When this regulatory 
element was cloned into a luciferase reporter construct, and co-transfected into 
a haematopoietic cell line EML with an Evi-1 overexpression vector, this Gata-2 
regulatory element enhanced luciferase activity compared to other upstream 
regions of this gene.  Yuasa et al (Yuasa et al., 2005) also demonstrate by 
chromatin immunoprecipitation-PCR (ChIP)-PCR in this cell line that EVI-1 
binds this enhancer specifically. 
1.5.2 Role of EVI-1 in adult haematopoiesis 
 
Due to the embryonic lethality of Evi-1 knockout a conditional knock-out model 
has been generated to study the role of Evi-1 in adult haematopoiesis (Goyama 
et al., 2008).  This was accomplished by crossing mice with floxed Evi-1 with 
Mx-Cre expressing mice.  Mature myeloid cells and lymphocytes were 
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unaffected when Evi-1 was excised.  However, the frequency of HSC was 
greatly reduced and Evi-1-/- HSCs lacked self-renewal and differentiation 
capacity as they did not contribute to mature haematopoietic cells when the 
mice were examined 4 weeks later.  Evi-1 +/- mice had a reduced number of 
HSCs and when these cells were transplanted with competitor wild-type HSCs, 
there was a reduced fraction of Evi-1+/- cells, indicating correct levels of Evi-1 
expression is important.  This defect in HSC function can be rescued by 
transfecting an Evi-1 expression vector (Kataoka et al., 2011). 
 
IRES-GFP labelled Evi-1 transgenic mice were generated to enable accurate 
sorting of Evi-1 expressing cells during development (Kataoka et al., 2011).  
The authors confirmed that Evi-1 was only expressed in the HSC population 
with subsequent loss of Evi-1 expression upon differentiation in vitro and in vivo 
studies.  Furthermore, the expression of Evi-1 is restricted to only the earliest 
long-term HSC which are naturally quiescent, possess self-renewal properties 
and have the most potent multi-lineage differentiation capacity. 
 
In summary, Evi-1 has an essential role in the development and maintenance of 
long-term HSCs, without any substantial role in mature differentiated cells. 
 
1.5.3 Features of EVI-1 as a transcription factor 
Several studies have shown that EVI-1 can bind DNA in a sequence specific 
manner through ten zinc fingers located in two separate domains situated 
towards the C-terminal.  From one study, a gel shift PCR method determined 
the consensus binding site for the first domain of seven zinc fingers as 
TGACAAGATAA (Perkins et al., 1991).  Further work to extend this, using GST 
fused to this first EVI-1 zinc finger domain, determined 
GA(C/T)AAGA(T/C)AAGATAA as a consensus binding sequence (Delwel et al., 
1993).  The second C-terminal distal domain of three zinc fingers bind a 
consensus sequence of GAAGATGAG (Funabiki et al., 1994).  The ability to 
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bind GATA-like motifs may be part of the mechanism of inhibition of GATA-1 
target genes (Kreider et al., 1993). 
Direct evidence of in vivo DNA interaction by ChIP-PCR has been 
demonstrated at a Gata-2 upstream enhancer which was described above 
(Yuasa et al., 2005).  To discover further gene targets another group 
transfected murine fibroblasts with EVI-1 coupled to VP16, a potent trans-
activator (Yatsula et al., 2005).  Candidate genes were identified by their 
upregulation on a gene expression array and these included Gata2, Gata3 and 
FOG2.  EVI-1 binding near Gata2 and FOG2 were confirmed by ChIP-PCR.  In 
an ovarian carcinoma cell line FLAG tagged EVI-1 was immunoprecipitated and 
subjected to high throughput sequencing (Bard-Chapeau et al., 2012).  
Although this is in another tissue type, this provides the only reliable genome 
wide evidence of direct EVI-1 DNA binding capacity to date.  12618 peaks were 
identified following appropriate validation.  EVI-1 bound genes correlated 
significantly by gene site enrichment analysis to previously published gene 
expression profiles for Evi-1 overexpression AML samples and to Evi-1 KO 
haematopoietic cells.  Binding motifs for GATA (GATAGA) (3178 peaks) and 
ETS (TCCT/G)(5097 peaks) were identified by de novo motif search, 
purportedly associated with the two separate DNA binding domains, however, 
only a minority (6-8%) of the ChIP seq peaks had the two peaks co-occurring.  
AP-1 motifs were also represented in EVI-1 binding sites with their Co-IP 
studies suggesting a direct physical interaction between FOS and EVI-1.  
Significant and previously identified targets include Gata-2, Fos and Jun 
(Tanaka et al., 1994). 
A second EVI-1 ChIP seq experiment in murine myeloid cell line (Glass et al., 
2013) was less informative, due to the quality of its ChIP-seq but confirmed 
Gata-2 as a putative target and suggested Cebpe might also be a direct EVI-1 
target.  
EVI-1 associates predominately with transcriptional co-repressors.  Reporter 
gene assays suggests a functional role for the association of EVI-1 with both 
class 1 and 2 HDAC.  One report suggested an association of HDAC1 and 4 
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(Chakraborty et al., 2001), whilst a second report corroborated the association 
with HDAC1 (Vinatzer et al., 2001).  This may be via a scaffolding protein C-
terminal binding protein (CtBP) (Palmer et al., 2001, Shi et al., 2003), which has 
been shown to be functionally important in the inhibition of the TGFβ signalling 
pathway (Izutsu et al., 2001). 
Histone 3 Lysine 9 trimethylation (H3K9me3) is a well-characterised epigenetic 
mark of heterochromatin which is important for gene repression and 
maintenance of nuclear integrity (Shilatifard, 2006).   EVI-1 possesses in vitro 
histone methyl transferase activity (Pinheiro et al., 2012) and has a redundant 
role in the formation of H3K9me1 in the cytoplasm of cell.  Double knockdown 
of both PRDM3 (Evi-1) and PRDM16 led to a loss of H3K9me3 and subsequent 
breakdown of nuclear lamina.  In this light, two independent reports confirming 
the association of EVI-1 with two histone methyltransferase that play an 
important role in the formation of H3K9me3: SuV39H1 and G9a is significant 
(Spensberger and Delwel, 2008, Cattaneo and Nucifora, 2008).  A third study 
suggests that this association is important in the immortalisation of murine bone 
marrow progenitor cells by Evi-1 transfection (Goyama et al., 2010).   
EVI-1 has the ability to modulate the activity of other transcription factors 
without directly binding DNA itself.  For example, EVI-1 can bind to SMAD3 
which normally acts in complex with SMAD4 as part of the TGFβ signalling 
pathway.  EVI-1 bound SMAD3/4 has a reduced DNA binding activity, and thus 
suppresses TGFβ mediated gene repression.  For this activity to occur, the 
presence of EVI-1 binding sites in the DNA are not required although the EVI-1 
zinc finger domains are required (Kurokawa et al., 1998b).  Similarly, EVI-1 
binds to a variety of other factors: GATA1, reducing its DNA binding capacity 
(Laricchia-Robbio et al., 2006); the C-terminus of PU.1 preventing appropriate 
JUN interaction with this transcription factor (Laricchia-Robbio et al., 2009); 
RUNX1, thereby reducing its DNA binding capacity (Senyuk et al., 2007) and 
C/EBPα, preventing its auto-regulatory transcriptional activity (Tokita et al., 
2007).  None of these mechanisms necessarily require direct DNA binding by 
EVI-1 itself.  
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In summary, direct evidence of EVI-1 repression at gene targets are scarce 
despite evidence for EVI-1 as a DNA binding factor and its association with co-
repressors.  An exception to this is the repression of PTEN by the recruitment of 
polycomb proteins from the PRC 2/3/4 class to an EVI-1 binding site in the 
PTEN promoter region (Yoshimi et al., 2011).  An association with an increase 
in Histone 3 Lysine 27 trimethylation (H3K27me3), another well characterised 
important mark of gene repression important in development, was seen at this 
genomic locus. 
1.6 RUNX1 fusion proteins in myeloid malignancies 
Mutations involving RUNX1 are one of the most commonly found abnormalities 
in Acute Myeloid Leukaemia (AML).  The function of RUNX1 can be disrupted in 
a number of ways: point mutations (Osato et al., 1999) disrupting the RUNT 
DNA binding domain, translocations affecting CBFβ which is required for 
optimal RUNX1 DNA binding (Liu et al., 1993)  and translocations of RUNX1 to 
other genes resulting in dysfunctional fusion products (Golub et al., 1995, 
Gamou et al., 1998). The most common fusion protein is RUNX1-ETO, (a 
product of the t(8;21) translocation)  (Miyoshi et al., 1993, Erickson et al., 1992).   
The product of another core-binding-factor translocation, t(3;21)(q26;q22), is 
RUNX1-EVI1.  The fusion partner, EVI-1 was first identified as a target of 
retroviral insertion in the AKXD mouse strain who develop myeloid leukaemia 
(Mucenski et al., 1988).  EVI-1 overexpression is a common finding in patients 
with acute myeloid leukaemia (AML) and is an independent poor prognostic 
factor on multivariate analysis (Groschel et al., 2010).  Evi-1 overexpression in 
murine bone marrow cells by retroviral infection results in a myelodysplastic 
condition that transforms into AML (Buonamici et al., 2004).  
These next sections will compare these two fusion proteins to elucidate 
common and distinct properties of core-binding factor fusion proteins. 
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1.7 Comparison of RUNX1-ETO and RUNX1-EVI-1 
In patients with t(8;21) translocations the breakpoints in chromosome 21 
clustered to three breakpoint cluster regions in intron 5 (Zhang et al., 2002).  
The breakpoint in chromosome 8 is clustered around intron 1b resulting in a 
fusion of the Runt domain of RUNX1 to four conserved Nervy Homology 
Regions (NHR) domains of ETO (Figure 1-4).  The NHR domains are capable 
of recruiting specific interacting partners and enable RUNX1-ETO to 
oligomerise with each other (see section 1.7.2).  Although there are two zinc 
fingers in the distal C-terminal end of the fusion protein, to date there is no 
evidence for DNA binding capability by this domain. 
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Figure 1-4 Structure of RUNX1, EVI-1, RUNX1-ETO and RUNX1-EVI-1 with 
their interacting partners 
Key AA- amino acids, RHD- Runt homology domain, TA- transactivation 
domain, NHR- nervy homology region, SET- Su(var)3-9 and 'Enhancer of zeste’ 
and Trithorax, ZF- zinc finger domain, RD- proline rich repressive domain, CBP- 
CREB binding protein, HDAC- histone deacetylase, CtBP- C-terminal binding 
protein, N-CoR- nuclear receptor co-repressor. 
The t(3;21) translocation results in a similar fusion protein: the RUNT domain is 
retained in a fusion with the entire MDS1-EVI-1 gene (Mitani et al., 1994, 
Nucifora et al., 1994).  This includes the SET domain containing PR region in 
the MDS gene.  The Su(var)3-9 and 'Enhancer of zeste' and Trithorax(SET) is 
an evolutionary conserved domain, first identified in drosophila, and has been 
shown to have histone methyltransferase activity (Pinheiro et al., 2012).  Both 
sets of zinc fingers with direct DNA binding activity (Morishita et al., 1995) are 
also retained.  However, variations in the location of the breakpoint alter the 
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fusion partner with some examples exchanging EVI-1 with the upstream gene 
EAP, or the exclusion of the SET domain containing MDS gene (Nucifora et al., 
1994, Lugthart et al., 2010).  Despite the presence of DNA binding domains in 
the fusion protein, only in vitro direct DNA binding is available (discussed further 
below). 
 
1.7.1 Clinical description of patients with core-binding factor 
fusion proteins 
Mutations involving RUNX1 remain the most frequent mutations in patients with 
AML.  Differing point mutations and cytogenetic abnormalities in patients are 
independent prognostic factors, based on multivariate analyses (Grimwade et 
al., 2010, Gaidzik et al., 2011). Here, we describe the clinical characteristics of 
patients with AML expressing the fusion proteins RUNX1-ETO and RUNX1-EVI-
1.  The distinct clinical characteristics of patients with each type of CBF AML 
suggest an intrinsic biological difference between the two fusion proteins.   
Epidemiology and prognosis 
t(8;21) (involving the heterodimeric partner of RUNX1, CBFβ) involves 7% of 
newly diagnosed younger patients with AML (Grimwade et al., 2010).  In 
patients above 60 years of age, the frequency of these translocations is 
reduced to 3% (Burnett et al., 2012). The presence of a translocation in AML 
involving core-binding factor (CBF) protein is universally recognised as a better 
prognostic factor by a number of independent cooperative groups (Grimwade et 
al., 2010, Byrd et al., 2002, Slovak et al., 2000).   Younger patients with t(8;21) 
or inv(16) (affecting CBFβ) have a 5 year overall survival of over 84% with 
advances attributed, in part, to the use of high dose cytarabine in remission 
consolidation therapy and the use of Gemtuzumab Ozogamacin (humanised 
anti-CD33 conjugated to calicheamicin, a DNA damaging agent) in remission 
induction treatment  (Hills et al., 2013, Loke et al., 2015). 
In contrast, the t(3;21)(q26;q22) which results in the fusion protein RUNX1-EVI-
1 is rarely found in patients with de novo AML, with only 9 patients in a cohort of 
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6515 (Lugthart et al., 2010). This fusion protein is more commonly found in 
those with therapy related MDS/AML (4 patients in a series of 144) (Rubin et al., 
1990) or as a secondary event in the transformation of CML from chronic phase 
to blast crisis (Rubin et al., 1987, Paquette et al., 2011).  The outcomes of 
patients with secondary AML or CML in blast crisis are poor due to chemo-
resistance of the underlying condition.  The-5 year event free survival for 
patients with AML and the presence of RUNX1-EVI-1 fusion is only 14% 
(Lugthart et al., 2010). 
Cooperating mutations 
The presence of recurrent cooperating mutations suggests possible synergistic 
oncogenic mechanisms.  Early hypotheses suggested, for the development of 
AML, a need for two independent mutations: “class I” mutations affecting cell 
growth and proliferation whilst a “class II” mutation disrupted cellular 
differentiation and apoptosis (Speck and Gilliland, 2002, Gilliland and Griffin, 
2002).  In keeping with this original paradigm, recurring additional molecular 
mutations in t(8;21) patients most frequently cause aberrant activation of cell 
signalling pathways.  The most common cooperating mutation is in the receptor 
tyrosine kinase KIT, found in 17% of AML patients with the t(8;21) translocation 
(Pollard et al., 2010, Krauth et al., 2014).  KIT is highly expressed in 
haematopoietic stem cells and is normally stimulated by the ligand SCF and is 
often over expressed in patients with RUNX1-ETO (Paschka and Dohner, 
2013).  The most common locations are in exon 17 encoding an activation loop, 
affecting the tyrosine kinase domain and exon 8 encoding an extracellular part 
of the receptor, affecting receptor dimerisation.  Retroviral transduction of 
RUNX1-ETO and either mutations in exon 8 or 17 of KIT into murine progenitor 
cells lead to an AML when transplanted into lethally irradiated mice (Nick et al., 
2012).  In general, KIT exon 17 mutations are associated with decreased event 
free survival and overall survival on multivariate analyses (Kim et al., 2013, Park 
et al., 2011).  However, it is notable some large studies had also found no 
significant influence on survival outcomes based on KIT mutation subgroup 
analyses (Pollard et al., 2010).  As such KIT mutation analysis has not been 
   
41 
 
incorporated as part of routine clinical practice.  However, the German AML SG 
cooperative group are investigating targeting KIT by the use of tyrosine kinase 
inhibitor dasatinib, in patients with newly diagnosed CBF AML in a phase III 
randomised controlled trial (clinical trials identifier NCT02013648). 
Other recurring molecular lesions often include other receptor tyrosine kinase 
mutations, such as in NRAS, KRAS, FLT3 (both internal tandem duplications 
and tyrosine kinase domain mutations), JAK2 V617F and CBL.  Epigenetic 
modifiers affected frequently include ASXL2 (part of the polycomb repressive 
complex mechanism, discussed above), as well as IDH1 and 2 (linked to DNA 
hypermethylation through TET2 disruption) (Krauth et al., 2014).  In targeted 
sequencing approach of 215 CBF leukaemia, 18% of t(8;21) AML had a 
mutation in the cohesin complex and these patients were at an increased risk of 
disease relapse after chemotherapy treatment (Duployez et al., 2016).  A 
recently discovered set of mutations cooperating with RUNX1-ETO are 
missense or truncation mutations in ZBTB7A (also known as LRF or Pokemon) 
(Hartmann et al., 2016).  23% of t(8;21) AML also had a mutation of ZBTBZ7A.  
ZBTB7A is a transcription factor and these mutations appear to disrupt the 
distal C-terminal zinc finger domains.  It has an important role in lymphopoiesis 
and erythropoiesis as well as the regulation of glycolysis (Lunardi et al., 2013, 
Liu et al., 2014, Masuda et al., 2016). 
Cooperating mutations with RUNX1-EVI-1 are more difficult to identify due to 
the rarity of the mutation.  However, there is a general association of NRAS 
mutations with inv(3) and other  3q26 chromosomal abnormalities, which 
includes patients with RUNX1-EVI-1  (Lugthart et al., 2010).  In this series of 9 
patients with RUNX1-EVI-1: NPM1, FLT3-ITD and C/EBPα mutation were not 
detected (H Dohner, personal correspondence).  In terms of chromosomal 
abnormalities, out of the 9 patients 4 had monosomy 7, 2 deletion 5q and 2 
complex karyotype.  The association with development of blast crisis in CML 
would suggest a corroborative function with the BCR-ABL fusion protein.  This 
is supported by murine studies which show that both BCR-ABL and RUNX1-
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EVI-1 transduction in progenitor cells are required for the development of an 
AML phenotype (Cuenco and Ren, 2001, Cuenco and Ren, 2004). 
1.7.2 RUNX1-ETO role in development of leukaemia 
Additional cooperative mutations are required for the development of 
leukaemia  
A number of independent lines of enquiry suggest that RUNX1-ETO expression 
alone is not sufficient to cause AML and require the acquisition of additional 
driver mutations.  Firstly, it is possible to isolate RUNX1-ETO transcripts from 
patients in long term remission (Miyamoto et al., 2000).  Stringent FACS sorting 
of haematopoietic cells demonstrate detectable levels of RUNX1-ETO 
transcripts in HSC, monocytes and B cells but not in T cells.  Secondly, Guthrie 
spot analyses allow the identification of mutations that had occurred during 
foetal development (Wiemels et al., 2002).  Despite the detection of the 
RUNX1-ETO translocation in neonatal blood, the development of AML occurred 
in patients with a delay of up to 10 years, and in some patients these transcripts 
were detectable long into remission.  Thirdly, transgenic mice with RUNX1-ETO 
driven from a myeloid promoter did not develop AML during their lifetime.  
However, they were predisposed to the development of AML when they were 
exposed to an alkylating agent, N-ethyl-N-nitrosurea compared to their wild-type 
littermates (Yuan et al., 2001).   
RUNX1-ETO is a dominant negative inhibitor of RUNX1 
Two murine models suggest that RUNX1-ETO behaves as a dominant negative 
inhibitor of RUNX1 (Yergeau et al., 1997, Okuda et al., 1998).  Knock in of 
RUNX-ETO in the Runx1 locus results in a constitutive heterozygous RUNX1-
ETO /Runx1 genotype.  These mice phenotypically resemble mice with Runx1 
knockout: they die at E13.5 with lack of normal fetal liver haematopoiesis and 
haemorrhages in the central nervous system, suggesting RUNX1-ETO 
disrupted native RUNX1 function.  This is supported by the use of gene reporter 
studies that utilise the GM-CSF promoter.  The ability of native RUNX1 to trans 
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activate a CAT reporter assay is abrogated by the presence of RUNX1-ETO 
(Frank et al., 1995).  RUNX1-ETO can also directly bind RUNX motif containing 
sequences in in vitro assays (Meyers et al., 1993) Genome-wide studies 
involving the depletion of RUNX1-ETO by siRNA has been accomplished 
(Ptasinska et al., 2012).  After siRNA knock down RUNX1-ETO and subsequent 
RUNX1 ChIP seq, it can be confirmed a third of binding sites occupied by 
RUNX1 were previously occupied by RUNX1-ETO. 
The importance of wildtype RUNX1 in maintaining survival of cells with RUNX1-
ETO has been seen in two studies (Ben-Ami et al., 2013). One study showed 
that knockdown of RUNX1 induced apoptosis in t(8;21) Kasumi-1 cell line, that 
was rescued by knockdown of RUNX1-ETO.  This is in part due to the 
previously recognised finding that RUNX1-ETO is pro-apoptotic (Burel et al., 
2001), and the wild-type RUNX1 counteracts this.  Furthermore, RUNX1 
appears to directly regulate a set of mitotic control genes that enables continued 
proliferation of these leukaemic cells (Ben-Ami et al., 2013).  In a second study, 
the authors suggest the presence of RUNX1 is a general pro-survival 
mechanism in other forms of AML, mediated through BCL2 (Goyama et al., 
2013). 
RUNX1-ETO increases proliferation and self-renewal properties of 
haematopoietic cells 
Due to the embryonic lethality of constitutive RUNX1-ETO knock-in transgenic 
mice, a conditional RUNX1-ETO knock in transgenic mouse provides a model 
for the direct role of the RUNX1-ETO translocation (Higuchi et al., 2002).  Cre 
mediated recombination resulted in the activation of the RUNX1-ETO allele 
through the deletion of a loxP flanked transcriptional stop cassette.  The result 
is a RUNX1-ETO allele driven by the endogenous Runx1 promoter, achieving 
physiologically expected mRNA levels in a lineage specific manner.  This model 
demonstrated that in long-term replating assays, that there was increased 
proliferation and a capacity for self-renewal.  However, there was no striking 
impediment to the ability to differentiate; with the visible presence of mixed 
lineage colonies.  This is supported by reports described above, where, despite 
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the presence of RUNX1-ETO in HSCs multi-lineage haematopoiesis remains.  
Ectopic expression of RUNX1-ETO in human CD34+ stem and progenitor cells 
isolated from cord blood results in their increased self-renewal properties 
(Mulloy et al., 2002). 
A recent, more refined model, with conditional expression of RUNX1-ETO in 
early haematopoietic progenitors have shown that the fusion protein can 
expand Granulocyte-Macrophage Progenitors (GMP), whilst HSC numbers are 
largely unaffected (Cabezas‐Wallscheid, 2013). These RUNX1-ETO expressing 
GMP cells have leukaemia initiating potential when transplanted into lethally 
irradiated mice.  The long latency in developing AML in this model once again 
emphasised the need for additional mutations in combination with RUNX1-ETO, 
in order to initiate leukaemia.  
RUNX1-ETO inhibits myeloid differentiation in fully transformed leukaemic 
cells 
 
In a U937T cell line expressing tetracycline inducible RUNX1-ETO, induction of 
the fusion protein leads to a pro-apoptotic stage with reduced neutrophilic 
differentiation ability (Burel et al., 2001). Furthermore, siRNA knockdown of 
RUNX1-ETO results in differentiation of the leukaemic blasts into more mature 
myeloid cells (Dunne et al., 2006, Ptasinska et al., 2012) and in a doxycycline 
inducible model of RUNX1-ETO, withdrawal of doxycycline and thus 
downregulation of RUNX1-ETO led to a decrease in leukaemic cell number 
(Cabezas‐Wallscheid, 2013).  These experiments suggest that the fusion 
protein is necessary for fully transformed cells to retain their leukaemic 
phenotype. 
 
Explanations for the phenotypic variations seen in these different models 
suggest several possibilities.  Firstly, dosages of the fusion protein appears to 
be a major difference; if the fusion protein is driven by the native Runx1  
promoter, the doses of the fusion protein would be lower, particularly in later, 
more differentiated lineages.  Secondly, the cellular context and content of the 
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transcription factor pool would be important and thus which progenitor type (e.g. 
HSC, GMP etc.) RUNX1-ETO is expressed in, would be crucial.  Finally, the 
presence of co-existing mutations may be required to reveal the clear 
differentiating block seen in t(8;21) AML.   
 
How might this differentiation block be affected?  C/EBPα is a key transcription 
factor of the myeloid lineage, directly regulating many genes involved in the 
differentiation of cells into mature granulocytes; which are absent in C/EBPα 
mutant mice (Zhang et al., 1997b).  C/EBPα also has a role in maintaining HSC 
quiescence (Ye et al., 2013).  Investigations have demonstrated RUNX1-ETO 
down regulates C/EBPα through two ways: the fusion protein can physically 
bind to C/EBPα, thereby preventing its ability to activate transcription of C/EBPα 
target genetic elements, as demonstrated through a luciferase reporter assay 
system (Westendorf et al., 1998).  This is important because C/EBPα activates 
its own promoter through an upstream stimulatory factor binding site 
(Timchenko et al., 1995, Legraverend et al., 1993).  It has been shown that 
expression of CEBPA itself is reduced through the inhibition of this 
autoregulatory mechanism, by RUNX1-ETO interaction with C/EBPα itself and 
not directly at the promoter of CEBPA.  This results in a reduction in C/EBPα 
levels, demonstrable in both cell lines and patients with the t(8;21) translocation 
(Pabst et al., 2001).  It has been shown that enforced C/EBPα expression in the 
t(8;21) Kasumi-1 cell line can rescue neutrophilic differentiation (Pabst et al., 
2001).  Finally, RUNX1-ETO may also regulate CEBPA through binding to its 
upstream enhancer (Avellino et al., 2016, Ptasinska et al., 2014). 
 
Recruitment of co-repressors by RUNX1-ETO represses target genes 
The loss of the transactivation domain of the native RUNX1 and its replacement 
by ETO is associated with de-acetylation of histone 3 lysine 9 on target genes 
(Ptasinska et al., 2012, Martens et al., 2012), which should result in reduced 
chromatin accessibility and repression of gene expression (Bannister and 
Kouzarides, 2011).  This probably occurs via co-repressor complex associated 
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with RUNX1-ETO such as N-CoR/mSin3/SMRT/HDAC.  Interaction of RUNX1-
ETO with N-CoR was initially identified through the use of a yeast-two-hybrid 
library screen (Wang et al., 1998) and the recruitment of SMRT to RUNX1-ETO 
subsequently shown to be directly dependent on the NHR domains (Liu et al., 
2007).  The ability of RUNX1-ETO to repress transcription has been shown to 
be dependent on its ability to associate with N-CoR (Lutterbach et al., 1998).  
The ability of RUNX1-ETO to recruit HDAC appears to be dependent on the 
presence of N-CoR (Gelmetti et al., 1998), loss of N-CoR association resulted in 
an inability to inhibit differentiation in a myeloid cell line model.  Depletion of 
RUNX1-ETO by siRNA leads to a return of histone 3 lysine 9 acetylation 
(Ptasinska et al., 2012, Martens et al., 2012) on a genome wide basis. 
RUNX1-ETO oligomerises and cooperates with other transcription factors 
in binding DNA 
Of the four NHR(1-4) in the ETO fusion partner, NHR 2 plays a crucial role in 
oligomerisation of RUNX1-ETO.  By x-ray crystallography, it was demonstrated 
that RUNX1-ETO forms a tetrameric structure, which is extremely stable and 
required extensive mutagenesis to disrupt its structure (Liu et al., 2006).  
RUNX1-ETO carrying mutant NHR2 domains which were unable to oligomerise, 
had compromised self-renewal capacity and ability to inhibit gene expression.  
Although, mutations that inhibited oligomerisation had no direct impact on the 
affinity of RUNX1-ETO to other co-repressors, the four-fold increase in surface 
area by the oligomer is likely to be important in the  recruitment of other proteins 
(Liu et al., 2006, Sun et al., 2013). 
Other than co-repressors, RUNX1-ETO acts cooperatively with other direct 
DNA binding transcription factors.  Examples of these include ETS family 
proteins, which also interact with the wild-type RUNX1, and this supported by 
the co-localisation of these binding motifs with RUNX1-ETO ChIP seq 
(Ptasinska et al., 2012, Martens et al., 2012).  Specific examples of this family 
include activating transcription factor ERG and FLI1.  ChIP-seq data for ERG, 
FLI-1 and RUNX1-ETO show strong overlap in their binding sites.  Through 
sequential re-ChIP experiments with first ERG and then RUNX1-ETO and also, 
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vice versa, it can be shown that they bind together at the same loci.  In a model 
where RUNX1-ETO is inducible, it was shown that FLI-1 bind to genomic loci 
prior to the binding of RUNX1-ETO (Martens et al., 2012). 
Another group of transcription factors which are bound by RUNX1-ETO are the 
E-protein family.  E proteins are widely expressed, and play important roles in 
cellular development (Lassar et al., 1991).  Mass spectrometric analyses of 
RUNX1-ETO bound complexes identified the E protein family member HEB 
(Zhang et al., 2004a).  In RUNX1-ETO the NHR1 domain bears extensive 
homology to TBP associated factor protein which is part of the TFIID 
transcription factor complex.  This domain was shown to be crucial in 
maintaining a high affinity interaction with HEB, and displaces co-activating 
histone acetylase complex p300/CAF from their binding site on the Activation 
Domain 1 (AD1) on HEB.  These results in suppression of HEB activated 
promoter activity.  The related E protein E2A is also an interacting partner of 
RUNX1-ETO but is bound with a lower affinity.  On a genome wide basis motif 
analyses show an enrichment of E-Box sites at RUNX1-ETO ChIP seq peaks 
(Ptasinska et al., 2012) (Sun et al., 2013).  It was later shown the oligomerised 
RUNX1-ETO may be important for the interaction with E proteins (Sun et al., 
2013) but this is not consistent with earlier data described above (Liu et al., 
2006).   
In addition, further analyses of RUNX1-ETO complexes identified LMO2 (with 
its partner LDB1) and LYL1.  ChIP seq of RUNX1-ETO, HEB, E2A and LMO2 
show shared genomic loci.  ShRNA knockdown of these components (i.e. 
HEB/E2A, LY1, LDB1 and LMO2) reduced the lethality of RUNX1-ETO induced 
leukaemia in mice (Sun et al., 2013). 
1.7.3 Comparison of the role of RUNX1-EVI-1 and RUNX1-ETO 
in the pathogenesis of leukaemia 
 
The two fusion proteins contain different C-terminal fusion partners and have 
different functional activities.  Notably, ETO is not a commonly found oncogenic 
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mutation in its own right, whilst as described already; EVI-1 is overexpressed in 
AML.  This is reflected in murine models where overexpression of Evi-1  results 
in a MDS phenotype (Buonamici et al., 2004).  In contrast, Evi-1 knockout mice 
demonstrate reduced leukaemic potential when transfected with potent 
oncogenic fusion proteins such as E2A-HLF and MLL-ENL (Goyama et al., 
2008).  However, the oncogenic potential of the fusion protein RUNX1-EVI-1 is 
not only a result of a loss of RUNX1 function and gain of EVI-1:  overexpression 
of EVI-1 in RUNX1 -/- murine bone marrow cells fails to transform the murine 
bone marrow cells, whilst the full length fusion protein was able to (Takeshita et 
al., 2008). 
Similarities between RUNX1-EVI-1 and RUNX1-ETO 
RUNX1-EVI-1 promotes an acute myeloid leukaemia but requires other 
mutations 
When mice were transplanted with bone marrow cells transduced with RUNX1-
EVI-1, they developed leukaemia within 5-13 months.  There was a reduced 
latency with subsequent serial transplants.  This suggests other cooperative 
mutations are required to accumulate with time before the onset of a full 
leukaemia (Cuenco et al., 2000). 
 
RUNX1-EVI-1 is found in secondary AML and CML in blast crisis (Rubin et al., 
1990, Rubin et al., 1987, Paquette et al., 2011) and is therefore likely to be a 
secondary driver mutation and not an initiating mutation.  Recent single cell 
gene expression analysis has confirmed that RUNX1-EVI-1 is a secondary 
mutation in a patient with CML in blast crisis (Nukina et al., 2014).  
RUNX1-EVI-1 acts as a dominant negative inhibitor of native RUNX1 
RUNX1-EVI-1 knocked into the RUNX1 locus initiates a similar phenotype to 
the RUNX1-ETO knock in mice (Maki et al., 2005) who die at E13.5 with a 
failure of adult haematopoiesis.  Haematopoietic cells from the fetal liver 
differentiate into dysplastic megakaryocytes and myeloid progenitors. 
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Like RUNX1-ETO, RUNX1-EVI-1 can also bind RUNX motif containing 
sequences, and does so with a higher affinity than native RUNX1 (Tanaka et 
al., 1995).  This may be due to increased binding affinity to CBFβ: in a co-
transfection model CBFβ and RUNX1-EVI-1 co-localise in the nucleus, by Co-IP 
and fluorescent microscopy (Tanaka et al., 1998).   
 
Finally, RUNX1-EVI-1 may bind to RUNX1 itself in Co-IP experiments using HA 
and FLAG tagged constructs (Senyuk et al., 2007).  This was confirmed by 
immunofluorescent microscopy, when 293T cells were transiently transfected by 
RUNX1-EVI-1 and RUNX1.  This ability is mediated through a distal EVI-1 
portion of the fusion protein as binding to RUNX1 is also a property that is 
conserved with EVI-1 and the isolated distal fragment. 
 
RUNX1-EVI-1 promotes malignant proliferation and self-renewal of affected 
cells 
RUNX1-EVI-1 knock in transgenic murine model (Maki et al., 2005), was 
embryonically lethal, with severely impaired fetal liver haematopoiesis.  The few 
haematopoietic progenitors that could be isolated from the fetal liver were 
dysplastic in appearances and demonstrate a significant increase in in vitro 
replating capacity.    
 
RUNX1-EVI-1 may inhibit differentiation through down-regulation of C/EBPα 
activity 
Fetal liver haematopoietic cells from Runx1-Evi-1 knock in transgenic murine 
model described above (Maki et al., 2005) had impaired differentiation, with a 
bias towards macrophage development in colony plating assays.  Murine 
myeloid progenitor LG-3 cells differentiate into granulocytic cells when they are 
exposed to G-CSF.  RUNX1-EVI1 is capable of inhibiting differentiation in this 
model (Tokita et al., 2007) but differentiation could be rescued by C/EBPα co-
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expression.  Direct binding of RUNX1-EVI1 to C/EBPα could be observed and 
this decreased C/EBPα DNA binding ability in EMSA and in luciferase reporter 
assays (Tokita et al., 2007).  It is unclear whether this results in a reduction in 
C/EBPα mRNA levels through inhibition of C/EBPα autoregulatory mechanism.  
 
RUNX1-EVI-1 Inhibition of C/EBPα may also occur via calreticulin.  Calreticulin 
is a multifunctional protein that can act as a chaperone for misfolded proteins 
but is also involved in intracellular signalling through sequestration of calcium 
ions in the endoplasmic reticulum (Luo and Lee, 2013).  In U937 cells 
transfected with RUNX1-EVI-1 and human patient samples, C/EBPα protein 
levels were disproportionately lower than the mRNA levels would suggest.  
Calreticulin was more highly expressed than expected in patients with RUNX1-
EVI-1 and this was recapitulated when RUNX1-EVI-1 was transfected in to a 
cell line.   Calreticulin may bind to C/EBPα mRNA, and prevent its translation 
(Timchenko et al., 2002).  Knockdown of calreticulin by siRNA restored C/EBPα 
levels (Helbling et al., 2004). 
 
RUNX1-EVI-1 oligomerisation  
Oligomerisation of oncoproteins improves their ability to recruit other active 
proteins.  Like RUNX1-ETO, RUNX1-EVI-1 can oligomerise with other 
molecules of the fusion protein (Senyuk et al., 2005).  A series of deletion 
mutants affecting different portions of the fusion protein showed that a series of 
domains, ranging from the RUNX1 through to both the proximal and distal Zinc 
finger portions are required for this self-interacting property.  Although deletion 
mutants of the distal zinc finger portions of RUNX1-EVI-1 impaired the ability of 
this fusion protein to inhibit differentiation (Senyuk et al., 2005), it is unclear 
whether this is specifically related to the loss of oligomerisation property of the 
fusion protein or whether this is due to the loss of other properties mediated by 
this portion of the fusion protein.  
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Differences between RUNX1-EVI-1 and RUNX1-ETO 
Although both CBF fusion proteins require additional mutations before the onset 
of an overt leukaemia, RUNX1-EVI-1 promotes a more aggressive leukaemia 
than RUNX1-ETO.  Mice transplanted with bone marrow cells expressing 
RUNX1-EVI-1 have a reduced latency to leukaemia (Cuenco et al., 2000) 
compared to bone marrow cells expressing RUNX1-ETO (Schessl et al., 2005, 
Schwieger et al., 2002).  The onset of leukaemia in RUNX1-EVI-1 transgenic 
mice (Maki et al., 2006) do not require administration of alkylating agents, unlike 
RUNX1-ETO transgenic mice (Yuan et al., 2001), or  in comparison at least 
have reduced latency to development of leukaemia (Cabezas‐Wallscheid, 
2013). 
 
Some differences between the two CBF fusion proteins are likely to be 
attributable to the C-terminal fusion partner EVI-1.  As described above, these 
include stimulation of the AP-1 pathway (Tanaka et al., 1995) and inhibition of 
the TGFβ pathway (Kurokawa et al., 1998a, Sood et al., 1999) through the 
Smad3 protein. With the native EVI-1 this is also mediated via the repressive 
complex CtBP containing HDAC (Izutsu et al., 2002). 
 
RUNX1-EVI-1 binds to CtBP as a co-repressor 
CtBP is a multifunctional co-repressor that can act as a scaffolding protein.  It 
exists in a complex that contains histone deacetylases (HDAC1), polycomb 
repressive complexes (HPC2), and H3K9 methyltransferases  (G9a)  (reviewed 
in (Chinnadurai, 2007)).  All of these enzymes promote a condensed chromatin 
configuration.  For example, in a cell line, in which the E-cadherin gene is not 
expressed, CtBP1 localises at the e-cadherin promoter and recruits HDAC1 and 
2, HPC2, and G9a.  This resulted in methylation of H3K9 and loss of H3K9 
acetylation (Shi et al., 2003). 
RUNX1-EVI-1 has been reported to recruit CtBP which was suggested to be in 
conjunction with inhibition of C/EBPα transcription (Tokita et al., 2007) and 
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RUNX1 mediated transactivation (Izutsu et al., 2002).  However, these 
experiments have only been performed through reporter assays, and the direct 
epigenetic mechanisms have not been elucidated. 
1.8 Aims of the project 
Although both CBF fusion proteins result from a translocation of the RUNX1 
gene it is unclear why the two leukaemia have such strikingly different clinical 
outcomes.  Understanding the precise mechanism of how the two CBF fusion 
proteins programs the epigenome will likely result in an explanation for this 
difference in prognoses of patients with these two mutations. This thesis 
therefore addresses the following open questions: 
How does the gene regulatory cistrome compare between RUNX1-ETO and 
RUNX1-EVI-1 expressing leukaemias? 
The two types of CBF AML differ greatly in their clinical characteristics.  It is 
unknown how this is reflected by differences in gene expression and the 
associated regulatory cistrome.  In this project we will characterise the 
epigenome, using RNA-seq and DNase-seq, of primary t(3;21), t(8;21) AML 
cells,  as well as normal PBSCs. 
How is RUNX1-EVI-1 directed to gene targets? 
RUNX1-ETO direct DNA binding ability has been demonstrated in vivo in 
patients and original cell lines from patients with this translocation.  DNA binding 
activity for RUNX1-EVI-1 has only been demonstrated by in-vitro studies and 
transfected cell lines in which the fusion protein has been over expressed.  We 
will identify RUNX1-EVI-1 binding targets by ChIP-seq and compare RUNX1-
EVI-1 binding sites to RUNX1-ETO targets. 
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What is the role of wild-type RUNX1 in t(3;21 )AML and how does this compare 
to its role in t(8;21) AML? 
Wild-type RUNX1 plays a vital role in RUNX1-ETO driven AML and the 
biological implication and mechanism for this has been carefully elucidated.  In 
t(3;21) leukaemia the binding pattern of RUNX1 as compared to RUNX1-EVI-1 
is unknown.  We aim to characterise RUNX1 binding sites in t(3;21) leukaemia 
by ChIP seq and compare these sites to RUNX1-EVI-1 targets in t(3;21) 
leukaemia as well as to RUNX1 binding sites in t(8;21) cells and in normal 
CD34 PBSCs. 
Is RUNX1-EVI-1 required to maintain the leukaemic phenotype of t(3;21) cells? 
RUNX1-ETO is required to maintain the leukaemic phenotype of t(8;21) AML 
cells.  However, the t(3;21) translocation is often a secondary event in the 
transformation of leukaemic cells and it is unknown whether the expression of 
RUNX1-EVI-1 is required to maintain its leukaemic phenotype.  We will 
characterise the changes to t(3;21) cells after RUNX1-EVI-1 knockdown by 
siRNA. 
What are the shared epigenetic mechanisms between the two CBF fusion 
proteins? 
Our group has previously documented the genome wide epigenetic 
reprogramming events that follow knock down of RUNX1-ETO in t(8;21) cells 
(Ptasinska et al., 2012, Ptasinska et al., 2014).  In this project we will identify 
the epigenetic re-programming events following RUNX1-EVI-1 knockdown in 
t(3;21) cells and identify common features seen following the knockdown of 
both CBF fusion proteins that may enable targeting of both CBF leukaemias. 
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Chapter 2. Methods and Materials  
2.1 Cell line culture 
Cells were maintained in a humidified incubator at 37°C with 5% CO2.  
t(3;21) SKH-1 and K562 cells were cultured in RPMI medium with 10% fetal calf 
serum (FCS) supplemented with glutamine and penicillin/streptomycin.  
t(8;21)Kasumi-1 cells were cultured in RPMI with 15% FCS supplemented with 
glutamine and penicillin/streptomycin.  HEK293T and HeLa cells were cultured 
in Dulbecco Modified Eagle Media (DMEM) with 10% FCS supplemented with 
glutamine and penicillin/streptomycin.   
2.2 Purification of blood samples from patients with AML 
Blood from t(3;21) patient 1 was diluted 1:1 with PBS and layered onto density 
gradient medium (Lymphoprep, Stem Cell technology, USA).  The blood-PBS-
Lymphoprep mix was subsequently centrifuged at 592xg (acceleration setting 4, 
no brakes).  After centrifugation, the mixture had separated into two phases with 
the mononuclear cells separated into a layer in between.  This midlayer was 
then isolated and incubated with 500 µl CD34+ microbeads (Miltenyl-Biotech, 
USA) for 15 minutes,  CD34 microbeads and cells were subsequently 
suspended in 5ml MACS buffer (Phosphate Buffer Saline (PBS) with 2mM 
EDTA and 0.5% BSA) and centrifuged at 300xg at room temperature.  The cell 
pellet was isolated and resuspended in 500 µl of MACS buffer and passed 
through a LS column (Miltenyl-Biotech, USA) placed in a magnetic field, which 
has been pre-rinsed with 2ml MACS buffer.  With the column still on the 
magnetic field, it was rinsed with thrice with 3ml MACS buffer.  The CD34+ cell 
fraction was isolated by removing the column from the magnetic field and 
flushed with 5ml of MACS buffer.  The CD34+ expression on this fraction was 
confirmed by flow cytometry before either immediate use for DNaseI 
hypersensitivity site mapping or RNA extraction by Trizol, as described below.  
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Cells from t(3;21) patient 2 was previously isolated by density gradient medium 
and cryopreserved at the Erasmus University Medical Centre, Netherlands.  
CD34+ cells were thawed with pre-warmed RPMI-1640 +10% FCS.  After 
centrifugation, the cell pellet was re-suspended in 750 µl MACS buffer (PBS 
with 0.5% BSA and 2mM EDTA) and 35µl CD34-PE, with a separate sample 
stained with IgG PE as an isotype control.  CD34+ cells were isolated by FACS 
using a MoFlo Astrios (Beckman Coulter, USA) and were then directly used for 
DNaseI hypersensitivity site mapping or underwent RNA extraction by Trizol, as 
described below.  
2.3 Purification of CD34+ mobilised peripheral blood stem cells 
CD34+ peripheral blood stem cells (PBSCs) from healthy adults were mobilised 
into the peripheral circulation by administrating donors with pegylated G-CSF 
(trade name: Lenograstim, Chugai Pharmaceuticals, Japan),  Suitable patient 
donors were identified by the NHS Blood and Transplant service (NHSBT).  
Cells were harvested from the patients by apheresis and stored by NHSBT in 
liquid nitrogen.  Cryopreserved cells were thawed at 37ºC using a waterbath 
and eluted from storage bag with a PBS/Glucose/Citrate solution (0.09% 
glucose + 3.3% FCS + 1mM sodium citrate).  After centrifugation at 300xg for 5 
minutes, the cell pellet was treated with DNaseI (Roche, Switzerland) at 
0.6mg/ml concentration in PBS/Glucose/Magnesium/Calcium solution (PBS+0.5 
mM MgCl2 + 1.2 mM CaCl2)  + 1 % FCS + 0.1 % glucose + 2 mM MgCl2) for 5 
minutes at room temperature.  Following DNaseI treatment the cells were once 
again diluted with PBS/Glucose/Citrate solution and the mononuclear layer 
isolated by density gradient medium and CD34+ beads separation by MACs 
columns, as described above.  
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Table 2-1 Details of patient samples. 
Details of patient samples included in this study.  t(8;21) patient 1 and 2 was processed before the commencement of this 
study.   
Lab name ID White 
cell 
count 
Separation 
method 
Age  Sex Stage of treatment Cytogenetics Clinical notes Mutations 
Birmingham 
GT027 
t(3;21) 
1 
23 MACS 44 F Presentation 46,XX,t(3;21)(q26
;q22),der(5)t(5;13)
(q2;q3),der(7)t(1;7
)(q3;q3[5]/47,idem
,+12,+der(21)t(3;2
1)[4] 
Therapy related AML 
(previous Myelofibrosis 
and T cell lymphoma) 
KRAS 
Rotterdam 
5354 
t(3;21) 
2 
54 FACS 72 M Presentation 46,XY,t(3;21)(q26
;q22),del(12)(p12
p13)[20] 
RAEB-t DNMT3, 
SRSF2 
H12812 t(8;21) 
1 
2.12 MACS 45 M Presentation 46,XY,t(8;21)(q22
;q22) 
AML - 
H18909 t(8;21) 
2 
53 MACS 53 M Presentation 46,XY,t(8;21)(q22
;q22) 
AML CBL, FLT3 
TKD 
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J209/R423 PBSC 
1 
N/A MACS 51 M N/A N/A Mobilised PBSCs- sibling 
donor for allogeneic stem 
cell transplant 
N/A 
J299/R454 PBSC
2 
N/A MACS 47 F N/A N/A Mobilised PBSCs- 
autologous stem cell 
transplant (CNS 
lymphoma) 
N/A 
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2.4 Culturing CD34+ mobilised peripheral blood stem cells 
Human CD34+ peripheral blood stem cells (PBSC) were maintained with Iscove 
Modified Dulbecco Media (IMDM) with 20% BIT9500 serum substitute (Stem 
Cell Technologies, US) with IL-3, IL-6, SCF, TPO, FLT3-L at 10ng/ml and SR1 
1µM (Stem Cell Technologies, US). 
2.5 siRNA mediated depletion of RUNX1-EVI-1 
1x107 cells were electroporated using an EPI 3500 (Fischer, Germany) 
electroporation at 350v, 10ms.  siRNA sequences (Axolabs, Germany) specific 
for the translocation breakpoint of Runx1-Evi-1 were 5'-
GAACCUCGAAAUAAUGAGUGU-3' (sense) and  5'-
ACUCAUUAUUUCGAGGUUCUC-3' (antisense).  Control siRNA was 5’-
CCUCGAAUUCGUUCUGAGAAG-3’ (sense) with 5’-UC 
UCAGAACGAAUUCGAGGUU-3’ (antisense).  siRNA was used at 200nM.  
After electroporation, the cells remained in their cuvettes for 5 minutes before 
being directly added to RPMI-1640 with 10% FCS, supplemented with 
penicillin/streptomycin and glutamine at a concentration of 0.5 x106 cells per ml 
and returned to an incubator kept at 37°C and 5% CO2. 
2.6 RNA extraction  
Pelleted cells from primary patient material were lysed by adding 1ml Trizol ™ 
(Life Technologies, US).  200µl of chloroform was added and the mixture was 
manually shaken for 15 seconds.  The mixture was incubated at room 
temperature for 3 minutes. The mixture was centrifuged at 12000xg for 15 
minutes at 4°C.  The top clear aqueous phase was removed and placed in a 
fresh tube.  0.5ml of 100% isopropanol was added to the isolated aqueous 
phase and incubated at room temperature for 10 minutes which was then 
transferred to a RNeasy Minielute column (Qiagen, USA) and centrifuged for 
15s at 8000xg. 350µl of RWI buffer from the RNeasy Kit was added to the 
column and centrifuged for 15s at 8000xg.  DNaseI 10µl and 70µl RDD buffer 
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(Qiagen, USA) were mixed and added to the column and incubated for 
15minutes at room temperature.  Afterwards, 350µl of RWI buffer from RNeasy 
Kit (Qiagen, USA) was added to the column and centrifuged for 15s at 8000xg.  
Following this 500µl of RPE buffer was added and centrifuged for 15s at 
8000xg.  The column was washed with 500µl 80% ethanol and centrifuged at 2 
minutes at 8000xg.  The column was dried by centrifugation at 5 minutes at 
8000xg.  RNA was eluted from the column by adding 12µl of water to the 
column followed by centrifugation at 5 minutes at 8000xg. 
RNA was isolated from SKH-1 cells by TrizolTM (Life Technologies, US) as by 
manufacturer’s instructions.  At the last step of the protocol RNA was 
resuspended in 17µl of RNAse free water to which was added 2µl of 10x buffer 
supplied with the Ambion Turbo DNaseI (Thermos Scientific, USA), of which 1 
µl was added.  All of which was incubated at 37ºC for 30 minutes.  The RNA 
solution was then purified using a Nucleospin RNA clean up column (Machery 
Nagel, France), according to their instructions.   The quality of RNA from all 
methods was assessed using a spectrophotometer, by the ratio of the 
absorbance at 260nM and 280nM wavelengths. RNA has a greater absorbance 
in the 260nM wavelength, Eukaryotic Total RNA PICO Bioanalyser chip (Agilent 
technologies, USA) allows visualisation of the size of the RNA molecules and 
thus, demonstrates whether the sample is degraded or not.   
2.7 RNA Seq library 
RNA-seq libraries were prepared with a Total RNA Ribo-zero library preparation 
kit (with ribosomal RNA depletion) (Illumina, USA) according to manufacturer’s 
instructions with the following alterations: 15 cycles of PCR was undertaken to 
amplify the library and adaptors for multiplexing were used at a 1:4 dilution.  
Library quality was checked by running the samples on a Bioanalyser and 
libraries were quantified using a Kapa library quantification kit (Kapa 
Biosystems, USA) and run in a pool of eight indexed libraries in two lane of a 
HiSeq 2500 (Illumina, USA) using rapid run chemistry with 100bp paired end 
reads. 
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2.8 cDNA synthesis 
1μg RNA was used to make cDNA with 0.5 μg OligoDT primer, Murine moloney 
reverse transcriptase and RNase Inhibitor (Promega, USA) according to the 
manufacturer’s protocol.   
2.9 Real-time polymerase chain reaction 
RT-PCR was performed using Sybr Green mix (Applied Biosystems, UK), at 2x 
dilution.  Primers were used at 100nM final concentration. cDNA was diluted 
either 1:10 or 1:50 depending on expression levels of targets.  A 7900HT 
system (Applied Biosystems, UK) was used to perform qPCR.  Analyses were 
performed in technical duplicates using a standard curve derived from RNA 
purified from the untreated cell line (1:10 followed by 1:5 dilutions).  Primer 
sequences are listed in the Appendix. 
2.10 Dead cell removal and Annexin V/PI staining for flow 
cytometry 
Dead cell removal was performed using negative selection on a MS column 
following incubation with Dead Cell Removal microbeads (Miltenyl Biotech, 
USA) as per manufacturer’s instructions.  Dead cell removal was performed on 
all samples prior to RNA extraction or DHSs mapping.  Annexin V-APC/PI 
staining (Ebiosciences, USA) or Annexin V-FITC/PI staining (BD Biosciences, 
USA) was performed according to manufacturer’s instructions.  Annexin V-APC 
staining was used for cells that expressed GFP (e.g. CEBPA-ER retrovirus 
transduced SKH-1), thereby preventing quantification of Annexin V-FITC 
surface staining, which were used for all other experiments.   
2.11 DNaseI hypersensitivity site mapping and size selection 
Prior to DNaseI digestion, apoptotic cells were removed using the Dead Cell 
Removal Kit (Miltenyl Biotech, UK) as per manufacturer’s instructions.  3x 107 
SKH-1 cells were suspended in 1ml DNase I buffer (0.3M sucrose, 60 mM KCl, 
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15 mM NaCl, 5 mM MgCl2, 10 mM Tris pH7.4).  Digestion on 4.5x106 cells was 
performed with DNase I (Worthington, DPPF grade) at 80 units/ml in DNase I 
buffer with 0.4% NP-40 and 2mM CaCl2 at 22ºC for 3 minutes.  The reaction 
was stopped with cell lysis buffer (0.3M NaAcetate, 10mM EDTA pH 7.4, 1% 
SDS) with 1mg/ml Proteinase K and incubated at 45ºC overnight.        
For DHS mapping in CD34+ purified t(3;21) patient cells and in SKH-1 
transfected with siRNA, lower cell numbers were available and therefore the 
DNaseI concentrations were reduced according to the cell numbers available: 
Sample Cell number per 
digestion 
Final concentration of 
DNaseI (units/ml) 
t(3;21) patient 1 1.1x106 9  
t(3;21) patient 2 350x103 3  
SKH-1 transfected with 
siRNA 
2.25x106 35 or 45  
 
The digested DNaseI material was treated with RNAseA (Sigma Aldrich, 
Germany) at a final concentration of 100µg/ml at 37ºC for 1 hr.  Genomic DNA 
was extracted using phenol/chloroform method: an equal volume of phenol was 
added to the reaction and placed on a rotator wheel for 45 minutes.  This was 
centrifuged for 5 minutes at 16000xg at room temperature. The top layer was 
transferred to a new tube and the process was repeated sequentially with 
phenol/chloroform and chloroform.  After purification by chloroform extraction, 
genomic DNA was precipitated with ethanol.  This was pelleted by 
centrifugation for 5 minutes, at 16000xg at 4°C.  The pellet was resuspended 
with 70% ethanol and centrifugation for 5 minutes, at 16000xg at 4°C.  The 
pellet was air-dried and dissolved by Tris-EDTA (40mM Tris Acetate 1mM 
EDTA). 
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DNaseI preferentially cleaves DNA in open chromatin regions (figure 1-2), but 
samples can be over digested by the nuclease, whereby heterochromatin and 
gene body regions may become digested as well.  Digestion was checked 
visually by running the samples on a 0.7% agarose gel (Figure 2-1 A), and by 
RT-PCR evaluating the ratio of open (TBP promoter) to closed regions of DNA 
(chromosome 18) and active gene body (beta-actin) to prevent selection of over 
digested samples (primers in appendix).  Optimal digestion is seen in samples 
where qPCR signal of TBP promoter is high as compared to the β-actin gene 
body or heterochromatin represented by chromosome 18.  Subsequently, 
between 2 to 10µg of DNaseI digested DNA (depending on material available) 
were run on a 1.2% agarose gel for selection of shorter fragments to increase 
the fraction of fragments captured from DHSs.  This is because nuclease 
cleavage is increased in open chromatin regions and therefore releases more 
short fragments, whilst longer fragments come from heterochromatin regions 
which are cleaved by nucleases at lower efficiency (figure 1-2 and figure 2-1E).  
Prior to loading on gel, the purified DNA was treated again with RNAseA (Sigma 
Aldrich, USA) at a final concentration of 100µg/ml at 37ºC for 1 hr.  50-300bp 
fragments were isolated and purified from the gel using a minielute gel 
extraction kit (Qiagen, USA) as per manufacturer’s instructions and validated by 
qPCR as before (Figure 2-1 B-C).  Following this, the size selected sample was 
validated again by RT-PCR, this time using shorter amplicons to enable 
detection of the shorter fragments enriched by the size selection process. 
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Figure 2-1 DNaseI treatment, size selection and NGS library preparation 
DHS mapping in untreated SKH-1.  
A) 0.7% agarose TAE gel, visualised with ethidium bromide, with DNaseI 
treated DNA run alongside a 1kb ladder (New England Biosciences, USA) with 
the 10kb marker labelled.  Each well was loaded with a digest made with a 
different concentration of DNaseI.  DNaseI concentrations used for each digest, 
increasing from 20u/ml to 80u/ml, are denoted above the gel.   
B) Size selection of DNaseI treated DNA.  Three digests made with different 
concentrations of DNaseI (60, 70 or 80u/ml) were loaded in the gel.  100bp 
ladder (New England Biosciences, USA) with the 300bp marker labelled.  50-
350bp fragments excised from the 1.2% agarose TAE gel.    
C) Validation by qPCR with amplicons corresponding to TBP promoter, β-actin 
gene body and chromosome 18 (negative control).  Fragments from 60, 70 or 
80u/ml DNaseI digested DNA were isolated by gel purification and used as 
templates for the qPCR experiments.  Vertical axis denotes ratio of β-
actin/chromosome 18, TBP/ β-actin or TBP/Chromosome 18. 
D) Library for NGS after 15 cycles of amplification loaded in wells in a 2% 
agarose TAE gel: excision of short 190-250bp fragments (sequenced) and 
longer fragments 250-350bp (not sequenced).  Input for library synthesis were 
size selected fragments from either 70 or 80u/ml digested DNA. Run alongside 
the samples was a 100bp ladder (New England Biosciences, USA) with the 
300bp marker labelled. 
E) Final qPCR validation of NGS library. Amplified, index-ligated material was 
gel purified as shown in D) and was used as a template for the qPCR validation.  
Results for “short’ fragments (190-250bp) alongside “long” fragments (250-
350bp) for comparison.  Short fragments are enriched from DHSs as nucleases 
cleave accessible DNA more efficiently than, inaccessible DNA (chromosome 
18) or less accessible DNA (β-actin gene body).  Hence, the ratio of both TBP/ 
β-actin and TBP/Chromosome 18 are higher in the shorter fragments than in the 
longer fragments. 
 
2.11.1 Library production of DNaseI material for high 
throughput sequencing 
A library suitable for high-throughput sequencing was prepared for untreated 
SKH-1 as follows.  The sample was purified by using a minielute PCR clean up 
kit (Qiagen, USA) in between the following steps.  All the enzymes used in 
library preparation were from New England Biolabs, USA.  Overhanging strands 
of DNA were repaired by Klenow large fragment polymerase, T4 polynucleotide 
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kinase and T4 DNA polymerase in ligase buffer with deoxynucleotides.  PCR at 
20 ºC for 30mins was undertaken.  Adenosine (0.2mM deoxyadenosine 
nucleotide) was added to 3’ ends by incubation with Klenow fragment (5’-3’ 
polymerase with 3’-5’ exonuclease only, in order to fill in blunt ends), in NEB 
Buffer 2, at 37 ºC for 30mins.  Illumina single read adaptors (part #1000521) 
used at 1/25 dilution were ligated to the fragments with T4 DNA ligase.  
Amplification of the library was performed by PCR using Phusion hot start 
polymerase with adaptor specific primers: 98°C for 30s, then 15 cycles of 98°C 
for 10s, 65°C for 10s, 72°C for 30s, finished with 72°C for 5 minutes.  This 
material was run on a 2% agarose gel and 180-250bp fragments were isolated 
using the Minielute gel extraction kit as above.  By concentrating shorter, sub-
nucleosomal fragments into the NGS library, the number of cleavage fragments 
from within DHSs which are sequenced are increased (Figure 1-2, 2-1 D-E).  At 
this stage the fragment size includes the adaptor sequences, 65bp in length, 
which is required to de-multiplex reads and to attach to the flow cell for cluster 
generation. 
Purified t(3;21) patient CD34+ blasts (t(3;21) patient 1) were treated with 
DNaseI.  After size selection, a library was prepared using Tru-seq DNA sample 
preparation kit (Illumina, USA) as per manufacturer’s protocol, except after 
adaptor ligation, one round of Ampure bead purification (Beckman Coulter, 
USA) was performed instead of two and no purification after PCR was 
performed before size selection of the 180-250bp fraction by agarose gel .   
Ampure bead purification was performed by mixing a ratio of 1.8:1 beads to 
reaction volume, then the beads were washed twice with 70% ethanol and the 
DNA was eluted off the beads with 50 μl water.                                                                                                                                                                                                                                                                                                                                                 
Finally, size selected DNaseI treated material from t(3;21) patient 2 and SKH-1 
transfected with RUNX1-EVI-1 or control siRNA was prepared for NGS using 
Microplex library preparation kit (Diagenode, Belgium).  14 cycles of PCR were 
used for t(3;21) patient 2 and 10-12 cycles of PCR for siRNA transfected SKH-1 
cells.  A final size selection step was performed by running the library on 1.5% 
TAE gel, followed by excision of 190-250bp sized gel fragment. 
   
 66 
The quality of the libraries was assessed on an Agilent 2100 bioanalyser.   
Libraries were subsequently run on two lanes of an Illumina Hiseq flow-cell for 
transcription factor footprinting, or as part of 12 indexed libraries in one lane of a 
NextSeq500 (Illumina, USA) for DHS mapping alone. 
 
2.12 ChIP-qPCR and ChIP-seq library preparation 
2.12.1 Double cross-linking  
A double cross-linking technique was used to optimise the efficiency of 
transcription factor chromatin immunoprecipitation (ChIP).  2 x 107 cells were 
washed thrice in PBS.  Di(N-succinimidyl) glutarate (DSG) (Sigma-Aldrich, 
Germany) at 850μg/ml was added to 2x106 cells per ml and were incubated for 
forty-five minutes.  Cells were washed four times and fixed with 1% 
formaldehyde (Pierce, Thermos Scientific, USA) for ten minutes.  Glycine to 
produce a final concentration of 100mM was added to stop the reaction.  The 
pellet was washed again with PBS.  Buffer A (HEPES pH 7.9 10mM, EDTA 
10mM, EGTA 0.5mM, Triton x100 0.25%, complete mini protease inhibitor 
cocktail (PIC) 1x (Sigma-Aldrich, Germany) was added for 10mins at 4°C and 
removed by centrifugation at 500g for 5 minutes.  This was repeated with buffer 
B (HEPES pH 7.9 10mM, EDTA 1mM, EGTA 0.5mM, Triton x100 0.01%, PIC 
1x).  The residual nuclei were then spun down at 16000xg at 4°C for 5 minutes 
and aliquoted at 2x107 cells for 4 immunoprecipitations.   
2.12.2 Chromatin immunoprecipitation (ChIP) 
Each aliquot of 2x107 cells was resuspended in 600μl of sonication buffer (Tris-
HCL pH8 25mM, NaCl 150mM, EDTA 2mM, Triton 100x 1%, SDS 0.25%, PIC 
1x).  300μl of nuclei in sonication buffer was placed in each polystyrene tube 
and sonicated at 75% amplitude, 26 cycles: 30s on and 30s off per cycle (Q800, 
Active Motif, USA).  Subsequently, 1.2ml of dilution buffer (Tris-HCL pH8 
25mM, NaCl 150mM, EDTA 2mM, Triton 100x 1%, glycerol 7.5%, PIC 1x) was 
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added to the pooled post sonication material.  This was divided equally between 
four immunoprecipitations (with 5% of input taken for validation).   
15μl protein G beads (Diagenode, Belgium) were washed twice with 500μl of 
50mM citrate phosphate buffer and once with 100mM sodium phosphate).  2μg 
antibody (EVI-1, C50E12, Cell signalling, lot 3; or RUNX1, Ab23980, Abcam lot 
144722) or 4µg antibody (C/EBPα,  A2814 Santa Cruz) was added to 10 μl 
100mM sodium phosphate, 0.5% BSA and incubated with protein G beads at 
4°C for 1 hour.  Chromatin was then added to the protein G beads with antibody 
and returned to 4°C for 4 hours.  Unbound chromatin was separated from the 
beads by magnet and the attached beads were washed by buffer 1 (Tris HCL 
20mM, NaCl 150mM, EDTA 2mM, Triton x100 1%, SDS 0.1%), twice with buffer 
2 (Tris HCL 20mM, NaCl 500mM, EDTA 2mM, Triton x100 1%, SDS 0.1%), LiCl 
buffer (Tris HCL 10mM, LiCl 250mM, EDTA 1mM, NP40 0.5%, sodium 
deoxychlolate 0.5%) and finally twice with wash buffer 4 (Tris HCL pH8, 10mM, 
NaCl 50mM, EDTA 1mM).  The column was eluted twice with 50 μl buffer 
(NaHCO3 100mM and SDS 1%) and the eluant containing the chromatin was 
pooled.  Crosslinks were reversed by incubating the samples at 65°C overnight 
in 500mM NaCl, 500 μg/ml proteinase K.  DNA was purified by Ampure beads 
(Beckman Coulter, USA), as above, with the DNA eluted off with 50μl water.  
Validation of the ChIP was performed by qPCR using a standard curve of 
genomic DNA from untreated SKH-1 cells (10ng/μl followed by serial 1:5 
dilutions).  The input material was diluted 1:5 with water and qPCR was 
performed as above with primers listed in appendix.  Validation was analysed 
as a ratio of the qPCR signal from the ChIP material over the input. 
2.12.3 Library production of ChIP material for high throughput 
sequencing 
Libraries for high throughput sequencing were prepared using the Tru-seq DNA 
sample preparation kit (Illumina, USA) or Kapa HyperPrep kit (Kapa 
biosystems, USA), as per manufacturer’s protocol.  18 cycles of PCR was 
performed and 200-350bp fragments were size selected by running the samples 
in an agarose gel.  Libraries were validated by qPCR, with an analysis of the 
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ChIP signal of a positive control region (e.g. PU.1 3H enhancer) over a negative 
control region (e.g. IVL).  Finally, libraries were quantified by Kapa library 
quantification kit (Kapa biosystems, USA) and run in a pool of four indexed 
libraries in one lane of a HiSeq 2500 (Illumina, USA) or 12 indexed libraries in 
one lane of a NextSeq 500 (Illumina, USA) using 50 cycle single-end reads. 
2.13 Cloning of RUNX1-EVI-1 into pSiew and LeGO vectors 
The pME18s-RUNX1-EVI-1 plasmid was a gift of Dr K Mitani (Dokkyo Medical 
University, Japan).  RUNX1-EVI-1 was amplified from the pME18s-RUNX1-EVI-
1 plasmid by PCR; 10ng of template and Phusion polymerase (NEB, USA) with 
3% DMSO.  Amplification conditions were 98 °C 30s, followed by 5 cycles of 
98°C 10s, 60°C 30s and 68°C 150s, followed by 25 cycles 98°C 10s, 68°C 30s 
and 72°C 150s, finished with 72°C 10mins. Primers incorporated a Bam-HI (5’) 
and NotI (3’) site.  The PCR product was purified by Ampure beads (Beckman 
Coulter, USA) as above, except material was eluted off with 40μl water.  1 μg of 
purified PCR product was digested with 10 units of NotI and BamHI.  The post 
digestion product was cleaned again by Ampure beads and was ligated to an 
empty LeGO-IG vector (gift from Boris Fehse, Hamburg, Germany) by T4 DNA 
ligase (NEB, USA) in a 3:1 digest to vector ratio.  Ligated vector was used to 
transform chemically competent TOP10 E.Coli (Life Technologies, UK) which 
was spread onto ampicillin containing agar.  DNA from picked colonies was 
purified with a silica-based column (Qiagen, USA) and inserts were confirmed 
by Sanger sequencing. 
To clone RUNX1-EVI-1 into the pSIEW vector, RUNX1-EVI-1 was amplified 
from the LeGO-IG vector using the PCR conditions as above, but this time with 
primers that incorporated an AscI (5’) and Bam-HI (3’) site.  The PCR product 
was purified by Ampure beads as above.  10 units of AscI and Bam-HI were 
used to digest the empty pSIEW vector and PCR product at 37ºC for 1 hour.  
The post digestion product was cleaned again by Ampure beads and was 
ligated to an empty vector by T4 DNA ligase (NEB, USA) in a 3:1 digest to 
vector ratio for 10 minutes at room temperature.  Ligated vector was used to 
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transform chemically competent TOP10 E.Coli (Life Technologies, UK) which 
was spread onto ampicillin containing agar.  DNA from picked colonies was 
purified with a silica-based column (Qiagen, USA) and inserts were confirmed 
by Sanger sequencing. 
pSIEW empty vector, pSIEW RUNX1-ETO and pSIEW DNCEBP vector was a 
gift from Olaf Heidenreich (Newcastle, UK) (Bomken et al., 2013).  The 
DNCEBP insert was originally developed by Charles Vinson (NIH, USA) (Krylov 
et al., 1995).  The CEBPA-ER plasmid was a gift of Thomas Graf (Barcelona, 
Spain) (Bussmann et al., 2009).  Schematic of regions flanked by LTR in the 
viral vectors shown in figure 2.    
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Figure 2-2 Schematic of viral vectors  
LTR-long terminal repeats: enables integration of intervening sequence into 
host genome.  cPPT: central polypurine tract recognition site for pro-viral DNA 
synthesis, increases transduction efficiency.  WPRE:  Woodchuck hepatitis 
virus post‐transcriptional regulatory element increases nuclear export of 
transgene.  IRES: internal ribosomal entry site allows synthesis of GFP.  sFFV: 
spleen focus forming virus promoter.  U6 promoter: allows cloning of shRNA if 
required. 
  
2.14 Retroviral production 
Lentiviruses are a part of the retrovirus family, and in this project pSIEW vector 
backbone (Empty, RUNX1-ETO, RUNX1-EVI-1 and DNCEBP) produces 
lentiviral particles.  Packaging and envelope genes are on a separate plasmid to 
prevent further virus particle generation once transduced into the target cell. In 
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this project we also used CEBPA-ER plasmid to produce γ-retrovirus particles, 
and these require different viral packaging plasmids and transduction method 
as will be described below. 
2.14.1 Transfection of HEK293T cells for lentiviral production  
HEK293T cells were re-plated 24 hour prior to transfection, so that at time of 
transfection they were 80-90% confluent.  On the day of transfection TransIT-
293T (Mirius, USA) was brought to room temperature.  Trans-IT-293T forms a 
complex with DNA plasmids to enable transfection into cells.  A DNA mix was 
made from plasmids (Backbone vector containing transgene 30µg, and the 
packaging vectors: Tat 1.2µg, Rev 1.2µg, Gag/Pol 1.2µg, VSV-G 2.4µg (gift 
from George Murphy, Boston, USA) (Sommer et al., 2009).  For each 15cm2 
2ml of Optimem serum free media was mixed with 90µl of TransIT-293 (Mirius, 
USA).  This was allowed to rest at room temperature for 15 minutes.  DNA mix 
was added to the TransIT-293 mixture and was left at room temperature for a 
further 15 minutes.  Fresh DMEM with 10% FCS supplemented with glutamine 
and penicillin/streptomycin was exchanged with previous media on the 
HEK293T plates.  The TransIT-293 – DNA mixture was then added dropwise to 
the HEK293T plate.  Viral supernatant was collected after 48 hours and 
subsequently every 12 hours for 36 hours. 
2.14.2 Transfection of HEK293T cells for CEBPA-ER virus 
production 
HEK293T cells and TransIT-293T (Mirius, USA) was prepared as above.  DNA 
mix was made from plasmids (Backbone vector containing transgene 36µg, Tat 
1.2µg, Gag/Pol 30µg, Env 9µg (gift from James Mulloy, Cincinnati, USA) and 
was sufficient for 3x 10cm2 dish.  For each 10cm2 dish 1.5ml of Optimem serum 
free media was mixed with 75µl of TransIT-293.  This was allowed to rest at 
room temperature for 15 minutes.  DNA mix was added to the TransIT-293 
mixture and was left at room temperature for a further 15 minutes.  Fresh 
DMEM with 10% FCS supplemented with glutamine and penicillin/streptomycin 
was exchanged with previous media on the HEK293T plates.  The TransIT-293 
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– DNA mixture was then added dropwise to the HEK293T plate.  Viral 
supernatant was collected after 48 hours and subsequently every 12 hours for 
36 hours. 
2.14.3 Virus concentration 
The virus concentration technique was the same for all viral particles.  Viral 
supernatant was centrifuged at 1660xg 4°C 15 minutes to pellet cell debris. The 
supernatant was then filtered through a 0.45m disc filter. 
The viral supernatant was concentrated using ultracentrifugation 120000xg for 2 
hours 4°C in a SW28 rotor in an OptimaTM 100k-XL centrifuge (Beckman 
Coulter, USA).  The supernatant was poured off and the viral pellet was re-
suspended with the residual fluid.  Alternatively the viral supernatant was 
concentrated using a Centricon Plus-70 100kDa filter (Millipore, USA), using the 
manufacturer’s instruction.  The column was pre-rinsed with sterile water and 
the column centrifuged at 2000xg, 25 minutes at 4 degrees.  The column was 
then inverted and the concentrate recovered by centrifugation at 1000xg for 2 
minutes. 
2.14.4 Titration of viruses on HEK293T cells 
Viruses were titrated before transduction of CD34+ PBSCs.  1x105 HEK293T 
cells were plated in each of 24 well plates 24 hours prior to transduction.  On 
day of transduction viral concentrate was serially diluted 1:10 with media and 
media in the wells replaced with 450l of fresh media.  50l of the concentrate 
and subsequent 1:10 serial dilutions was added to the HEK293T cells.  
Polybrene at a final concentration of 8g/ml was also added prior to 
spinoculation at 1500xg for 2 hours at 32°C.  The principle of spinoculation is 
that through centrifugal force, viral particles and the cells due for transduction 
co-localise, thereby increasing the odds of viral entry into the cells.  The plate 
was subsequently returned to the incubator overnight and at the next morning 
the viral media was removed and exchanged with fresh media.  Viral 
transduction was estimated by eGFP percentage by flow cytometry 5 days after 
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viral transduction.  Cells were washed with PBS and fixed with 1% 
formaldehyde for 10 minutes at room temperature.  After washing again, the 
cells were detached by washing with PBS and taken to the flow cytometer.  
Dilution points with 1-20% eGFP positive cells were used to estimate the viral 
titre.  At least an average of two dilutions is required for an accurate estimate. 
eGFP-titre formula: Transducing Units/ml = (F × N)/ (100 × V × Df), 
F=percentage of eGFP positive cells (in %) 
N=number of cells spinoculated (1x105 in this example) 
V= Volume of diluted viruses added to each well (50l in this example) 
Df=dilution factor of the viral concentrate at to each wells (x1 for the first well in 
this example) 
2.14.5 Lentiviral transduction of CD34+ PBSCs and SKH-1 
Cryopreserved CD34+ PBSCs were thawed with warmed IMDM with 20% 
BIT9500 serum substitute.  The CD34+ PBSCs were incubated overnight in 
IMDM with serum substitute with cytokines and SR1 mix as described above in 
section 2.4. 
CD34+ were transduced with viral concentrates (at a MOI of up to 36) with 
polybrene at 4g/ml by spinoculation at 1500xg for 2 hours at 32°C in non-
tissue culture treated plates.  The plate was subsequently returned to the 
incubator overnight and at the next morning the viral media was removed and 
exchanged with fresh media.  Viral transduction was estimated by eGFP 
percentage by flow cytometry 5 days after viral transduction.  Cell sorting by 
FACS was undertaken by staining with either CD34-PE or CD34-APC (both 
Miltenyl Biotech, UK) and corresponding isotype control. 
SKH-1 cells were transduced with lenitviruses (pSIEW empty vector or pSIEW 
DNCEBP) in the same manner, except polybrene was used at 8µg/ml.  Cell 
sorting for GFP positive cells was undertaken by FACS. 
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2.14.6 Retroviral transduction with Retronectin 
CEBPA-ER vector required RectroNectin (recombinant human fibronectin 
fragment, Takara, Japan) assisted transduction.  RectroNectin has two domains 
that allow binding to a target cell expressing the integrin VLA-4 or VLA-5, but 
also has a third domain that enables binding to viral particles 
((http://www.clontech.com/GB/Products/Viral_Transduction/Hematopoietic_Cell
_Transduction/ibcGetAttachment.jsp?cItemId=61561&fileId=6521143&sitex=10
030:22372:US),  accessed 3rd September, 2016).  Non-tissue culture treated 6 
well plate was incubated with 2ml RetroNectin solution in PBS at 24µg/ml for 2 
hours at room temperature. The RectroNectin solution was subsequently 
removed and the plate blocked with 2ml PBS with 2% BSA for 20minutes at 
room temperature.  Finally, the PBS/BSA solution was removed and the wells 
washed with 2ml Hank Balanced Salt solution containing 2.5% HEPES. 
Concentrated virus was coated onto the wells by centrifugation for 45 minutes 
at 2000xg at room temperature.  Virus loading was repeated once more before 
1x106 SKH-1 cells, in media mixed with concentrated virus (50:50 ratio), at a 
final concentration of 0.5x106 /ml was added to the wells with polybrene at 
8µg/ml.  The plate was left overnight at 37ºC, 5% CO2 in a humidified incubator.  
On the next day, the cells were centrifuged at 300xg at room temperature for 5 
minutes and the cells were re-suspended in standard RPMI 1640 with 10% 
FCS, supplemented with penicillin, streptomycin and glutamine.  CEBPA-ER 
transduced SKH-1 cells were isolated by FACS using GFP labelling. 
2.15 Titrating 17 β-estradiol treatment of CEBPA-ER SKH-1 cells 
CEBPA-ER plasmid encodes a C/EBPα protein fused to an oestrogen receptor 
ligand binding domain.  Upon binding to estradiol, the fusion protein can 
translocate into the nucleus (Umek et al., 1991).  We tested different 
concentrations of 17 β estradiol (Sigma Aldrich, Germany), after 48 hour 
exposure, on CEBPA-ER SKH-1, using expression of CD11b APC by flow 
cytometry as a read-out.  
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Figure 2-3 Titration of 17β-Estradiol on CEBPA-ER SKH-1 cells 
Flow cytometry of mock treated or CEBPA-ER transduced SKH-1 cells treated 
for 48 hours with either vehicle only (ethanol) or 17β-Estradiol.  Cells stained 
with CD11b-APC.  CEBPA-ER vector contains a sequence encoding GFP. 
A) Flow cytometry plot showing percentage of SKH1 cells in each quadrant B) 
Graph showing CD11b positive percentage of total cells following titration of 
doses of 17β-Estradiol after 48 hours. 
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2.16 Methylcellulose colony forming culture assay of CEBPA-
ER cells. 
Mock transduced and CEBPA-ER transduced SKH-1 cells were kept at 
0.25x106 cells per ml and treated with either 10nM 17β-Estradiol or equivalent 
volume of ethanol for 48 hours.   
IMDM with 2.6% methylcellulose premixed was obtained from Stem Cell 
Technologies, USA (H4100 methocult).  To 1.2ml of pre-mixed media, a further 
1.2ml of IMDM, and 600μl of heat-inactivated FCS were added, HEPES (Sigma 
Aldrich, Germany) was also added for a final concentration of 25mM.  17β-
estradiol was added for a final concentration of 10nM, and in the comparative 
assay an equal volume of ethanol was added.     
To each 3ml mixture of methylcellulose, IMDM and FCS 15000 cells were 
added and were shaken vigorously.  1.1ml of this mix of cells and 
methylcellulose media was added to a 35mm non-tissue culture treated dish, in 
duplicate.  These small dishes were subsequently placed in a larger 150mm 
plate humidified by a well in the centre containing sterile water.  These dishes 
were kept in an incubator at 37°C and 5% CO2.  Colonies of more than 20 cells 
were counted after 7-10 days and for each experiment an average was taken of 
the two replicates.    
2.17 Antibody staining for flow cytometry 
15x104 were centrifuged at 300xg and washed with MACS buffer.  The cell 
pellet was resuspended in 50µl MACS buffer and 2µl of antibody was added 
and incubated for 15minutes at 4ºC in the dark.  After incubation, the cells was 
washed once with MACS buffer before resuspension in 300µl MACS buffer and 
analysed on Cyan ADP (Beckman Coulter, USA).  Data was analysed on 
Summit 4.3 (Beckman Coulter, USA).  Antibodies used in this project are listed 
below. 
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2.18 Whole cell lysate preparation by RIPA buffer lysis 
Whole cell lysate was made by lysing 5x106 cells using RIPA buffer (50 mM Tris 
pH7.4, 150 mM NaCl, 0.25% Na-deoxycholate, 1% NP40, 1mM PMSF, 
complete mini protease inhibitor cocktail (PIC) 1x (Sigma-Aldrich, Germany)).  
After incubation on ice for 15 minutes, the sample was sonicated for 1 min using 
a Bioruptor (Diagenode, Belgium) at 4°C.   
2.18.1 Quantification by Bradford reagent 
Protein extracts were quantified using Bradford protein reagent (Bio-Rad, USA) 
and 595nM absorbance quantified by spectrophotometry. Absolute 
concentrations were determined using a standard curve from a known 
concentration of BSA (Pierce, USA). 
2.19 Nuclear extract 
Nuclear extracts were prepared using a co-immunoprecipitation kit (Active Motif, 
USA).   
2.20 Western blotting  
Cell lysate or nuclear extracts was run on an acrylamide gel and transferred to 
nitrocellulose membrane.  This was probed with the antibodies described in the 
appendix.   Enhanced chemiluminescence by SuperSignal PICO (Thermos 
Scientific, USA) was used to develop the membrane.  Chemiluminescence was 
detected using either developer or Chemidoc XRS system (BioRad, USA). 
2.21 Lipofectamine transfection of RUNX1-EVI-1 plasmid 
HEK293T and HeLa cells were transfected by lipofectamine (Life Technologies, 
UK) as per manufacturer’s protocol. 
 
   
 78 
DATA ANALYSIS 
2.22 Analysis of CEBPA expression in large cohorts of patients 
with AML 
RSEM normalised count from either normal karyotype AML (n=63) vs CBF 
fusion protein AML (t(8;21): n=7, t(3;21): n =1 ) from the TCGA project 
(https://genome-cancer.ucsc.edu/proj/site/hgHeatmap/# accessed 30th June 
2016, dataset labelled “TCGA acute myeloid leukemia (LAML) gene expression 
by RNA-seq (Illumina HiSeq)’). Normalised signal from gene expression 
microarray transformed by Log2 from Verhaak et al., 2009 (Verhaak et al., 
2009) was also analysed.  Normal karyotype AML (n=187) vs CBF fusion 
protein AML (t(8;21): n=35, t(3;21): n =1 ).  Data downloaded from GEO, 
accession number GSE6891, accessed 30th July 2016.  Boxplot generated by 
SPSS v21 (IBM, USA). Unpaired T-test used to compare gene expression 
between groups. 
2.23 ChIP and DNaseI sequencing data Analysis 
2.23.1 Alignment 
Sequences from all ChIP and DNaseI sequencing experiments in fastq format 
were mapped onto the reference human genome version hg38, Genome 
Reference Consortium GRCh38.  The quality control statistics for the samples 
were obtained using FastQC software 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The raw reads 
were aligned to the reference genome using Bowtie2 (Langmead and Salzberg, 
2012). Reads from ChIP-seq data that were uniquely aligned to chromosomal 
positions were retained and duplicate reads were removed from the aligned 
data using Picard tools (http://broadinstitute.github.io/picard/). The aligned 
reads were used to generate density profiles using “genomeCoverageBed” 
function from bedtools (http://bedtools.readthedocs.org/en/latest/). These tag 
densities were displayed using the UCSC Genome Browser (Kent et al., 2002). 
The numbers of aligned reads are listed in Table S7.  RUNX/ETO ChIP is the 
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pool of publically available data downloaded from GEO with accession numbers 
GSM1113429, GSM1113430 (Ben-Ami, et. al, 2013) and GSM1082306 (Wang 
et. al, 2013).  
2.23.2 Peak calling 
Regions of enrichment (peaks) of ChIP and DNAse1 sequencing data were 
identified using DFilter software (Kumar et al., 2013) with recommended 
parameters (-bs=100 -ks=50 –refine). Peak overlaps, gene annotations were 
performed using in-house scripts. High confidence ChIP-Seq peaks were 
defined as those overlapping peaks in the DNaseI-seq data. Overlaps between 
ChIP and DNasel sequencing were defined by requiring the summit of a peak in 
the ChIP dataset to lie between start and end coordinates of a peak in the 
DNasel data. Peaks were allocated to genes if located in either their promoters 
or within the region of 2000 bp downstream and 2000 bp upstream of the 
transcription start sites (TSS), as intragenic if not in the promoter but within the 
gene body region, or if  intergenic, to the nearest gene located within 100 kb. 
Overlaps between ChIP-seq peaks were defined by requiring the summits of 
two peaks to lie within +/-200 bp. 
2.23.3 Clustering of ChIP and DNaseI sequencing data 
Hierarchical clustering with Euclidean distance and complete linkage clustering 
was used for clustering of transcription factors based on similar binding patterns 
of different ChIP-seq data, in SKH-1 cells. The high confidence peaks for all 
transcription factors were intersected and merged when overlapping. The read 
counts for all union peaks were normalised with regards to total reads depth 
counts and then Pearson’s correlation coefficients were calculated between 
samples using log2 of the normalised read counts. A correlation matrix was 
generated and Pearson correlation coefficients are displayed after hierarchical 
clustering as a heatmap. Colors in the heatmap indicate the strength of 
association between each pair of transcription factors. Heat maps were 
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generated using Mev from TM4 microarray software suite (Saeed et al., 2006). 
Same way was used for DNase-seq data clustering. 
2.23.4 Average tag density profile and heatmap  
The tag density and average profiles were generated by calculating the tag 
density normalised as coverage per million reads within 4kb of the DNAse1 
peak summit. The read counts for all union peaks that were computed. 
Coverages were calculated for all union peaks and ranked by log2 fold change. 
Heatmap images were generated via Java TreeView 
(http://jtreeview.sourceforge.net/) and average profiles were plotted using R 
(https://www.r-project.org/). 
2.23.5 Motif identification and clustering 
De novo motif analysis was performed on peaks using HOMER (Benner et.al 
2010). Motif lengths of 6, 8, 10, and 12 bp were identified in within ± 200 bp 
from the peak summit. The top enriched motifs with a significant p value score 
were recorded. The annotatePeaks function in HOMER was used to find 
occurrences of motifs in peaks. In this case we used known motif position 
weight matrices (PWM) from HOMER database.  
2.23.6 Motif clustering 
Digital footprinting of t(3;21) AML patients 1 and 2 and t(8;21) AML patients 1 
and 2 from DNaseI high-depth sequencing data was performed using the 
Wellington algorithm (Piper et al., 2013) with FDR=0.01. For the heatmap that 
shows hierarchical clustering of motif occurrences within RUNX1/EVI1 footprints 
a motif positions search was done within peaks that are only footprinted in 
t(3;21) patients. The distance between the centres of each motif pairs was 
calculated and the motif frequency was counted if the first motif was within 
50bps distance from the second motif. Z-scores were calculated from the mean 
and standard deviation of motif frequencies observed in random sets using 
bootstrap analysis.  For bootstrapping, peak sets with a population equal to that 
of the footprinted peaks were randomly obtained from the union of t(3;21), 
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t(8;21) and CD34+ DNase-seq footprints. Motif search was repeated for each 
random set and then the mean and the standard deviation for the total motif 
frequencies of the random peak sets were calculated and compared with the 
actual motif frequencies to obtain the Z- scores. A matrix was generated and Z 
scores were displayed after hierarchical clustering as a heat map. Red colour 
means that motifs are overrepresented and grey colour indicates that motif is 
underrepresented. The same procedure was repeated with RUNX1/ETO and 
RUNX1 peaks that are only footprinted in t(8;21) patients and where motif 
search was done exactly within the footprint coordinates and the random sets 
were generated from the total patient’s footprints. 
2.23.7 Motif enrichment  
To identify motifs (identified by HOMER) that are relatively enriched in the distal 
transcription factors (TFs) sites of one cell type compared to another or one TF 
compared to another from same cell type we considered all possible 
comparisons, these being TF sites in (A) which are not shared with each of the 
other TFs (B).  For a given set j of TFs, we defined a motif enrichment score 
(Sij) for motif i in peak set j as 
𝑆𝑖𝑗
𝑛𝑖𝑗 𝑀𝑗⁄
∑ 𝑛𝑖𝑗𝑗 ∑ 𝑀𝑗𝑗⁄
 
where nij is the number of peaks in each subset j (j=1,2,…,12)  containing motif i 
(i=1, 2,….,I), I is the total number of motifs used in the test, and Mj the total 
number of peaks in each subset j (j=1,2,…,30).  A matrix was generated and 
the motif enrichment scores were displayed as a heatmap after hierarchical 
clustering with Euclidean distance and complete linkage. The heatmap was 
generated using Mev from TM4 microarray software suite (Saeed et al., 2006).  
2.24 RNA-seq data Analysis 
RNA-Seq reads were aligned to the hg38 human genome build using STAR. 
Separate density profiles for the positive and negative strand were generated 
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for RNA-seq data. Fragments per Kilobase of transcript per Million mapped 
reads (FPKM) values for each gene were extracted using Cufflinks and 
differentially expressed genes were extracted using the limma R package 
(Ritchie et., al. 2015), in this case the count data was used as an input to limma.  
All genes with p-value ≤ 0.01 were considered and at least 1.5-fold changes 
between before and after RUNX1/EVI1 knock down. The differentially 
expressed genes for the AML patients were considered with at least 2-fold 
changes using the CD34+ PBSC as a control. 
The correlation between any two samples was obtained as the Pearson 
correlation coefficient of expression values over all genes. A correlation matrix 
was thus generated for all the samples and hierarchically clustered. 
Clustering of gene expression was carried out on signal intensity for all 
expressed genes and on fold-changes for genes associated with at least a 1.5-
fold change. Hierarchical clustering was used with Euclidean distance and 
average linkage clustering. Heatmaps were generated using Mev (Saeed et al., 
2006). 
The GSEA software (Subramanian et al., 2005) was used to perform gene set 
enrichment analysis on group of genes.  The normalised enrichment score 
(NES), the p-value and the FDR q-value are displayed on the enrichment plot. 
Gene ontology (GO) analysis was performed using Bingo (Maere et al., 2005) 
and David online tool at david.abcc.ncifcrf.gov (Huang da et al., 2009) using 
Hypergeometric for overrepresentation and Benjamini and Hochberg (FDR) 
correction for multiple testing corrections. KEGG Pathway network analysis was 
performed using clueGO tools (Bindea et al., 2009) with kappa score = 0.3. The 
right-sided enrichment (depletion) test based on the hypergeometric distribution 
was used for terms and groups. Groups were created by iterative merging of 
initially defined groups based on the kappa score threshold. The relationship 
between the selected terms is defined based on their shared genes and the 
final groups are randomly coloured where one, two colours or more represents 
that a gene/term is a member of one, two or more groups respectively. The size 
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of the nodes reflects the enrichment significance of the terms. The network is 
laid out using the layout algorithm supported by Cytoscape. 
2.24.1 Gene ontology (GO) Clustering 
Gene ontology (GO) analysis was perform for the up and down regulated genes 
that change expression 1.5 fold after  RUNX1/EVI1 Knock down in SKH-1 cells 
and  similar analysis was also perform for the up and down regulated genes that 
change expression after RUNX1/ETO Knock down in Kasumi-1 cells. GO terms 
from all four groups were combined and a matrix with GO terms enrichment p-
values was generated then a hierarchical clustering was used with Euclidean 
distance and average linkage. 
2.25 Accession Numbers 
The data generated in this study were deposited at NCBI under accession 
number GSE87286. 
Previous published data were downloaded from the Short Read Archive 
(accessions RUNX1 AML blast CD34+ ChIP-Seq: GSM1466000, CD34+ 
PBSC-1 DNAse1-Seq: GSM1466003, t(8;21) patient#1 DNAse1-seq: 
GSM1466005,  t(8;21) patient#2  DNAse1-seq: GSM1466004, RNA-seq from 
Kasumi-1 cells: GSE54478, RUNX1 kasumi-1 cells: GSM850823). RUNX/ETO 
ChIP-Seq is the combination of publically available data downloaded from GEO 
with accession numbers GSM1113429, GSM1113430 and GSM1082306. 
2.26 Tables of Primers and Antibodies 
Table 2-2 Primers for RT-qPCR 
Name Forward Reverse 
GAPDH CCTGGCCAAGGTCATCCAT AGGGGCCATCCACAGTCTT 
RUNX1-EVI-
1 
CCACAGAGCCATCAAAATCA TCTGGCATTTCTTCCAAAGG 
RUNX1 CCCTCAGCCTCAGAGTCAGAT AGGCAATGGATCCCAGGTAT 
CEBPA GAGGGACCGGAGTTATGACA AGACGCGCACATTCACATT 
CEBPB GACAAGCACAGCGACGAGTA CTCCAGGTTGCGCATCTT 
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GATA2 CAGACGAAGGCAACCATTTT GCTCAGACCACCAAGTCTCC 
HOXA9 GTGATGCCATTTGGGCTTAT 
 
GGGGTGAGAGAAGGGAGAAG 
 
MEIS1 CAGAAAAAGCAGTTGGCACA GGTCTATCATGGGCTGCACT 
CSF1R GCGGGACTATACCAATCTGC 
 
AGCAGGTCAGGTGCTCACTA 
MPO CCAACAACATCGACATCTGG GCTGAACACACCCTCGTTCT 
CTSG TCCTGGTGCGAGAAGACTTTG  GGTGTTTTCCCGTCTCTGGA 
CEBPA-ER GCTGGAGTTGACCAGTGACA AAGGTTGGCAGCTCTCATGTC 
 
Table 2-3 Primers for validating DNaseI 
Target Forward Reverse 
Actin  (short) GCAATGATCTGAGGAGGGAAGGG AGCTGTCACATCCAGGGT
CCTCA 
TBP promoter 
(short) 
CTGGCGGAAGTGACATTATCAA CCCGACCTCACTGAACCC 
Chromosome 18 
(short) 
AGGTCCCAGGACATATCCATT GTTCAAATTGTGTTTTGTG
GTTA 
Actin  (long) GCAATGATCTGAGGAGGGAAGGG GTGTCTTTCCTGCCTGAG
CTGAC 
TBP promoter 
(long) 
CTGGCGGAAGTGACATTATCAA GCCAGCGGAAGCGAAGTT
A 
Chromosome 18  
(long)  
ACTCCCCTTTCATGCTTCTG AGGTCCCAGGACATATCC
ATT 
 
Table 2-4 Primers for ChIP-qPCR 
Target Forward Reverse 
PU.1 3H Enh AACAGGAAGCGCCCAGTCA TGTGCGGTGCCTGTGGTAAT 
IVL GCCGTGCTTTGGAGTTCTTA CCTCTGCTGCTGCCACTT 
MPO CAACACACTCACACCCCACT TGGGAACTCTAAGTGGGCAG 
CTSG AGACCGTGTAATCCAAGCCA TCTCGGCACTGACTTAGCAG 
TREM1 ACAAGGCACCACAATGACCT GGCCTCATATCCTGTTGTGC 
SIGLEC1 GTATCAGGGGCTGCTTCCTC CTGGGTTGGACAGTAGAGCT 
 
Table 2-5 Primers of DNaseI PCR (figure 3-21 C) 
Primers for MPO, TREM1 and SIGLEC1 as above 
Target Forward Reverse 
CTSG GGTTTCATCACCCAAGGCTG TGGCTTGGATTACACGGTCT 
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Table 2-6 Antibodies for probing Western blots 
Antibody target Company Serial number 
EVI-1 Cell Signalling  2593 
RUNX1 (C-terminal epitope) Abcam  23980 
RUNX1 (N-terminal epitope) Cell Signalling 4334 
C/EBPα Abcam 40761 
FLAG epitope Sigma F3165 
GAPDH Abcam  8245 
Anti-Rabbit HRP Cell signalling  7074 
Anti-Mouse HRP Jackson  115 035 062 
 
Table 2-7 Antibodies for ChIP 
Antibody target Company Serial number 
EVI-1 Cell Signalling  2593 
RUNX1 Abcam  23980 
C/EBPα Santa Cruz A2814 
 
Table 2-8 Antibodies for Flow cytometry 
Antibody target-flurochrome Company Serial number 
CD34-APC Miltenyl-biotech 10098139 
CD34-PE Miltenyl-biotech 130081002 
CD117-APC (Clone A3C6E21) Miltenyl-biotech 130091733 
CD11b-APC Miltenyl-biotech 130091241 
CD11b PE (Clone M1/70) Ebiosciences 120011281 
CD14-FITC Miltenyl-biotech 130080701 
CD14-PE (Clone MΦP9) BD Biosciences 562691 
Annexin V-FITC/PI kit BD Pharmingen 556547 
Annexin V-APC/PI kit Ebiosciences 88-8005-74  
IgG FITC Miltenyl-biotech 130093192 
IgG PE Miltenyl-biotech 130093193 
IgG APC Miltenyl-biotech 130093194 
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Chapter 3. Results 
3.1 Epigenetic landscapes differ between t(3;21) and t(8;21) 
leukaemia 
3.1.1 DNase-seq identifies distinct epigenetic features of t(3;21) 
as compared to t(8;21) leukaemia in patient CD34+ blasts 
DHS are nuclease accessible regions that represent gene regulatory elements 
(Cockerill, 2011).  We have previously shown that different pattern of DHSs is 
associated with FLT3-ITD mutant AML as compared to normal karyotype AML 
(Cauchy et al., 2015).  This was proof of principle that distinct DHS signatures 
are identifiable and can be linked to specific AML subtypes.  Given the clinical 
differences in patients with t(3;21) and t(8;21) AML we sought to identify the 
underlying differences in epigenetic landscape through genome-wide mapping 
of DHSs by DNase-seq.  We purified CD34+ populations from patients with 
t(3;21) AML using cell-surface antibody labelling and compared this to DNase-
seq data from t(8;21) CD34+ patient blasts that have been previously generated 
by the lab  (Ptasinska et al., 2012, Ptasinska et al., 2014).  As controls we used 
CD34+ purified G-CSF mobilised PBSCs from healthy donors undergoing 
apheresis for stem cell transplantation (sample details in table 2-1).  All DNaseI-
seq libraries were run at high read depth (50 cycles, single end), with alignment 
statistics and peaks identified shown in table 3-1.  Corresponding RNA-seq 
libraries for all samples were run at 100 cycle, paired ends.  The number of 
reads aligned for each experiment are shown in table 3-2.  We also performed 
the same experiments on t(3;21) SKH-1 cell line expressing RUNX1-EVI-1 
(Mitani et al., 1994). 
Table 3-1 DNase-seq sequencing results 
DNase-seq reads alignment and peaks detected in t(3;21) SKH-1 cell line, 
primary CD34+ AML blasts and normal CD34+ PBSC. 
DNase-seq Dataset Aligned reads (n) Peaks (n) 
CD34 J209 (PBSC 1) 173,261,382 36,041 
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CD34 R299 (PBSC 2) 205,284,104 36,088 
t(3;21) SKH1 cell line 348,530,966 28,821 
GT027 (t(3;21) patient 1) 407,335,267 31,532 
AML5354 (t(3;21) patient 
2) 237,196,453 35,666 
H12812  (t(8;21) patient 
1) 405,680,774 32,262 
H18901 (t(8;21) patient 2) 387,658,545 35,052 
Table 3-2 RNA-seq reads alignment 
RNA-seq reads alignment in t(3;21) SKH-1 cell line, primary CD34+ AML blasts 
and normal CD34+ PBSC. 
RNA-seq Dataset Aligned reads (n) 
t(3;21) SKH-1 cell line replicate 1 30334985 
t(3;21) SKH-1 cell line replicate 2 11898204 
CD34 R454 (PBSC 1) 16538775 
CD34 R423 (PBSC 2) 12402996 
H12812  (t(8;21) patient 1) 12347883 
H18901 (t(8;21) patient 2) 11331201 
GT027 (t(3;21) patient 1) 48166460 
AML5354 (t(3;21) patient 2) 11969780 
 
Reads were processed and aligned to the hg38 assembly.  UCSC browser 
screenshots (Kent et al., 2002) demonstrate differences in gene expression and 
DHSs responsible for these differences between t(8;21) and t(3;21) leukaemia 
(figure 3-1). For example, MEIS1 is a critical rate-limiting regulator of LSC 
potential in leukaemias induced by MLL fusion proteins (Wong et al., 2007).  
Here, MEIS1 was expressed in t(3;21) but not in t(8;21) leukaemias and this 
correlated with the presence of a DHS in the promoter and a previously 
characterised distal enhancer (Xiang et al., 2014) in the t(3;21) but not t(8;21) 
samples.  MEIS1 and HOXA9 directly interact with each other to immortalise 
myeloid progenitors (Schnabel et al., 2000).  Both HOXA9 and HOXA10 were 
expressed in t(3;21) cells but not t(8;21) leukaemia  (figure 3-1A).  ROBO1 is a 
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cell surface receptor and is thought to be a tumour suppressor in MDS and AML 
(Xu et al., 2015).  ROBO1 and CACNA2D2 were expressed in t(8;21) but not 
t(3;21) leukaemia (figure 3-1B).  This fact was associated with differences in 
DHSs between each type of leukaemia at both these genes, suggesting these 
differences in gene expression between each CBF leukaemia are due to 
differences in activity of gene regulatory elements.     
 
Figure 3-1 Epigenetic landscapes differ between CBF leukaemia which is 
associated with differences in gene expression.   
UCSC browser screenshot of DNase-seq and RNA-seq aligned reads from two 
patients with t(3;21) AML, two patients with t(8;21) AML, t(3;21) cell line and 
normal CD34+ PBSC.  MEIS1, HOXA9 and HOXA10 are expressed in t(3;21) 
but not t(8;21) cells.  ROBO1 and CACNA2D2 are expressed in t(8;21) but not 
t(3;21) cells.      
A) MEIS1 locus showing the presence of a DHS at the promoter and distal 
enhancer +140kb from the promoter in t(3;21) cells but not in t(8;21) cells.  DHS 
are present in the promoter of HOXA9 and HOXA10 loci in t(3;21) cells but not 
in t(8;21) cells.   
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B) DHS are present at promoter and regulatory elements in ROBO1 and 
CACNA2D2 in t(8;21) but not in t(3;21) cells. 
 
These examples of specific differences between t(3;21) and t(8;21) AML are 
part of a genome wide pattern of differences between the two types of AML. 
Figure 3-2A shows that in a hierarchical clustering of DNase-seq signals, t(8;21) 
leukaemias cluster separately to t(3;21) cells and normal PBSCs.   A pairwise 
analysis of the overlap in DHSs show that t(8;21) leukaemia, t(3;21) leukaemia 
and the normal PBSCs form three major, separate, clusters (figure 3-2B).  
Notably, the t(3;21) cell line and patient blasts formed a central cluster because 
of the substantial overlap in DHSs.  90% of DHSs found in t(3;21) cell line were 
also found in t(3;21) patient CD34+ blasts. In contrast, approximately 70% of 
DHSs in t(3;21) cell line were found in either t(8;21) AML or normal PBSCs.  
This strong correlation between t(3;21) cell line and patient samples validates 
the t(3;21) cell line as a model for studying the epigenome of t(3;21) leukaemia.   
Figure 3-2C shows substantial overlap in DHSs between each t(3;21) patient, 
but also a large overlap with normal PBSCs, demonstrating that they share a 
large number of gene regulatory elements.  To identify the underlying drivers of 
the differences in DHSs between t(3;21) and t(8;21) leukaemia we determined 
DHSs found in leukaemia from both t(3;21) or both t(8;21) (figure 3-2D) and 
then performed de novo motif analyses on DHSs unique to each leukaemia type 
(figure 3-2E).  We found GATA and IRF motifs were unique to t(3;21) specific 
DHSs, whilst E-box and CEBP motifs were unique to t(8;21) specific DHSs.   
The identification of unique motifs can be used in association with the gene 
expression data to suggest which transcription factor might be specifically 
involved in the regulation of each leukaemia.  For example, the enrichment of 
GATA motif containing DHSs in t(3;21) as compared to t(8;21) cells may be due 
to GATA2.  GATA2 is more highly expressed in t(3;21) leukaemia than in t(8;21) 
leukaemia (figure 3-7E).  GATA2 is a critical regulator of HSC homeostasis: 
knockout of Gata2 in mice prevents the formation of HSCs (Tsai et al., 1994) 
and over-expression of Gata2 results in a block of haematopoietic differentiation 
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(Persons et al., 1999). The identification of  E-box motifs unique to DHS specific 
for  t(8;21) leukaemia as opposed to t(3;21) leukaemia are consistent with the 
recognised direct interaction of E-box transcription factors such as HEB and 
E2A with RUNX1-ETO (Sun et al., 2013, Ptasinska et al., 2014).  As E-box 
transcription factors interact directly with the NHR domain (figure1-4) (Sun et 
al., 2013), this interaction is unique to RUNX1-ETO and not to RUNX1-EVI-1. 
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Figure 3-2 DHS patterns segregate patients according to CBF fusion 
translocation 
A) t(3;21) leukaemia segregates with CD34+ PBSC and away from t(8;21) 
leukaemia.  DNase-seq data from two patients with t(3;21), two patients with 
t(8;21), two independent CD34+ PBSC and t(3;21) SKH-1 cell line were 
analysed.  The matrix shows the correlation in DNase-seq data between the 
different samples. Clustering of samples is based on the strength of correlation 
between samples.   
B) Three major clusters are comprised of either CD34+ PBSCs, t(3;21) 
leukaemia (both primary patient samples and cell line) and finally t(8;21) 
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leukaemia from primary patient material. Overlap of DHS peaks in a pairwise 
comparison between each sample (t(3;21) patient and cell line with t(8;21) 
patients and normal CD34+PBSC).   
C) Large number of DHSs are shared between both t(3;21) primary patient 
CD34+ purified cells and healthy CD34+ PBSCs. Venn diagram showing peak 
overlaps between t(3;21) patient 1, t(3;21) patient 2 and normal CD34+ PBSC.   
D) Identification of DHSs unique to either t(3;21) or t(8;21) leukaemia.  Venn 
diagram showing DNase-seq peak overlaps between t(3;21) patients (both 
patients combined), and t(8;21) patients (both patients combined).   
E) IRF and GATA motifs are unique to t(3;21) specific DHSs, whilst E-box and 
C/EBP motifs are unique to t(8;21) specific DHSs.  De novo motif discovery in 
distal DHSs unique to t(3;21) as compared to  t(8;21) patients, and in distal 
DHSs unique to t(8;21) compared to t(3;21) patients, as shown in D).   
 
3.1.2 Gene expression differs between patients with different 
CBF leukaemia 
Having demonstrated a distinct DHS signature in t(8;21) leukaemia as 
compared to t(3;21) leukaemia, we wanted to know whether this translated into 
differences in gene expression between the cells expressing the two forms of 
CBF fusion protein.  To answer this question, we used unsupervised clustering 
techniques to group the same samples based on their gene expression profiles, 
as measured by RNA-seq.  RNA-seq signals from t(8;21) CD34+ patient cells, 
t(3;21) CD34+ patient cells  and normal PBSCs clustered independently 
(figure3-3A).  Principle component analysis (PCA) provides another way of 
grouping this datasets in an unsupervised manner.  PCA transforms the large 
number of RNA-seq measurements (dimensions) to components that represent 
the majority of variance between the data points.  In the PCA plot (figure3-3B) 
the distance between the data points represent the degree of variance between 
the datasets.  Separation along the two principle components that explain the 
majority of the variance (PC1 and PC2) result in segregation depending on the 
cell type.  On the whole, the different samples from the same leukaemia or cell 
type cluster together.   Along PC3, however, the two t(3;21) patients are further 
apart compared to the other pairs of samples.  Absolute gene expression levels 
of genes, differentially expressed as compared to normal CD34+ PBSCs (1.5 
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fold), are represented in a heat map in figure 3-3C.  This result demonstrates 
distinct gene expression patterns for each type of CBF leukaemia.   
Finally, we wanted to know if the distinct DHS profiles seen in each CBF 
leukaemia directly result in differences in expression of the neighbouring genes.  
To this end we plotted the DNase-seq tag counts of t(3;21) patient 2 and t(8;21) 
patient 1, according to fold change in DNase-seq signal between the two 
patients (figure3-3D).  Hence, the DHSs specific to the t(3;21) leukaemia are at 
the top, whilst DHSs specific to the t(8;21) leukaemia are at the bottom.  Along 
the same genomic coordinates we plotted a heatmap based on the fold-change 
in gene expression between t(3;21) patient 2 and either t(8;21) patient 1 or 
patient 2.  This analysis shows that DHSs specific to t(3;21) leukaemia are 
neighbouring genes which are expressed in the RUNX1-EVI-1 driven leukaemia 
more highly than in RUNX1-ETO leukaemia.  In contrast, DHSs specific to 
t(8;21) leukaemia are nearest genes which are specifically expressed in t(8;21) 
leukaemia, as compared to the t(3;21) leukaemia. 
These analyses taken together confirm that the distinct DHS profile seen in 
t(8;21) patients, as compared to t(3;21) patients results in distinct gene 
expression patterns in t(8;21) leukaemia as compared to t(3;21) cells and 
together with the previous analysis (figure3-2) identifies unique regulators of 
gene expression which define each type of CBF leukaemia. 
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Figure 3-3 Gene expression segregates patients according to CBF 
translocation 
A) Gene expression signals from patients with t(8;21) leukaemia cluster 
separately to those from patients  with t(3;21) leukaemia. Correlation clustering 
of RNA-seq signals in t(3;21) patients and the SKH-1 cell line with t(8;21) 
patients and normal CD34+PBSC.   
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B) Principle component analysis showing separate clustering of t(3;21) patients, 
t(3;21) cell line, t(8;21) patients and normal CD34+PBSC based on RNA-seq 
signal. 
C) RNA-seq in patients with t(3;21) leukaemia cluster apart from patients with 
t(8;21) leukaemia.  Hierarchical clustering of each RNA-seq experiment by gene 
expression (fold change in comparison with normal CD34+ PBSCs (log2)).  
Clustering based on the differentially expressed genes from each patient with 
CBF leukaemia.   
D)  DHSs specific to each CBF leukaemia activate a subset of genes specific to 
the type of leukaemia.  Ranking of DNase-seq tag counts from high to low 
signal within DHS from t(3;21) patient 2 and t(8;21) patient 1 (grey) and SKH-1 
(turquoise).  Signals were ordered in terms of t(3;21) to t(8;21) DNase-seq 
signal fold-change: (t(3;21) specific DHSs: top, t(8;21) specific DHSs: bottom).  
To the right, the heatmap shows the expression of nearest genes ordered 
according to the same coordinates, showing the fold change of FPKM values 
between t(3;21) patient 2 with either t(8;21) patient 1 or patient 2.  The colour 
key represents gene expression fold change between patient with t(3;21) over 
t(8;21): (green higher in t(3;21), red higher in t(8;21).  Genes more highly 
expressed in t(3;21) patient 2 as compared to t(8;21) patients are located at 
the,, genes expressed at a lower level in t(3;21) patient 2 as compared to 
t(8;21) patients are located at the bottom. 
 
3.2 RUNX1 and CBF fusion proteins bind to different sites in 
t(3;21) and t(8;21) leukaemia  
In chapter 3.1 we have demonstrated fundamental differences in the epigenetic 
landscape between t(3;21) and t(8;21) AML (chapter 3.1.1 and 3.1.2).  These 
differences results in differentially expressed genes that drive the respective 
leukaemia phenotype.  We next asked whether RUNX1 and both CBF fusion 
proteins bound to the same targets in the different types of AML, despite these 
differences in their epigenome, as both proteins retain the RUNT DNA binding 
domain originating from the RUNX1 portion of the translocation.  We therefore 
performed ChIP-seq for RUNX1 and RUNX1-EVI-1 in t(3;21) SKH-1 cells to 
complement our pre-existing RUNX1 and RUNX1-ETO data in t(8;21) Kasumi-1 
cells (Ptasinska et al., 2012).  As a model of t(3;21) leukaemia we used the 
SKH-1 cell line, which is derived from a patient with CML in blast crisis, and 
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hence also the t(9;22) translocation  (Mitani et al., 1994).  We demonstrated in 
figure 3-2, that approximately 90% of the DHSs present in the SKH-1 cell line 
were also present in the primary patient samples with the t(3;21) translocation, 
validating the use of this cell line in epigenetic studies.  Kasumi-1 was derived 
from a relapsed t(8;21) leukaemia in a paediatric patient (Asou et al., 1991), and 
has been extensively used as a model of t(8;21) leukaemia.   
EVI-1 is not expressed in the SKH-1 cell line   
In order to perform ChIP-seq of RUNX1-EVI-1 using an EVI-1 antibody, we first 
examined whether the untranslocated EVI-1 was expressed in the SKH-1 cells.  
Figure 3-4A demonstrates that an EVI-1 antibody binds only to a protein of the 
size consistent with RUNX1-EVI-1 (Mitani et al., 1994) demonstrating that EVI1 
is not expressed.  A product of the same size was also bound by a RUNX1 
antibody that detects a N-terminal epitope of RUNX1 involved in the fusion 
protein.  This band was absent when RUNX1-EVI-1 was depleted by siRNA 
targeting the fusion breakpoint (see Chapter 3.4), and was present in another 
cell line only when it was transfected with a RUNX1-EVI-1 plasmid.  We also 
wanted to perform ChIP-seq against the untranslocated RUNX1 product.  To do 
this we had to identify an antibody that bound specifically to the wild-type 
RUNX1 but not RUNX1-EVI-1.  Figure 3-4B demonstrates that the RUNX1 C-
terminal epitope antibody detects only the untranslocated RUNX1 product, as 
this epitope is not present in the RUNX1-EVI-1 fusion protein.  
These experiments demonstrate that an antibody for EVI-1 only binds RUNX1-
EVI-1 in t(3;21) SKH-1 cells and that an antibody for the RUNX1 C-terminus 
only binds the product of the untranslocated RUNX1 allele.  RUNX1 and 
RUNX1-EVI-1 ChIP-seq in the t(3;21) SKH-1 cell line was then performed using 
these antibodies.  High confidence ChIP-seq peaks were then identified by only 
selecting ChIP-seq peaks which coincide with the presence of DHSs.  Figure 3-
4C show that RUNX1 and both CBF fusion proteins predominantly bind to sites 
distal to the promoter. 
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Table 3-3 ChIP-seq in untreated t(3;21) SKH-1, t(8;21) Kasumi-1 and 
normal CD34+ PBSC 
High confidence peaks are ChIP-seq peaks that overlap with a DHS. 
ChIP Dataset Total peaks (n) High Confidence Peaks (n) 
Anti-RUNX1 SKH1 15,609 10,922 
Ant-EVI1 SKH1 14.992 8,947 
Anti RUNX1 Kasumi1 14,972 10,080 
Anti-ETO Kasumi1 14,765 9,435 
Anti-RUNX1 CD34+PBSC 13,951 11,226 
 
3.2.1 Binding sites for RUNX1 and CBF fusion proteins differ 
between t(8;21) and t(3;21) leukaemia 
RUNX1 and CBF fusion protein targets which are shared between both t(3;21) 
and t(8;21) leukaemia include enhancers for SPI1 and CSF1R (Follows et al., 
2005, Leddin et al., 2011) (figure 3-4E). SPI1 encodes the transcription factor 
PU.1 which is expressed in macrophages and B cells (Klemsz et al., 1990, 
DeKoter and Singh, 2000) and acts in opposition to GFI-1 to dictate 
differentiation of myeloid cells into either neutrophils or macrophages (Dahl et 
al., 2006, Dahl et al., 2003).  An upstream regulatory element (URE) bound by 
RUNX1 and CBF fusion protein in both types of AML, has previously been 
shown to be important in maintaining myeloid specific expression of SPI1 (Li et 
al., 2001).  CSF1R encodes a receptor for the cytokine M-CSF and is essential 
for macrophage development (Dai et al., 2002).  An enhancer for CSF1R, 
bound by both RUNX1 and CBF fusion proteins in both leukaemias, termed 
“fms intronic regulatory element” (FIRE) has previously been deleted in 
transgenic mouse models, whereby, the expression of CSF1R is reduced 
(Himes et al., 2001).  In keeping with the similarities in both RUNX1 and CBF 
fusion protein binding in both leukaemias at these loci, SPI1 expression is 
similar between t(3;21) and t(8;21) cells (figure3-4D), whilst CSF1R is not 
expressed in either cell type.   
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In contrast, both GATA2 and MEIS1 are more highly expressed in t(3;21) than 
in t(8;21) cells (figure3-4E).  GATA2 levels, as previously mentioned, are critical 
for correct HSC homeostasis.  Similarly, whilst Meis1 knockout mice are 
capable of forming HSCs, they demonstrate defects in competitively 
repopulating lethally irradiated mice (Hisa et al., 2004).  In keeping with the 
differences in DHS profile at these loci (for MEIS1 figure 3-1A), between t(8;21) 
and t(3;21) AML patients.  Both RUNX1 and RUNX1-EVI-1 are bound at the 
promoter at MEIS1 whilst in t(8;21) cells RUNX1 and RUNX1-ETO do bind 
there (figure 3-4F).  At GATA2, RUNX1 is bound to the proximal promoter in 
t(3;21) but not in t(8;21) cells (Rodrigues et al., 2012). RUNX1 and RUNX1-ETO 
bind a distal enhancer shown to regulate GATA2 (Groschel et al., 2014) but this 
is not bound by neither RUNX1 nor RUNX1-EVI-1 in the t(3;21) cells.   
The differences in RUNX1-ETO and RUNX1-EVI-1 binding, alongside 
differences in RUNX1 binding in each leukaemia are therefore associated with 
differential expression of key haematopoietic transcription factors.  This feature 
may be responsible for the differences in phenotype of the leukaemia seen in 
the patients (see chapter 1.7.1).  Furthermore, differences in RUNX1 and CBF 
fusion protein binding between each leukaemia appears to be associated with 
differences in the DHSs between t(3;21) and t(8;21) AML.  
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Figure 3-4 Common and distinct gene targets of RUNX1 and CBF fusion 
proteins in t(3;21) as compared to t(8;21) leukaemia 
A-B) Anti EVI-1 antibody binds specifically to RUNX1-EVI-1 and anti RUNX1 (C-
terminal epitope) antibody binds specifically to wild-type RUNX1.  
A) Western blot with nuclear extracts. From left to right: t(3;21) SKH-1 cells 
(untreated or transfected with control siRNA or RUNX1-EVI-1 siRNA), HEK293T 
cells (transfected with either empty vector or RUNX1-EVI-1 vector), and t(8;21) 
Kasumi-1 cells. Size in kDa to the left of blot.  Western blots were probed with 
either an anti-EVI-1 or an anti-RUNX1 (N-terminal epitope antibody) as 
indicated.   Anti-EVI-1 and anti-RUNX1 (N-terminal epitope) antibodies detect a 
RUNX1-EVI-1 specific band (black arrow).  This band is absent in SKH-1 
transfected with a RUNX1-EVI-1 specific siRNA and is present in HEK293T 
cells only when transfected with a RUNX1-EVI-1 plasmid.  In Kasumi-1 nuclear 
extract, EVI-1 antibody does not detect anything, whilst the N-terminal RUNX1 
antibody also detects RUNX1-ETO (which is smaller than RUNX1-EVI-1) (blue 
arrow).  The 52kDa band is wild type RUNX1 (red arrow).  Anti-H3 antibody 
used as a loading control. 
B) Western blot of whole cell lysates from SKH-1, Kasumi-1, HEK293T and 
Jurkat cells.  Blot probed with an antibody against the c-terminal epitope of 
RUNX1.  RUNX1 (c-terminal epitope) antibody only detects untranslocated 
RUNX1 product in t(3;21) SKH-1 and t(8;21) Kasumi-1.  HEK293T as negative 
control and Jurkat as positive control.  An anti-GAPDH antibody was used to 
highlight the loading control. 
C) Percentage of binding sites by promoter, intragenic and intergenic region for 
RUNX1 and EVI-1 (RUNX1-EVI-1) ChIP seq in SKH-1 and RUNX1 and ETO 
(RUNX1-ETO) ChIP-seq in Kasumi-1. 
D) Expression of SPI1¸ GATA2 and MEIS1 by RNA-seq (FPKM values) in 
CD34+ purified cells from two patients with t(3;21) AML and two patients with 
t(8;21) AML.  Alongside this are FPKM values from RNA-seq of SKH-1, 
(average of two technical replicates shown) for the same genes.  Expression of 
SPI1 is the same in both t(3;21) and t(8;21) cells.  MEIS1 is expressed in t(3;21) 
but not in t(8;21) cells.  GATA2 is more highly expressed in t(3;21) cells as 
compared to t(8;21) cells.   
E-F) UCSC browser screen shots of aligned reads from ChIP-seq of RUNX1 
and RUNX1-EVI-1 binding in SKH-1 cells, RUNX1 and RUNX1-ETO binding 
from Kasumi-1 cells and RUNX1 from normal CD34+ PBSC. 
E) RUNX1 binding in both t(3;21) and t(8;21) cells, and both RUNX1-EVI-1 and 
RUNX1-ETO bind at enhancers in CSF1R,  and SPI1 loci. 
F) RUNX1 and RUNX1-EVI-1 bind at GATA2 and MEIS1 loci in t(3;21) but 
these genes are not bound by RUNX1 or RUNX1-ETO in t(8;21) cells.  RUNX1 
and RUNX1-ETO bind at a distal enhancer for GATA2. 
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3.2.2 Binding sites differ because unique motifs are found in 
specific RUNX1, RUNX1-EVI-1 and RUNX1-ETO targets 
The above-described experiments show that despite both CBF fusion proteins 
retaining the RUNT DNA binding domain they bound to distinct binding sites for 
each fusion protein.  To quantify these differences of the overall binding 
patterns of RUNX1 and each CBF fusion protein on a genome wide level, we 
performed a correlation analysis of the peaks of all four ChIP-seq experiments 
(RUNX1 and RUNX1-ETO in t(8;21) Kasumi-1 cells and RUNX1 and RUNX1-
EVI-1 in t(3;21) SKH-1 cells).  
Figure 3-5A shows that RUNX1 binding sequences cluster according to their 
cell line of origin and with the binding sites of the respective fusion proteins, 
which, in turn, cluster independently for t(8;21) cells and t(3;21) cells (figure 3-
5A). In addition, we compared the RUNX1 binding pattern with that of normal 
PBSCs (Cauchy et al., 2015). Again, RUNX1 ChIP-seq binding sites from 
normal PBSCs cluster independently to either leukaemia.  This suggests that 
the RUNX1 binding pattern was unique to either t(3;21) or t(8;21) leukaemia.  
Indeed, RUNX1 binding pattern bore a closer similarity to the CBF fusion 
protein within that cell line, than to RUNX1 in the other CBF leukaemia. 
To understand the mechanisms driving  these differences in binding between 
the CBF fusion proteins in each type of AML we identified the sites bound 
specifically by each fusion protein and performed a de novo motif analysis at 
these sites using HOMER (Heinz et al., 2010).  This analysis revealed that 
GATA motifs were enriched in RUNX1-EVI-1 specific binding sites, whilst CEBP 
and E-box motifs were enriched in RUNX1-ETO specific binding sites (figure 3-
5B). This result was consistent with our de novo motif analyses in the DHSs 
specific to each leukaemia (figure 3-2).  We also compared the motifs enriched 
in the binding sites for RUNX1 and each CBF fusion protein (figure 3-5C and D) 
to determine whether or not a particular motif characterises specific CBF fusion 
protein binding sites in each leukaemia.  Again, there was a large percentage of 
E-box motifs in the sites specific to RUNX1-ETO as compared to RUNX1 in 
t(8;21) cells. 
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Figure 3-5 RUNX1 and CBF fusion proteins binding partially overlaps 
within each type of AML and binding sites contain transcription factor 
binding motifs unique to each CBF fusion protein. 
A) RUNX1 and RUNX1-ETO binding sites in t(8;21) leukaemia cluster 
separately to RUNX1 and RUNX1-EVI-1 in t(3;21) leukaemia.  Hierarchical 
clustering of correlation between ChIP-seq experiments: RUNX1 and RUNX1-
ETO in t(8;21) Kasumi-1, RUNX1 and RUNX1-EVI-1 in t(3;21) SKH-1 and 
RUNX1 in CD34+ PBSC.   
B-D) Venn diagram of overlaps between ChIP-seq peaks from different 
experiments with tables comparing de novo motif analyses of distal sites unique 
to each transcription factor: 
B) Comparison of RUNX1-EVI-1 binding sites in t(3;21) SKH-1 with RUNX1-
ETO binding sites in t(8;21) Kasumi-1 cells (Ptasinska et al., 2012). The motif 
analysis on the right shows GATA motifs in RUNX1-EVI-1 unique binding sites 
(left) and CEBP and E-Box motifs in RUNX1-ETO unique binding sites. 
C) Comparison of RUNX1-EVI-1 binding sites with RUNX1 sites in t(3;21) SKH-
1.  The motif analysis on the right shows CTCF in RUNX1-EVI-1 unique binding 
sites and RFX1 in RUNX1 unique binding sites.   
D) Comparison of RUNX1 1 binding sites with RUNX1-ETO in t(8;21) Kasumi-1 
cells.  The motif analysis on the right shows E-Box in RUNX1-ETO unique 
binding sites and CTCF in RUNX1 unique binding sites. 
 
The differences between RUNX1-EVI-1 and RUNX1-ETO targets could be 
confirmed by looking at the percentage overlap of ChIP-seq peaks.   Figure 3-
6A shows that for each leukaemia type, a large percentage of binding sites are 
shared between RUNX1 and the different CBF fusion proteins.  In contrast, 
even for the same transcription factor (RUNX1) the percentage of shared 
targets in t(3;21) and t(8;21) leukaemia is comparatively reduced.   
In order to understand the reasons for this pattern of binding site overlap we 
examined whether particular motifs were enriched in binding sites specific to 
each experiment.  This analysis involved the identification of peaks specific for 
each ChIP-seq experiment in a pairwise comparison of all experiments.  We 
then identified known transcription factor binding motifs in these specific peaks. 
In order to determine whether or not motifs were truly enriched in one particular 
ChIP seq experiment, they were then compared to the union of all the 
discovered motifs in a pairwise comparison (analysis scheme shown in figure 3-
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6B).  This analysis was then subjected to a clustering analysis, with a resultant 
heatmap showing which known motifs were enriched as compared to their 
background occurrence (figure 3-6C).  This analysis highlighted transcription 
factor families shaping chromatin accessibility specific for each particular cell 
type.  The figure shows that enriched motifs in t(8;21) clustered separately to 
enriched motifs in t(3;21) leukaemia.  Known motifs enriched in RUNX1 peaks 
in t(8;21) leukaemia include RUNX, GFI1B and CEBP.  In contrast, motifs 
enriched in RUNX1 or RUNX1-EVI-1 peaks in t(3;21) leukaemia included 
GATA, HOXA9 and AP1.  Enrichment for E-box motifs in RUNX1-ETO specific 
peaks was specific to this fusion protein and was not found in any of the other 
ChIP-seq peaks. 
The separate segregation of enriched motifs in transcription factor binding sites 
between t(3;21) and t(8;21) leukaemia in this analysis, is consistent with the 
separated clustering in the correlation clustering of the ChIP-seq experiments in 
figure 3-5A and 3-6A.  Furthermore, the enriched motifs found in the simple 
pairwise comparisons between ChIP-seq experiments in figure 3-5B and D are 
replicated as part of the results of this analysis in figure 3-6C.  Together these 
analyses suggest that interactions of RUNX1-EVI-1 and RUNX1-ETO with 
different transcription factors in each leukaemia results in differences in binding 
pattern of each CBF fusion protein. 
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Figure 3-6 Clustering identifies unique patterns of enriched transcription 
factor binding motifs within RUNX1 and CBF fusion protein binding sites 
within each type of AML 
A) Overlap between RUNX1 and core-binding factor fusion protein within, but 
not between, each leukaemia.  Percentage of overlapping peaks at distal sites: 
pair wise comparison of wild-type RUNX1, RUNX1-ETO and RUNX1-EVI-1 in 
t(3;21) and t(8;21) leukaemia.   
B) Analysis scheme for pairwise analysis of ChIP-seq data for each CBF 
leukaemia.  Peak overlap was performed for each combination of ChIP-seq 
peak data.  This identified peaks unique to each type of AML.  Enrichment score 
was calculated by the level of motif enrichment in the unique peaks, as 
compared to union of peaks in the pair of experiments. Clustering analysis 
performed on the motif enrichment. 
C) Hierarchical clustering of motifs discovered in the pairwise comparison 
between RUNX1 and CBF fusion ChIP-seq peaks between t(3;21) and t(8;21) 
leukaemia. The heat map representing motif enrichment as described in B).  
Unique peaks from ChIP-seq experiments in t(8;21) cells cluster separately to 
unique peaks from ChIP-seq experiments in t(3;21) cells which identifies 
enriched motifs unique to each ChIP-seq experiment. For example, enrichment 
of E-Box motifs in RUNX1-ETO ChIP-seq in comparison to RUNX1 ChIP-seq in 
t(8;21) cells (marked on diagram).  GATA and STAT5 motifs (highlighted) 
enriched in RUNX1-EVI-1 and RUNX1 binding sites in t(3;21) leukaemia.  ETS 
motif (highlighted) enriched in RUNX1 binding sites in t(8;21) cells and in 
RUNX1 and RUNX1-EVI-1 binding sites in t(3;21) cells. Bound RUNX1 and 
CBF fusion protein complexes differ between primary t(3;21)  and t(8;21) cells 
 
The differences in motif enrichment between the different CBF fusion protein 
and RUNX1 binding sites suggest that they may bind cooperatively with 
differentially expressed transcription factors in each leukaemia (figure 3-6C).  
However, this analysis does not prove that the motifs are actually occupied by a 
transcription factor, nor does it necessarily demonstrate that they are relevant in 
patient samples, and not only in the cell line in which the ChIP-seq experiments 
were performed.  Therefore, we analysed high read depth DNase-seq data from 
t(3;21) and t(8;21) AML patient samples with our Wellington footprinting 
algorithm (Piper et al., 2013) to determine whether  or not these motifs were 
directly bound by transcription factors in the patient samples, at RUNX1 or CBF 
fusion protein bound sites revealed by ChIP-seq in the cell lines.  Wellington 
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identifies DNA-Sequences protected from DNaseI digestion within DNaseI 
hypersensitive sites. 
To identify co-localising transcription factors we calculated the distance 
between transcription factor occupied (“footprinted”) motifs and motifs for 
defined transcription factors as co-localising if they were within 50bp of each 
other.  We also generated a pooled set of all footprinted motifs, identified from 
t(3;21), t(8;21) and CD34+ cells (Ptasinska et al., 2014, Cauchy et al., 2015).  
We then performed a bootstrapping analysis to assess whether these 
footprinted motifs co-localise more than would be expected from their 
occurrence in this pooled set of all occupied motifs.  Bootstrapping analysis is 
based on re-sampling the pool of all occupied motifs in order to determine 
probability of the motifs co-localising simply by chance.  Finally after hierarchical 
clustering of the footprint co-occurrence, the z-scores were displayed as a 
heatmap (figure 3-7A-D).  The red intensity correlates with increasing likelihood 
that the two transcription factors binding co-localise.   
Figure 3-7A and B shows the results of this analysis for RUNX1 bound sites in 
cells of patients with a t(3;21) and t(8;21) leukaemia, respectively. In these 
analyses, co-localising footprinted motifs in the patients were identified at 
RUNX1 binding sites identified in the cell lines using ChIP-seq. The analysis 
shows that at RUNX1 bound sites in t(3;21) patient samples, occupied ERG, 
PU.1, GATA and AP-1 motifs co-localise.  In contrast, in t(8;21) patients 
occupied RUNX1 motifs co-localise with ERG and CEBP transcription factors.   
Figure 3-7C and D show the same analysis for RUNX1-EVI-1 and RUNX1-ETO 
in t(3;21) and t(8;21) cells, respectively.  This analysis shows that in t(8;21) 
patient cells, occupied E-Box sites co-localise with RUNX and ETS (ERG/PU.1) 
bound transcription factors at RUNX1-ETO binding sites.  This is in keeping with 
previous mass-spectrometry based data demonstrating that RUNX1-ETO forms 
a complex with E-box proteins such as HEB and E2A (Sun et al., 2013).  
However, it was not known which transcription factors co-localise with RUNX1-
EVI-1and to facilitate its binding at target genes.  Here we show that, in t(3;21) 
patient cells, at RUNX1-EVI-1 bound sites ETS (ERG/PU.1) factor motifs are 
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clustering together with AP-1 and GATA motifs (figure 3-7C). Interestingly, 
RUNX motifs were not part of this cluster.  
Given the high enrichment of the GATA motif in both RUNX1 and RUNX1-EVI-1 
binding sites in t(3;21) cells, but not in RUNX1 and RUNX1-ETO in t(8;21) cells, 
we queried which GATA factor was likely to bind there.  Although RUNX1-EVI-1 
can bind GATA motifs in vitro (Delwel et al., 1993),  the consensus motif they 
identified is a longer composite motif that would not explain the presence of the 
GATA motifs in RUNX1 bound regions.  Of the GATA family of transcription 
factors, in t(3;21) cells only GATA1 and 2 are expressed, whereby GATA2 is 
more highly expressed than GATA1 (figure 3-7E), and is more highly expressed 
in t(3;21) cells than in t(8;21) cells.  To test whether our identified DHS are 
generally capable of binding GATA2, we analysed a GATA2 ChIP-seq data set 
from another leukaemic cell-line TF1 (Mazumdar et al., 2015) and filtered 
GATA2 binding sites against DHSs in the SKH-1 cell line.  Following this we 
show a substantial overlap of these GATA2 binding sites with those of RUNX1 
and RUNX1-EVI-1 (figure 3-7F). 
Taken together, these data suggests that RUNX1, RUNX1-EVI-1 and RUNX1-
ETO occupy different targets in each CBF leukaemia and form different 
transcription factor complexes in both cell lines and purified primary leukaemic 
blasts from patients.  This finding provides a mechanistic explanation to the 
difference between each CBF leukaemia. 
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Figure 3-7 Identification of different RUNX1 and CBF fusion protein 
complexes in t(8;21) compared to t(3;21) patient cells 
A-B) Heatmap showing co-localisation of occupied transcription factor binding 
motifs in t(3;21) or t(8;21) cells in association with RUNX1 binding in each 
leukaemia.  Enrichment (red) of occupied GATA, AP-1, ERG and PU.1 motifs at 
RUNX1 bound sites in t(3;21) patient samples.  In contrast, enrichment (red) of 
RUNX, ERG and CEBP footprinted motifs at RUNX1 bound sites in t(8;21) 
patient samples.  Bootstrap analysis of footprinted motifs in RUNX1 binding 
sites from t(3;21) or t(8;21) leukaemia.  Footprint probabilities from either t(3;21) 
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patient 2 or t(8;21) patient 1.  RUNX1 binding sites from ChIP-seq in A) t(3;21) 
SKH-1 and B) t(8;21) Kasumi-1 cell line.  
C-D) Heatmap showing co-localisation of transcription factor binding motifs in 
t(3;21) or t(8;21) cells in association with CBF fusion protein binding in each 
leukaemia.  Enrichment (red) of occupied GATA, AP-1, ERG and PU.1 motifs at 
RUNX1-EVI-1 bound sites in t(3;21) patient samples in contrast to the 
enrichment (red) of footprinted RUNX, ERG and E-Box motifs at RUNX1-ETO 
bound sites in t(8;21) patient samples.  Bootstrap analysis of footprinted motifs 
from patients within RUNX1-EVI-1 or RUNX1-ETO bound sites.  C) RUNX1-
EVI-1 binding sites from t(3;21) SKH-1 cell line and D) RUNX1-ETO binding 
sites from t(8;21) Kasumi-1 cell line.  Footprint probabilities from either t(3;21) 
leukaemia patient 2 (for RUNX1-EVI-1 targets) or t(8;21) leukaemia patient 1 
(for RUNX1-ETO targets).   
E) Expression of GATA2 and GATA1 in SKH1 (average of independent 
replicates), t(3;21) and t(8;21) patients  (two patients for each CBF leukaemia) 
based on FPKM values from RNA-seq. 
F) Peak overlaps from anti-GATA2 ChIP-seq in TF1 cells (previously published) 
(Mazumdar et al., 2015) and from SKH-1 cells, anti-EVI-1 (RUNX1-EVI-1) and 
anti-RUNX1 ChIP-seq (this project). GATA2 binding sites from TF1 cells co-
localise with DHSs in SKH-1 cells.  Substantial overlap of binding sites for all 
three transcription factors. 
 
3.3 Characterization of RUNX1-EVI-1 and RUNX1-ETO mediated 
gene deregulation in normal human precursor cells 
Apart from the difference in fusion partners between RUNX1-EVI-1 and 
RUNX1-ETO, the two types of AML differ in terms of cooperating mutations.  
The differences in cooperative mutations between the t(3;21) and t(8;21) 
primary AML samples are listed in table 2-1.  The t(3;21) SKH-1 cell line also 
has a t(9;22) which produces the fusion kinase BCR-ABL (Mitani et al., 1994).  
Similarly, the t(8;21) Kasumi-1 cell line carries mutations that also affect  
tyrosine kinase signalling, spliceosome and polycomb regulation ( KIT N822K, 
SRSF12 R179Q, ASXL1 G646fs*12) (COSMIC catalogue of mutations, 
https://cansar.icr.ac.uk/cansar/cell-lines/KASUMI-1/mutations/ accessed 18th 
July 2016).   We therefore wanted to determine the extent to which the 
differences in the epigenome and binding of RUNX1 and the CBF fusion 
proteins were a result of these cooperative mutations, or which were a direct 
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consequence of the different structures of CBF fusion proteins themselves.  To 
address this question we used lentiviral transduction to express either RUNX1-
ETO or RUNX1-EVI-1 in CD34+ purified PBSCs from healthy donors, and 
aimed to profile their chromatin accessibility using ATAC-seq (assay for 
transposase accessible chromatin using sequencing (Buenrostro et al., 2013)) 
and measure gene expression by RNA-seq. 
Using amplicons specific to either RUNX1-EVI-1 or RUNX1-ETO, we show by 
RT-qPCR, that we can successfully express each CBF fusion gene in 
CD34+PBSCs (figure 3-8A).  Figure 3-7B shows flow cytometry of 
CD34+PBSCS expressing GFP from either an empty, RUNX1-ETO or RUNX1-
EVI-1 vector (figure 3-8B).  
Successfully transduced RUNX1-EVI-1 CD34+ PBSCs could not persist in long-
term liquid culture (figure 3-8C), in contrast to RUNX1-ETO transduced CD34+ 
PBSCs.  A caveat of the experiments in figure 3-8C-E  was that MOI of RUNX1-
EVI-1 virus titre tended to be far lower than either empty or RUNX1-ETO virus 
titres due to the size of the RUNX1-EVI-1 transgene (RUNX1-EVI-1 vector: 
14425bp, RUNX1-ETO vector: 12557bp and empty vector: 10209bp). Currently 
we therefore cannot say whether the inability of outgrowth of transduced clones 
is a result of inefficient transduction or toxicity of the RUX1-EVI1 fusion protein 
in a normal cellular background. 
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Figure 3-8 RUNX1-ETO but not RUNX1-EVI-1 expressing normal CD34+ 
PBSCs persist in long term culture 
A)-B) RUNX1-ETO and RUNX1-EVI-1 can be expressed in purified CD34+ 
PBSC by lentiviral transduction.  CD34+ PBSCs transduced with empty vector, 
or vector with either RUNX1-EVI-1 or RUNX1-ETO transgene.  Successfully 
transduced cells were marked by expression of GFP from the lentiviral 
backbone.  
A) RT-qPCR for either RUNX1-ETO or RUNX1-EVI-1 in CD34+ PBSCs 
transduced with either empty, RUNX1-ETO or RUNX1-EVI-1 pSIEW vector.  
Expression levels were calculated relative to GAPDH. 
B) Flow cytometry of CD34+ PBSCs 2 days after transduction with either empty, 
RUNX1-ETO or RUNX1-EVI-1 pSIEW vector, stained with CD34-PE.  Also 
shown are untreated CD34+ PBSCs either unstained or stained with IgG PE.   
C) RUNX1-ETO, but not RUNX1-EVI-1 persist in PBSC in long term culture.  
Flow cytometry of CD34+ PBSCs 29 days after transduction with either empty, 
RUNX1-ETO or RUNX1-EVI-1 pSIEW vector, stained with CD34-PE.   
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3.4 RUNX1-EVI-1 is necessary to maintain t(3;21) leukaemia 
Our inability to maintain RUNX1-EVI-1 expressing CD34+ PBSCs in contrast to 
RUNX1-ETO expressing CD34+ PBSCs may be consistent with the observation 
that RUNX1-EVI-1 is often seen in leukaemias as a second mutation (section 
1.73), and therefore requires the cooperation with other mutations.  It is known 
that RUNX1-ETO is a mutation that precedes the acquisition of others (Wiemels 
et al., 2002, Miyamoto et al., 2000), whilst RUNX1-EVI-1 is acquired in the 
presence of other preceding mutations (Nukina et al., 2014, Paquette et al., 
2011, Rubin et al., 1990, Rubin et al., 1987).  Given these observation, we 
wished to determine whether RUNX1-EVI-1 was required to maintain the full 
leukaemic potential of t(3;21) cells.  To this end, we designed siRNA that 
targeted the fusion junction between RUNX1 and EVI-1, thereby specifically 
depleting RUNX1-EVI-1 but leaving the product of the untranslocated RUNX1 
allele intact (figure 3-9A). The decrease in protein levels after RUNX1-EVI-1 
siRNA transfection is shown in figure 3-4A, whilst the decrease in mRNA levels 
is shown in figure 3-9A.   We then repeated this transfection to maintain the 
knockdown of RUNX1-EVI-1 (figure 3-9B).  
RUNX1-EVI1 knock-down led to a concomitant decrease in the stem cell and 
early progenitor marker CD34 (figure 3-9C-D) which was associated with down 
regulation of genes important for stem cell function and associated with 
malignant transformation: HOXA9, MEIS1 and GATA2 (Kroon et al., 1998, 
Schnabel et al., 2000, Lawrence et al., 2005, Rodrigues et al., 2005) (as 
mentioned in chapter 3.1.1).  In contrast, genes expressed in differentiated 
myeloid cells increased in levels, and continued to do so at the last recorded 
measurement of the time course at day 14: CSF1R, CTSG, MPO (Borregaard 
et al., 2007, Dai et al., 2002) (figure 3-9E-F).  Despite these increases in 
expression of genes required for monocyte function, the CD14 surface marker 
was not upregulated following RUNX1-EVI-1 knockdown (figure3-9G). 
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Thus, although RUNX1-EVI-1 may not be a primary mutation in the 
development of AML, it is required to maintain the early block in differentiation 
which is a hallmark of this disease.  This would be consistent with other well-
characterised mutations in AML, such as NPM1 (Falini et al., 2005), which are 
secondary mutations but play a critical role in the development of the disease 
(Papaemmanuil et al., 2016, Mupo et al., 2013).   
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Figure 3-9 siRNA depletion of RUNX1-EVI-1 results in differentiation of 
t(3;21) SKH-1 cells 
A) Experimental scheme.  Cells were transfected with siRNA every 72 hrs and 
cells were collected for RNA on days 2, 4, 7, 10, 14.  DNaseI treated cells and 
chromatin were collected on days 2 and 10.  Flow cytometry was performed on 
day 10 and 14. 
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B) RUNX1-EVI-1 mRNA decrease in SKH-1 cells treated with RUNX1-EVI-1 
siRNA, as compared to control siRNA treatment.  RUNX1 mRNA levels are 
unaffected by RUNX1-EVI-1 siRNA as compared to control siRNA.  RT-qPCR 
showing mRNA levels of the indicated genes relative to GAPDH and normalised 
to untreated cells.  RUNX1-EVI-1 or RUNX1 mRNA levels in SKH-1 transfected 
with either specific RUNX1-EVI-1 siRNA or control siRNA.  The graph shows 
the mean and SEM of 4 independent experiments.   
C-D) RUNX1-EVI-1 siRNA results in a decrease of CD34 on the SKH-1 cell 
surface.  Flow cytometric analysis of SKH-1 cells co-staining with CD117-APC 
and CD34-PE: untreated, or after 14 days with either electroporation alone or 
control siRNA or RUNX1-EVI-1 siRNA transfection.  Gating based on 
CD34+CD117+ untreated SKH-1 cells.  C) Representative flow cytometry plots 
(CD34-PE versus CD117-APC) D) percentage of CD34+CD117+ cells.  Mean 
of 6 independent experiments and error bars represent S.E.M.  * denotes 
p<0.05 by paired t-test. 
E-F) RUNX1-EVI-1 siRNA results in down regulation of MEIS1, GATA2 and 
HOXA9 but upregulation of MPO, CSF1R and CTSG; as compared to control 
siRNA treatment alone.  mRNA levels in SKH-1 cells following treatment with 
RUNX1-EVI-1 siRNA as compared to control siRNA transfection, relative to 
GAPDH expression. mRNA levels relative to those from untreated SKH-1.  E) 
mRNA levels of genes required for haematopoietic stem cell function (GATA2, 
MEIS1 and HOXA9) and F) genes expressed after myeloid differentiation 
(MPO, CTSG and CSF1R).  The graph displays mean and SEM of 4 
independent experiments.   
G) CD14 levels on SKH-1 cells do not increase after RUNX1-EVI-1 siRNA.  
Flow cytometric analysis of t(3;21) SKH-1 cells stained with CD14-FITC: SKH-1 
either untreated, or with 14 days of either electroporation alone, or control 
siRNA or RUNX1-EVI-1 siRNA transfection. MFI (median) of CD14 FITC on 
treated cells relative to untreated SKH-1.  Graph of mean and SEM of 6 
independent experiments. 
 
3.4.1 Effects of RUNX1-EVI-1 siRNA are specific to SKH-1 and 
not K562 cells 
K562 and SKH-1 cells are both derived from patients with CML in blast crisis 
(Mitani et al., 1994, Lozzio and Lozzio, 1975) and express the BCR-ABL fusion 
protein.  To ensure that the effects of RUNX1-EVI-1 siRNA on the differentiation 
and apoptosis of the SKH-1 cells are specific to RUNX1-EVI-1 expressing cells 
we repeated these siRNA transfection experiments in the K562 cell line.  
Transfection with RUNX1-EVI-1 siRNA resulted in an increase in apoptosis in 
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the t(3;21) SKH-1 cells but not K562 cell line  (figure 3-10A-B).  RUNX1-EVI-1 
siRNA also specifically reduced the growth of SKH-1 cells but did not affect the 
growth of K562 cells (figure 3-10C).  Finally, in contrast to figure 3-9E-F, in 
K562 cells there were no changes in expression of key genes involved in 
haematopoiesis, following 14 days of treatment with RUNX1-EVI-1 siRNA as 
compared to control siRNA transfection.  Therefore, we can conclude that the 
differentiation and apoptosis of SKH-1 cells, following RUNX1-EVI-1 siRNA 
transfection, is a result of the knockdown of RUNX1-EVI-1, and not to non-
specific effects related to the experimental process.  
 
Figure 3-10 The effects of RUNX1-EVI-1 siRNA is specific to t(3;21) SKH-1 
cells 
A –C) Knockdown of RUNX1-EVI-1 results in reduced cell growth and increased 
apoptosis of SKH-1 but not K562 cells.  Annexin V FITC and PI staining in SKH-
1 and K562 cells either untreated or after 14 days with electroporation alone or, 
either, control siRNA or RUNX1-EVI-1 siRNA transfection.  A) Representative 
plots showing Annexin V-FITC and PI signals. B) Percentage of Annexin V 
stained cells. The graph shows mean and SEM of at least 3 independent 
experiments.  * denotes p<0.05 by unpaired t-test.  C) Growth rates of SKH-1 
(dashed lines) and K562 cells (solid lines) treated with RUNX1-EVI-1 siRNA 
relative to treatment with control siRNA.  The graph shows mean and SEM of at 
least 3 independent experiments.   
   
 118 
D) Effects of RUNX1-EVI-1 knock-down on expression of genes involved in 
haematopoiesis are specific to SKH-1 and not K562.  Graph shows mRNA 
levels of genes expressed after myeloid differentiation (MPO and CEBPA) and 
required for haematopoietic stem cell function (GATA2 and MEIS1), relative to 
GAPDH and normalised to untreated cells in K562 cells after RUNX1-EVI-1 
siRNA as compared to control siRNA transfection.  The graph shows the mean 
and SEM of 3 independent experiments. 
 
3.5 RUNX1-EVI-1 directly regulates key regulators of leukaemic 
cell identity 
Having shown that RUNX1-EVI-1 is required for the maintenance of the 
leukaemic phenotype, we wished to identify which genes are directly regulated 
by RUNX1-EVI-1. 
In order to identify gene expression changes following RUNX1-EVI-1 
knockdown we analysed RNA-seq of SKH-1 cells following either RUNX1-EVI-1 
siRNA transfection, or control siRNA transfection.  We then used RUNX1-EVI-1 
ChIP-seq to identify targets of the fusion protein that change expression. 
3.5.1 RUNX1-EVI-1 knockdown results in loss of a stem cell 
gene expression program 
Genome wide changes in gene expression following 2, 4 and 10 days after 
RUNX1-EVI-1 or control siRNA transfection of SKH-1 cells were characterised 
by RNA-seq.  The aligned reads of RNA-seq are presented in table 3-4. Figure 
3-11A shows hierarchical clustering of RNA-seq signals for two independent 
knock-down time courses demonstrating a strong concordance between the 
replicates.  Clustering also shows that after 4 or 10 days treatment, RNA-seq 
data in SKH-1 cells treated with RUNX1-EVI-1 siRNA cluster separately to 
SKH-1 cells treated with control siRNA alone. However, after 2 days of siRNA 
treatment alone, both control siRNA and RUNX1-EVI-1 siRNA treated RNA-seq 
samples form a cluster apart from the two latter time points.  This suggests that 
changes in gene expression in SKH-1 cells after 4 or 10 days of RUNX1-EVI-1 
siRNA as compared to control siRNA treatment is greater than after 2 days of 
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RUNX1-EVI-1 siRNA transfection.  This is confirmed by figure 3-11B which is a 
bar graph that show the number of genes that ether increase or decrease in 
expression (at least 1.5 fold difference between RUNX1-EVI-1 siRNA and 
control siRNA treatment).  Overall, more genes were downregulated than 
upregulated. The number of genes that responded progressively increased in 
number over the course of time. By 10 days after RUNX1-EVI-1knockdown, 180 
genes were upregulated and 339 genes were downregulated. The heatmap in 
figure 3-11C depicts all the genes that changed expression in RUNX1-EVI-1 
siRNA transfected cells as compared to control siRNA transfection alone, and 
clusters the RNA-seq data from each time point after 2, 4 or 10 days of siRNA 
treatment in an unsupervised fashion.  Figure 3-11C shows that genes 
changing expression do so with increasing magnitude as the time course 
progresses, which is depicted by the increasing intensity of the colours in this 
heatmap.  This timespan suggests that changes in regulation of certain genes 
may require time, in order to take place.  Alternatively, the changes of gene 
expression at later time points may also be a result of wider changes in the 
transcriptional network of these cells initiated by changes in RUNX1-EVI-1 
binding. Finally, the progressive changes in gene expression over time following 
RUNX1-EVI-1 knockdown may also be reflective of the gradual degradation of 
the fusion protein following initial RUNX1-EVI-1 siRNA transfection leading to a 
cell autonomous response and cellular heterogeneity. 
Having manually validated that a number of genes critical for stem cell function 
were downregulated following RUNX1-EVI-1 knockdown, we wished to identify 
whether or not these changes were consistent more broadly by a loss of a 
coordinated stem cell gene expression program.  Eppert et al profiled gene 
expression in, FACS sorted, functionally validated HSCs and LSCs from 
primary AML samples (Eppert et al., 2011).  This gene signature was validated 
outside of the xenograft model as this HSC and LSC gene set was shown to 
have prognostic value in large, independent cohorts of AML patients.  Gene Set 
Enrichment Analysis (GSEA) (Subramanian et al., 2005)  is a bioinformatics 
technique that ranks genes by expression levels in one sample and determines 
statistically, how well represented is an independently defined set of genes.  
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GSEA analysis demonstrated that both the HSC and LSC gene signature 
(Eppert et al., 2011) were enriched in the genes that were down-regulated 
following RUNX1-EVI-1 knockdown (figure 3-11D). 
Next, we used KEGG pathway analysis to categorise sets of genes that change 
expression following RUNX1-EVI-1 knockdown.  This analysis maps the large 
number of genes that are differentially expressed in RUNX1-EVI-1 siRNA 
transfected cells as compared to control siRNA, to their known roles.  This 
enables a description of common and highly represented functions that change 
following RUNX1-EVI-1 knockdown.  Up-regulated pathways included 
“Lysosome” (e.g. CTSG, ASAH1, and GLA) and “FcγR mediated phagocytosis” 
(e.g. FCGR2A, NCF1, GAB) (figure 3-11E) which are functions characteristic of 
fully differentiated neutrophils and monocytes/macrophages.  Down regulated 
gene classes include “Transcriptional misregulation in cancer” (including MYCN, 
WT1, ID2, JUP, ERG, COMMD3-BMI-1) and “Cell adhesion molecules” (e.g. 
CD34, ICAM3, ITGA9).   
Together, this suggests that RUNX1-EVI-1 knockdown results in a loss of a 
stem cell specific program characterised by changes in expression of epigenetic 
regulators vital for their function, with an up-regulation of genes required for 
terminal myeloid function.  This is in concordance with the phenotypic changes 
in SKH-1 cells following RUNX1-EVI-1 knockdown described in chapter 3.4. 
Table 3-4 RUNX1-EVI-1 or control siRNA transfected SKH-1 RNA-seq 
reads alignment 
Control siRNA (siMM) or RUNX1-EVI-1 siRNA (siREVI1) transfected cells.  
RNA –seq in SKH-1 cells after either 2 (D2), 4 (D4) or 10 (D10) days of siRNA 
treatment.  Two biological replicates performed (Rep1 and Rep2). 
RNA-seq Dataset Aligned reads (n) 
siMM_D2_Rep1 43584690 
siMM_D2_Rep2 41344409 
siMM_D4_Rep1 33410586 
siMM_D4_Rep2 44832782 
siMM_D10_Rep1 22705489 
siMM_D10_Rep2 22419529 
siREVI1_D2_Rep1 43782238 
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siREVI1_D2_Rep2 23157018 
siREVI1_D4_Rep1 37541312 
siREVI1_D4_Rep2 53187360 
siREVI1_D10_Rep1 17656510 
siREVI1_D10_Rep2 30380957 
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Figure 3-11 Progressive changes in gene expression following RUNX1-
EVI-1 knockdown results in a loss of stem cell gene expression program 
RNA-seq analysis of SKH-1 cells after either RUNX1-EVI-1 or control siRNA 
treatment for 2, 4 or 10 days. Biological replicates at each time point and with 
each treatment condition are indicated. 
A) Hierarchical clustering of Pearson correlation coefficients between two 
biological replicates (#1 and #2) of each treatment condition (siMM: control 
siRNA; siREVI1: RUNX1-EVI-1 siRNA).  Independent replicates cluster together 
but also three major clusters: samples from day 2 timepoint (both control siRNA 
and RUNX1-EVI-1 siRNA treated samples), samples from control siRNA treated 
samples at day 4 and 10, and samples from RUNX1-EVI-1 siRNA treated 
samples at day 4 and day 10.  
B) Bar plot shows number of down-regulated genes and up-regulated genes at 
each timepoint (2, 4, or 10 days of treatment).  Numbers of both up-regulated 
and down-regulated genes increase as the duration of siRNA transfection 
lengthens. Values based on the average RNA-seq signal in two independent 
replicates in SKH-1 cells transfected with either RUNX1-EVI-1 siRNA or control 
siRNA.  This is used to determine the number of differentially expressed genes 
in SKH-1 cells that change expression 1.5 fold after RUNX1-EVI-1 siRNA as 
compared to control siRNA transfection.   
C) Samples at different time points of treatment clustered by RNA-seq. SKH-1 
cells treated for 10 days with RUNX1-EVI-1 siRNA cluster away from those 
treated for 2 or 4 days alone.  Heat map of genes which change expression 1.5 
fold after RUNX1-EVI-1 siRNA transfection, as compared to control siRNA.  The 
graph shows the average of two independent replicates.  Heat map colour 
intensity is related to the degree of differential expression (fold-change (FC)) 
between RUNX1-EVI-1 siRNA and control siRNA treatment.   
D) Gene set enrichment analysis (GSEA) of RNA-seq from SKH-1 cells after 10 
days of treatment with either RUNX1-EVI-1 siRNA (siREVI1) or control siRNA 
(siMM).  Loss of enrichment of genes associated with either haematopoietic or 
leukaemic stem cell when SKH-1 are treated with RUNX1-EVI-1 siRNA.   
E) KEGG pathway for genes up-regulated in expression in SKH-1 cells treated 
after 10 days of RUNX1-EVI-1 siRNA as compared to control siRNA. 
F)  KEGG pathway for genes downregulated in expression in SKH-1 cells 
treated after 10 days of RUNX1-EVI-1 siRNA as compared to control siRNA. 
3.5.2 RUNX1-EVI-1 directly targets key genes involved in 
differentiation and cell survival. 
By integrating ChIP-seq of RUNX1-EVI-1 with changes in gene expression 
following RUNX1-EVI-1 knockdown we can identify which genes are directly 
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regulated by RUNX1-EVI-1 and whether RUNX1-EVI-1 acts as an activator and 
repressor of genes. 
Figure 3-12A show that between 40-50% of genes which change expression by 
day 10 are direct targets of RUNX1-EVI-1.  Targets of RUNX1-EVI-1 included 
both up and down regulated genes following RUNX1-EVI-1 knockdown.  
Changes in gene expression earlier in the time course are more likely to be a 
direct result of changes to RUNX1-EVI-1 binding, as later events may be 
influenced by indirect changes, for example, downstream of a RUNX1-EVI-1 
target which in itself is a regulator.  At day 2 after RUNX1-EVI-1 knockdown, 
more genes were up-regulated, than down regulated and a greater proportion of 
the total set of genes which are up-regulated were RUNX1-EVI-1 targets.  
Overall, this suggests that although RUNX1-EVI-1 may act as a transcriptional 
repressor, it may also lead to the activation of other loci. 
 Having noted the large proportion of genes that changed expression are 
RUNX1-EVI-1 targets, it was not surprising to note that KEGG pathway analysis 
of RUNX1-EVI-1 targets that change expression bear a strong similarity to 
those already shown in figure 3-11.  Figure 3-12B demonstrates that RUNX1-
EVI-1 appears to directly repress genes that are required in granulocytes and 
monocytes, such as genes important for phagocytosis and the key transcription 
factor CEBPA.  Simultaneously RUNX1-EVI-1 may directly or indirectly activate 
genes involved in “transcriptional mis-regulation in cancer” such as ERG and 
WT1, as well as TGFB1.  These genes are involved in the maintenance of stem 
cell properties, and are often deregulated in cancerous cells.  For example, 
WT1 is involved in the regulation of quiescence in haematopoietic stem cells 
(Ellisen et al., 2001) and is over-expressed in poor prognosis AML (Rampal and 
Figueroa, 2016). 
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Figure 3-12 Identification of RUNX1-EVI-1 targets responding to siRNA 
treatment 
A) Percentage of differentially expressed genes which are RUNX1-EVI-1 ChIP-
seq targets. The fraction displayed on top of columns represents absolute 
number of differentially expressed genes shown as: RUNX1-EVI-1 targets/total 
number of differentially expressed genes.  Differentially expressed genes are 
those which have at 1.5 fold change in gene expression between RUNX1-EVI-1 
siRNA as compared to control siRNA treatment, either after 2, 4 or 10 days of 
siRNA treatment. 
B)-C) RUNX1-EVI-1 expression leads to both activation of leukaemia pathways 
as well as the repression of terminal myeloid differentiation.  KEGG pathway for 
RUNX1-EVI-1 ChIP-seq target genes which are at least 1.5 fold differentially 
expressed, between RUNX1-EVI-1 siRNA and control siRNA treated cells (after 
10 days of treatment). B) Pathways upregulated following RUNX1-EVI-1 
knockdown and C) pathways downregulated following RUNX1-EVI-1 
knockdown. 
 
3.6 C/EBPα remodels the epigenome of SKH-1 cells following 
RUNX1-EVI-1 knockdown 
3.6.1 DHS mapping in SKH-1 following RUNX1-EVI-1 
knockdown increases DHS containing CEBP motifs. 
Having identified the changes in gene expression in SKH-1 cells following 
RUNX1-EVI-1 knockdown, we characterised the alterations in the epigenome 
driving these changes.  DHSs are enriched for gene regulatory elements such 
as enhancers (Cockerill, 2011).  In order to identify changes in these gene 
regulatory elements we performed DNase-seq in SKH-1 cells following either 2 
or 10 days of either control or RUNX1-EVI-1 siRNA transfection.  The 
sequencing parameters of these experiments are presented in table 3-5 below. 
Table 3-5 DNase seq in SKH-1 after 2 or 10 days treatment of control or 
RUNX1-EVI-1 siRNA 
DNase-seq Dataset Aligned reads (n) Peaks (n) 
Control siRNA Day 2 17,680,722 21,261 
RUNX1-EVI-1 siRNA Day 2 22,242,583 22,312 
Control siRNA Day 10 8,531,753 16,456 
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RUNX1-EVI-1 siRNA Day 10 19,976,087 18,672 
 
After 2 days of RUNX1-EVI-1 siRNA treatment, there were relatively few genes 
change expression and hence relatively few DHSs change in their accessibility 
(figure 3-11C and 3-13A). After 10 days of RUNX1-EVI-1 siRNA treatment, a 
greater number of genes changed expression and thus a greater number of 
DHSs changed in their accessibility.  Figure 3-13B and C depict changes in 
DHSs following RUNX1-EVI-1 knockdown.  For example, after 10 days of 
siRNA treatment (Figure 3-13D) 294 DHSs were reduced in hypersensitivity, the 
majority remained unchanged but 2510 DHSs were increased in 
hypersensitivity, following RUNX1-EVI-1 knockdown.   However, already after 2 
days as well as after 10 days of knock-down, sites increasing in hypersensitivity 
following RUNX1-EVI-1 were enriched for CEBP motifs in a de novo motif 
analysis.  This suggests an increased role for the CEBP family of transcription 
factors in SKH-1 cells following knockdown of RUNX1-EVI-1.  This finding is 
reflective of our findings for the importance of C/EBPα in driving differentiation 
of t(8;21) cells, following RUNX1-ETO knockdown (Ptasinska et al., 2014). 
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Figure 3-13 RUNX1-EVI-1 knockdown results in increase in DHSs with 
C/EBP motifs 
DNase-seq in SKH-1 after 2 or 10 days of either control or RUNX1-EVI-1 siRNA 
treatment.   
A) Identification of DHSs found only in SKH-1 treated with control siRNA, only in 
SKH-1 treated with RUNX1-EVI-1 siRNA, or found in SKH-1 treated with either 
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siRNA.  Venn diagram of peak overlaps after either 2 or 10 days of either 
control or RUNX1-EVI-1 siRNA treatment. 
B-C) Enrichment of CEBP motif containing DHSs in SKH-1 following 
transfection of RUNX1-EVI-1 specific siRNA.  DNase-seq tag density within +/-
4Kb window centred on DNase-seq peaks in SKH-1 treated with B) 2 days or C) 
10 days of control siRNA.  To the right, aligned to the same coordinates are 
DNase-seq tag densities for SKH-1 treated with RUNX1-EVI-1 siRNA.   
Tables showing de novo motif discovery in DHS present in both control and 
RUNX1-EVI-1 siRNA treated cells (labelled shared peaks) or only in RUNX1-
EVI-1 siRNA treated cells (labelled RUNX1-EVI-1 unique peaks) are shown on 
the right. 
 
To determine the significance of the changes in chromatin accessibility after 
knock-down, we sought to understand whether they were associated with 
changes in gene expression of their neighbouring genes by subdividing them 
into three groups.  The majority of gene expression changes occurred at DHSs 
that did not change (group 2, figure 3-14A).  However, group 1 DHSs that had 
decreased in hypersensitivity following RUNX1-EVI-1 knockdown show a 
decrease in expression of neighbouring genes.  Group 3 DHSs that increase in 
hypersensitivity following RUNX1-EVI-1 siRNA, showed an increase in 
expression of neighbouring genes at the initial time point.   
To assess which motifs were specifically enriched in any of these three groups 
of DHSs, we plotted the underlying motif frequencies at the same DHS loci 
(figure 3-14B).  This demonstrates an enrichment of GATA motif containing 
DHSs in group 1.  This is consistent with a decrease in expression of GATA2 
following RUNX1-EVI-1 knockdown in SKH-1 cells (figure 3-9E)  
In contrast, DHSs increasing in accessibility after RUNX1-EVI-1 knockdown 
showed and enrichment of CEBP motifs (group 3).  RUNX motifs containing 
DHSs also increase in accessibility following RUNX1-EVI-1 knockdown (figure 
3-14B) suggesting a potential cooperativity between RUNX and CEBP 
transcription factors.  Although RUNX1 expression was unchanged (figure 3-
9A), cooperativity between RUNX1 and CEBP transcription factors in binding 
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DNA has previously been documented (Zhang et al., 1996, Petrovick et al., 
1998).  In this study, we characterise this further in figure 3-17, 3-18 and 3-21 
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Figure 3-14 Changes in DHS accessibility by RUNX1-EVI-1 siRNA correlate 
with changes in the expression of nearby genes 
Profiles of the DNase-seq tag densities, in +/-4Kb windows centred on peaks, 
for SKH-1 treated for 10 days with either control or RUNX1-EVI-1 siRNA. Group 
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1 peaks are DHSs which decrease in accessibility following RUNX1-EVI-1 
knockdown.  Group 2 peaks are DHSs whose accessibility is unchanged 
following RUNX1-EVI-1 knockdown.  Group 3 peaks are DHS which increase in 
accessibility following RUNX1-EVI-1 knockdown. 
A) Group 1 DHSs are largely associated with decrease in expression of 
neighbouring genes.  Group 3 DHSs are associated with increase in expression 
of neighbouring genes after 2 days of siRNA treatment.  Gene expression levels 
of associated genes at the same coordinates are shown to the right, depicted as 
RUNX1-EVI-1 siRNA log2 fold change, after 2, 4 or 10 days of siRNA treatment 
as compared to control RNA treatment.  
B) Motif content of Group 1 – 3 DHSs showing that GATA motif containing 
DHSs decrease in accessibility following RUNX1-EVI-1 knockdown whereas 
RUNX1 and CEBP motif containing DHSs increase in accessibility following 
RUNX1-EVI-1 knockdown. Motif densities are plotted to the right within +/-1 Kb 
windows) of the DHSs centre. 
 
3.6.2 CBF fusion genes in both t(3;21) and t(8;21) leukaemia 
deregulates C/EBPα expression 
We next investigated which CEBP transcription factor might bind DHSs which 
increasing in accessibility in SKH-1 following RUNX1-EVI-1 knockdown (figure 
3-14A).  CEBPA was prominent as it was a direct target of RUNX1-EVI-1 (figure 
3-12).  Manual RT-qPCR and Western blotting confirmed that C/EBPα mRNA 
and protein levels increased after RUNX1-EVI-1 knockdown (Figure 3-15A-B).  
We checked the RNA levels of all six members of the CEBP transcription factor 
family (Figure 3-15C) following RUNX1-EVI-1 knockdown.  This showed that 
CEBPA and CEBPD RNA both increased in SKH-1 cells transfected with 
RUNX1-EVI-1 siRNA as compared to control siRNA.  However, CEBPA RNA 
levels were approximately 3 fold higher than CEBPD.  CEBPE RNA levels 
remained low throughout the time course of RUNX1-EVI-1 knockdown.  This is 
of interest because in t(8;21) cells following RUNX1-ETO knockdown, CEBPA, 
CEBPD and CEBPE RNA levels also increase (Ptasinska et al., 2012, 
Ptasinska et al., 2014).  CEBPE expression is principally required for the 
terminal development and appearance of neutrophils (Yamanaka et al., 1997), 
although some defects in macrophage function is seen in Cebpe null mice 
(Tavor et al., 2002).  This suggests that the differentiation of t(3;21) cells 
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remains incomplete, following knockdown of RUNX1-EVI-1, as compared to 
t(8;21) cells, following knockdown of RUNX1-ETO. 
   
 134 
 
Figure 3-15 CEBPA expression increases after RUNX1-EVI-1 knockdown 
A) CEBPA but not CEBPB mRNA levels increase following knockdown of 
RUNX1-EVI-1 in t(3;21) cells.  RT-qPCR of mRNA levels relative to GAPDH 
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and normalised to untreated cells of CEBPA and CEBPB in SKH-1 after 
RUNX1-EVI-1 siRNA as compared to control siRNA transfection. Cells 
harvested 2, 4, 7, 10 or 14 days after start of time course.  The graph shows the 
mean and SEM of 4 independent experiments.   
B) C/EBPα protein levels increase in SKH-1 cells following knockdown of 
RUNX1-EVI-1.  Western blot from whole cell lysates in t(3;21) SKH-1 cell 
treated with control siRNA or RUNX1-EVI-1 siRNA after 2 and 10 days probed 
with an anti-C/EBPα antibody. Whole cell lysates from HEK293T and THP-1 
were used as negative control and positive control, respectively. The GAPDH 
signal served as loading control. 
C) Expression of C/EBP transcription factors after RUNX1-EVI-1 knockdown.  
Increase in CEBPA and CEBPD RNA levels following RUNX1-EVI-1 knockdown 
in SKH-1 cells.  CEBPA, CEBPB, CEBPD, CEBPE, CEBPZ and CEBPG FPKM 
from RNA-seq in SKH-1 cells after 2, 4 and 10 days treatment with either 
control siRNA or RUNX1-EVI-1 siRNA.   
 
CEBPA is also upregulated following RUNX1—ETO knockdown in t(8;21) 
Kasumi-1 cells (Ptasinska et al., 2014).  We therefore asked whether CEBPA 
was commonly down regulated in CBF fusion AML in general using publically 
available RNA-seq data from an independent cohort of patients (Cancer 
Genome Atlas Research, 2013).  A comparison of normalised RSEM values 
from RNA-seq in the normal karyotype AML vs CBF fusion leukaemia (seven 
t(8;21) and one t(3;21) AML) shows that CEBPA is expressed at a significantly 
lower level in CBF fusion leukaemia than normal karyotype leukaemia (figure3-
16A).  Similarly in another independent cohort of AML patients (Verhaak et al., 
2009), CEBPA is significantly down-regulated in CBF fusion leukaemia as 
compared to normal karyotype AML.  Of note, in both cohorts, t(3;21) AML 
CEPBA  expression is close to the median of the rest of the t(8;21) AML CEBPA 
expression.   
Furthermore, CEBPA mutations are mutually exclusive from t(8;21) leukaemias 
suggesting they act on the same pathways: 13 CEBPA mutant AML are 
independent of 8 CBF fusion leukaemia (Cancer Genome Atlas Research, 
2013); 66 CEBPA biallelic mutant AML are independent of 60 t(8;21) AML 
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(Papaemmanuil et al., 2016); 9 t(3;21) AML are without CEBPA mutations (H 
Dohner, personal correspondence). 
To further examine whether gene expression changes following RUNX1-EVI-1 
and RUNX1-ETO knockdown involve the same developmental pathways we 
clustered GO terms in genes responding to knockdown of either RUNX1-EVI-1 
or RUNX1-ETO.  Figure 3-16B demonstrate that despite the differences 
between the two types of AML, changing gene expression patterns both 
converge on the same pathways following CBF fusion protein knockdown.  GO 
terms that are shared include “myeloid leukocyte mediated immunity”, “myeloid 
cell differentiation and “leukocyte degranulation”.  This suggests that a core-set 
of genes are reprogrammed following knockdown of RUNX1-EVI-1 in t(3;21) 
cells and RUNX1-ETO  in t(8;21) cells. 
To examine the molecular mechanism of this conversion, we used our ChIP-
Seq data to see whether RUNX1-ETO and RUNX1-EVI1 bound to the CEBPA 
locus. An enhancer located at +42kb from the promoter of CEBPA is an 
important cis-regulatory element of this gene that is required for myeloid lineage 
priming (Avellino et al., 2016).  Both RUNX1-ETO and RUNX1-EVI-1 bind to 
this element (figure 3-16C) and may therefore share similar mechanisms of 
CEBPA repression. Despite the difference in epigenomic landscape in t(3;21) 
and t(8;21) leukaemia,  this data suggests that CEBPA down-regulation is a 
hallmark of both CBF fusion protein leukaemia, likely driven through modulation 
of the same distal enhancer of CEBPA. 
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Figure 3-16 C/EBPα is a common up-regulated target after RUNX1-EVI-1 
and RUNX1-ETO knockdown 
A-B) CEBPA mRNA is down-regulated in CBF leukaemia as compared to 
normal karyotype AML. 
A) RSEM normalised count of CEBPA expression (red dot indicates t(3;21) 
sample), in either normal karyotype AML (n=63) vs  CBF fusion protein AML 
(t(8;21): n=7, t(3;21): n =1 ) from the TCGA project (https://genome-
cancer.ucsc.edu/proj/site/hgHeatmap/# accessed 30th June 2016).   Unpaired 
T-test used for comparison of gene expression values. 
B) Normalised signal from gene expression microarray transformed by Log2 
from Verhaak et al., 2009 (Verhaak et al., 2009) for CEBPA (red dot indicates 
t(3;21) sample).  Normal karyotype AML (n=187) vs CBF fusion protein AML 
(t(8;21): n=35, t(3;21): n =1 ).  Data downloaded from GEO, accession number 
GSE6891, accessed 30th July 2016.   
C) Comparison of knockdown of CBF fusion protein in both types of AML 
identifies changes in biological processes common to both cell types.  
Hierarchical clustering of GO terms for up-regulated or down-regulated genes 
after either CBF fusion siRNA (siRUNX1-EVI1: RUNX1-EVI-1 siRNA; siRUNX1-
ETO: RUNX1-ETO siRNA), as compared to control siRNA.  Expression was 
measured after 10 days of treatment in SKH-1 cells or 4 days of treatment in 
Kasumi-1 cells.  The threshold for differentially expressed genes was defined as 
1.5 fold difference in expression between CBF fusion siRNA vs control siRNA 
treated cells.   
D) RUNX1 and CBF fusion proteins in both t(3;21) and t(8;21) cells bind to the 
CEBPA +47Kb enhancer.  UCSC browser screen at CEBPA of ChIP-seq of 
RUNX1, and either RUNX1-ETO in Kasumi-1 or RUNX1-EVI-1 in SKH-1. 
 
3.6.3 RUNX1-EVI-1 knockdown results in a genome wide 
increase of C/EBPα binding. 
Having characterised the changes in accessibility of cis-regulatory elements 
after RUNX1-EVI-1 knockdown, and up regulation of CEBPA expression 
following RUNX1-EVI-1 knockdown, we examined where C/EBPα was binding 
after RUNX1-EVI-1 knockdown. Identification of C/EBPα binding sites informs 
our understanding of the mechanism by which this transcription factor causes 
differentiation of the cells following RUNX1-EVI-1 knockdown. We therefore 
performed ChIP-seq for C/EBPα and also for RUNX1 and RUNX1-EVI-1 as 
controls, in SKH-1 cells after 10 days of either control or RUNX1-EVI-1 siRNA 
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transfection.  We also performed a RUNX1 and RUNX1-EVI-1 ChIP-seq after 2 
days of either control or RUNX1-EVI-1 siRNA transfection.  The parameters of 
the ChIP-seq experiments (table 3-6) and annotation of binding sites are as 
shown below (table-3-6 and figure 3-17A).  Examining specifically the RUNX1-
EVI-1 bound regions, figure 3-17B depicts the average global profile of the 
different ChIP-seq experiments at these sites.  As expected, RUNX1-EVI-1 
binding decreased following RUNX1-EVI-1 knockdown.  At the sites bound by 
RUNX1-EVI-1, RUNX1 binding was largely invariant.  However, C/EBPα binding 
was greatly increased at sites previously bound by RUNX1-EVI-1.   
Examples of the changes in C/EBPα binding after RUNX1-EVI-1 siRNA are 
depicted in figure 3-17C-D.  Some of the target genes with increased binding by 
C/EBPα, following RUNX1-EVI-1 knockdown, are required for terminal myeloid 
differentiation, e.g. MPO and CTSG.  These genes increased in expression, 
following RUNX1-EVI-1 knockdown.  However, following RUNX1-EVI-1 
knockdown, C/EBPα also increased binding to a number of genes which 
became repressed.  These genes are required for stem cell function and are 
frequently deregulated in leukaemias, such as GATA2, MEIS1, and MYCN (Ye 
et al., 2013, Kawagoe et al., 2007).  This suggests that increase in CEBPA 
expression after RUNX1-EVI-1 knockdown results in increased binding of 
C/EBPα at key genes that regulate haematopoietic differentiation and required 
for terminal myeloid function.   
Table 3-6 ChIP seq in SKH-1 after 2 days (D2) or 10 days (D10) treatment 
of control (MM) or RUNX1-EVI-1 siRNA (KD) 
High confidence peaks are ChIP-seq peaks that also coincide with DHSs. 
ChIP-seq Dataset Aligned reads (n) Peaks (n) High Confidence Peaks (n) 
Anti-EVI1 D10 MM 20,350,942 12,842 7,252 
Anti-EVI1 D10 KD  29,752295 2,014 1,208 
Anti-RUNX1 D2 MM 12,556,575 14,510 12,142 
Anti-RUNX1 D2 KD  7,123,119 14,165 10,983 
Anti-RUNX1 D10 MM 19,147,420 15,185 10,346 
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Anti-RUNX1 D10 KD  20,959,942 15,592 9,944 
Anti- C/EBPα D10 MM 23,509,134 9,346 7,016 
Anti- C/EBPα D10 KD  29,564,903 11,808 8,639 
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Figure 3-17 C/EBPα binding increases at both myeloid specific and stem 
cell associated genes after RUNX1-EVI-1 knockdown in SKH-1 cells 
A) Genomic distribution of binding sites by promoter, intragenic and intergenic 
region for RUNX1, EVI-1 (RUNX1-EVI-1) and C/EBPα ChIP seq peaks in 
t(3;21) SKH-1 after 10 days of either control (MM) or RUNX1-EVI-1 (KD) siRNA. 
B) Changes in binding of RUNX1 and C/EBPα at RUNX1-EVI-1 shared sites 
after RUNX1-EVI-1 knockdown in SKH-1 cells.  RUNX1-EVI-1 DNA binding 
decreased, and C/EBPα binding increased at the same sites following RUNX1-
EVI-1 knockdown Average profiles of EVI-1 (RUNX1-EVI-1), RUNX1 and 
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C/EBPα ChIP-seq centred on EVI-1 peaks in a 4 kb window in SKH-1 cells 
after10 days of treatment with either control (MM) or RUNX1-EVI-1 (KD) siRNA. 
C-D) Changes in RUNX1-EVI-1, RUNX1 and C/EBPα binding in SKH-1 after 
RUNX1-EVI-1 knockdown.  UCSC browser screen shots of the distribution of 
RNA-seq, DNase-seq and ChIP-seq aligned reads 10 days after either control 
siRNA or RUNX1-EVI-1 siRNA treatment c) MPO and CTSG and d) MEIS1, 
MYCN and GATA2 loci. MPO and CTSG expression increased and this 
increase was accompanied by increases in DNase accessibility, RUNX1 and 
C/EBPα binding, following RUNX1-EVI-1.  MEIS1, GATA2 and MYCN 
expression decreased following RUNX1-EVI-1 knockdown which was 
accompanied by increases in C/EBPα binding at these loci. 
We noted that the increased expression of certain genes such as MPO and 
CTSG was accompanied by changes in DNaseI accessibility and increased 
binding of C/EBPα and RUNX1 (figure 3-17).  However, it was unclear as to 
whether this was a genome wide phenomenon. To examine this relationship 
between the changes in DHSs and the differences in transcription factor binding 
following RUNX1-EVI-1 knockdown in more detail, we plotted a tag density heat 
map centred on the DHS peaks that were identified in SKH-1 cells transfected 
for 10 days with either control or RUNX1-EVI-1 siRNA,.  Alongside the same 
genomic coordinates we plotted tag density heat maps from each of the ChIP-
seq experiments (RUNX1-EVI-1, RUNX1 and C/EBPα in SKH-1 transfected for 
10 days with either control or RUNX1-EVI-1 siRNA) (Figure 3-18A).  This 
analysis shows that RUNX1-EVI-1 binding is globally depleted after knock-
down.  After RUNX1-EVI-1 siRNA transfection, RUNX1 binding was largely 
unchanged, except for an increase in binding in DHS which became more 
hypersensitive following knockdown of RUNX1-EVI-1.  C/EBPα binding after 
RUNX1-EVI-1 knockdown was increased globally, but especially at the DHSs 
with increased hypersensitivity.  Using the TF1 GATA2 ChIP-seq data we also 
noted that the DHSs with decreased hypersensitivity were enriched for GATA2 
binding (figure 3-18B). 
To understand whether the changes in transcription factor binding was caused 
by direct DNA binding or, indirectly through an intermediate transcription factor 
we analysed the underlying motifs of the transcription factor binding sites 
following RUNX1-EVI-1 knockdown.  Analysis of enriched motifs within RUNX1 
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ChIP seq binding sites 2 days post siRNA treatment show little difference in 
motif enrichment with or without RUNX1-EVI1 knock-down (figure 3-18C).  After 
10 days of RUNX1-EVI-1 siRNA treatment, both RUNX1 and C/EBPα ChIP 
peaks showed a loss of GATA motifs.  Following RUNX1-EVI-1 siRNA 
transfection, both RUNX1 and C/EBPα de novo binding sites were enriched for 
CEBP motifs (figure 3-18D-E).  CEBP and GATA motifs were not found in 
RUNX1 binding sites present in both control and RUNX1-EVI-1 siRNA 
transfected cells.   
This data suggests that RUNX1 and C/EBPα binding sites which are lost 
following RUNX1-EVI-1 knockdown, are bound in association with a GATA 
transcription factor, most likely GATA2.  In contrast, the new RUNX1 binding 
sites appearing following RUNX1-EVI-1 knockdown are characterised by CEBP 
motifs.  This is in keeping with the increase in CEBP and RUNX motif containing 
DHSs following RUNX1-EVI-1 knockdown.   
The data taken together in this section suggests that the mechanism behind the 
changes in SKH-1 cells following RUNX1-EVI-1 knockdown is the up-regulation 
of CEBPA and its genome-wide binding to key loci causing the repression of 
stem cells genes and driving myeloid differentiation.       
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Figure 3-18 Global increase in C/EBPα binding after RUNX1-EVI-1 
knockdown in SKH-1 cells 
A) Heatmap showing read densities of ChIP-Seq peaks centred on DHS peaks 
in SKH-1 cells treated with control siRNA within +/-4Kb windows.  Aligned to 
these coordinates are DHS peaks in SKH-1 cells treated with RUNX1-EVI-1 
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siRNA, followed by ChIP-seq of RUNX1-EVI-1, RUNX1 and C/EBPα in SKH-1 
cells after either 10 days of either control or RUNX1-EVI-1 siRNA treatment.  
Increased DNaseI accessibility was seen in in 2510 sites following RUNX1-EVI-
1 knockdown with increased binding of RUNX1 and C/EBPα at these sites.   
B)   Profiles of the DNase-seq tag density, in +/-4Kb windows centred on peaks, 
for SKH-1 treated for 10 days with either control or RUNX1-EVI-1 siRNA. 
Plotted to the right, GATA2 ChIP-seq tag density measured in the TF1 cell line 
(GSE73207), showing higher GATA2 binding at DHSs which decrease in 
accessibility following RUNX1-EVI-1 knockdown. 
C-D) RUNX1-EVI-1 knockdown results in a loss of RUNX1 binding sites with 
GATA motifs and an increase in sites with enriched C/EBP motifs after 10 days 
of RUNX1-EVI-1 siRNA treatment.  Left panel: Venn diagram showing peak 
overlaps from RUNX1 ChIP-seq after either C) 2 days or D) 10 days of control 
or RUNX1-EVI-1 siRNA transfection. The right panels show de novo motif 
analyses from distal peaks found after either siRNA treatment, or, specifically 
only after control siRNA or RUNX1-EVI-1 siRNA. 
E) RUNX1-EVI-1 knockdown results in loss of C/EBPα binding sites with an 
enrichment of GATA motifs and an increase in sites with an enrichment of 
C/EBP motifs.  Left panel: Venn diagram showing peak overlaps from C/EBPα 
ChIP-seq after either 10 days of control or RUNX1-EVI-1 siRNA.  The right 
panels show de novo analyses from distal peaks found after either siRNA 
treatment, or, specifically only after control siRNA or RUNX1-EVI-1 siRNA. 
 
3.7 The response to RUNX1-EVI-1 knockdown is blocked by 
dominant negative C/EBP (DNCEBP) peptide 
3.7.1 Phenotypic changes of RUNX1-EVI-1 knockdown is 
inhibited by presence of DNCEBP 
To investigate whether C/EBPα DNA binding was required for the downstream 
effects of RUNX1-EVI-1 knockdown, we generated SKH-1 cells expressing a 
dominant negative CEBP peptide (DNCEBP). This DNCEBP peptide has been 
shown to dimerise with all CEBP transcription factors and prevent binding to 
DNA (Krylov et al., 1995).  To this end, we transduced SKH-1 cells with 
lentiviruses carrying either an empty or a vector expressing a FLAG epitope 
tagged DNCEBP peptide.  Expression of DNCEBP peptide was confirmed by 
Western blotting (figure3-19A) using an antibody against the FLAG tag. We 
then serially transfected the transduced SKH-1 cells with either control or 
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RUNX1-EVI-1 siRNA over a 14 day period (figure 3-19B). Both empty vector 
and DNCEBP vector transduced SKH-1 cells were treated in parallel.  
Knockdown of RUNX1-EVI-1 in each cell line was confirmed by Western blot 
and RT-qPCR (figure 3-19A and B).   
 
Figure 3-19 The down-stream effects of RUNX1-EVI-1 knock-down are 
blocked in SKH-1 cells transduced with a DNCEBP peptide 
A) Western blot with whole cell lysates from untreated, empty or DNCEBP 
vector transduced SKH-1 cells, transfected with either control or RUNX1-EVI-1 
siRNA after 14 days.  The blot was probed with EVI-1, FLAG or GAPDH 
antibodies as indicated.  Knock-down of RUNX1-EVI-1 was performed in both 
empty vector and DNCEBP vector expressing SKH-1. DNCEBP peptide 
expression was confirmed by probing with an anti-FLAG antibody (middle 
panel).    
B) Experimental scheme for performing RUNX1-EVI-1 knockdown in either 
empty vector or DNCEBP vector transduced SKH-1 cells with transfection with 
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either control siRNA or RUNX1-EVI-1 siRNA being performed on days 0, 3, 6, 9 
or 12.  Cells were harvested to collect for RNA, chromatin, DNaseI or flow 
cytometry on indicated days. 
C) Analysis of mRNA levels relative to GAPDH after control or RUNX1-EVI-1 
siRNA transfection (4, 10 or 14 days of treatment).  RUNX1-EVI-1 or RUNX1 
mRNA levels in either empty vector or DNCEBP vector transduced SKH-1 were 
measured at the indicated days, showing a reduction of RUNX1-EVI-1 mRNA in 
both empty and DNCEBP vector transduced cells following RUNX1-EVI-1 
siRNA transfection. 
 
SKH-1 cells that were transduced with an empty vector showed a decrease in 
CD34 expression and a decline in growth rate when serially transfected with 
RUNX1-EVI-1 siRNA as compared to control cells.  In contrast, SKH-1 cells 
transduced with a vector expressing the DNCEBP peptide displayed neither a 
change in surface levels of CD34 nor a decline in growth (figure 3-20A-C).  We 
measured the expression of the key stem cell genes HOXA9, GATA2 and 
MEIS1 which all decreased in empty vector transduced SKH-1 following 
knockdown of RUNX1-EVI-1. However, in DNCEBP transduced SKH-1 there 
was no change in HOXA9 expression following RUNX1-EVI-1 knockdown.  
Expression of GATA2 and MEIS1 still declined, but this remained expressed at 
a higher level (figure 3-20D).  CTSG, MPO, and CSF1R, all of which are 
markers of terminal myeloid differentiation, decreased as expected in empty 
vector transduced SKH-1 following RUNX1-EVI-1 sRNA transfection, whilst in 
SKH-1 expressing DNCEBP, RUNX1-EVI-1 knock-down had no effect on the 
expression of these genes (figure 3-20E).  It is therefore clear that the 
phenotypic changes following RUNX1-EVI-1 (figure 3-9) require C/EBPα DNA 
binding.  However, despite up regulation of these genes required for myeloid 
differentiation, neither CD14 nor CD11b expression changed in empty vector 
transduced SKH-1 following RUNX1-EVI-1 siRNA transfection, suggesting the 
differentiation process remained incomplete. 
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Figure 3-20 DNCEBP expression blocks the phenotypic changes seen in 
SKH-1 cells following RUNX1-EVI-1 knockdown 
A) Reduction in cell growth by RUNX1-EVI-1 siRNA is abrogated by DNCEBP 
peptide.  Growth rate of empty (solid lines) or DNCEBP (dashed lines) vector 
transduced SKH-1, transfected with RUNX1-EVI-1 siRNA, relative to control 
siRNA treatment.  The graph shows the mean and SEM of 3 independent 
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experiments.  * denotes p<0.05 by unpaired t-test between RUNX1-EVI-1 
siRNA transfected empty and DNCEBP vector transduced SKH-1, and paired t-
test between control and RUNX1-EVI-1 siRNA transfected empty vector 
transduced SKH-1 cells, after 14 days of siRNA treatment. 
B-C) DNCEBP prevents downregulation of CD34 by RUNX1-EVI-1 siRNA 
transfection.  Flow cytometry of empty and DNCEBP vector transduced SKH-1 
cells, untreated or after 14 days of either mock, control or RUNX1-EVI-1 siRNA 
treatment.  B) Representative overlay of histogram with CD34-APC staining, C) 
The graph shows the MFI (median), mean of 3 independent experiments with 
error bars representing SEM.  *denotes p<0.05 by paired t-test. 
D) DNCEBP prevents downregulation of HOXA9 and abrogates down-
regulation of GATA2 and MEIS1 expression.  mRNA levels by RT-qPCR 
relative to GAPDH after RUNX1-EVI-1 siRNA transfection (4, 10 or 14 days of 
treatment). HOXA9 expression decreased in empty vector transduced SKH-1 
transfected with RUNX1-EVI-1 siRNA as compared to control siRNA, but this 
decrease is abrogated in DNCEBP vector transduced SKH-1. GATA2 and 
MEIS1 follow a similar pattern but the impact of DNCEBP is reduced.   The 
graph shows the mean and SEM of 3 independent experiments. 
E) DNCEBP prevents up-regulation of MPO, CSF1R and CTSG following 
RUNX1-EVI-1 knockdown.  mRNA levels by RT-qPCR relative to GAPDH after 
control RUNX1-EVI-1 siRNA transfection (4, 10 or 14 days of treatment). MPO, 
CSF1R and CTSG increases after transfection with RUNX1-EVI-1 siRNA, as 
compared to control siRNA, in empty vector transduced cells but not in 
DNCEBP vector transduced cells.  The graph shows the average and SEM of 3 
independent experiments. 
F-G) Myelopoiesis following RUNX1-EVI-1 knockdown is incomplete. Flow 
cytometric analysis of either empty or DNCEPB vector transduced SKH-1 cells 
untreated, or after 14 days of either electroporation alone, or after control or 
RUNX1-EVI-1 siRNA transfection. MFI (median) of either F) CD14 or G) CD11b 
staining, relative to non-electroporated cells after 14 days of treatment.  The 
graph shows the mean and SEM of 3 independent experiments. 
 
3.7.2 DNCEBP expression alters regulation of gene expression 
by C/EBPα 
We demonstrated in figure 3-17 and 3-18 that DHSs that increase in nuclease 
accessibility were associated with increases in C/EBPα and RUNX1 binding.  
However, it was unclear whether this increase in DHS hypersensitivity could be 
seen in the absence of CEBPα, and whether CEBPα binding was required for 
RUNX1 binding. We chose examples of several loci where DHS became more 
   
 150 
accessible (MPO enhancer, CTSG promoter (figure 3-17C); TREM1 promoter, 
SIGLEC1 enhancer (figure3-21A)).  These sites are associated with genes 
expressed in mature myeloid cells (Borregaard et al., 2007, Barral et al., 2010, 
Klesney-Tait et al., 2013).  C/EBPα bound to these sites after RUNX1-EVI-1 
knockdown in empty vector transduced SKH-1, but in the presence of DNCEBP 
binding was blocked.  Similarly, RUNX1 bound to these sites in empty vector 
transduced SKH-1 cells following RUNX1-EVI-1 knockdown, but in the absence 
of C/EBPα binding in DNCEBP expressing SKH-1, RUNX1 was unable to bind 
to these sites (figure 3-21B).  Finally, following RUNX1-EVI-1 knockdown, 
chromatin remains inaccessible at these sites in DNCEBP vector expressing 
SKH-1 cells, as compared to control cells (figure 3-21C).  This result suggests 
that following RUNX1-EVI-1 knock-down and CEBPA up-regulation, C/EBPα 
DNA binding cooperates with RUNX1 to increase chromatin accessibility to up-
regulate genes required for terminal myeloid function. 
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Figure 3-21 C/EBPα DNA binding is required to recruit RUNX1 and open 
previously inaccessible chromatin 
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A) UCSC browser screen-shot showing changes in RUNX1-EVI-1, RUNX1 and 
C/EBPα binding after RUNX1-EVI-1 knockdown at TREM1 and SIGLEC1 loci.  
Increased chromatin accessibility following RUNX1-EVI-1 knockdown is 
associated with increased C/EBPα and RUNX1 DNA binding at these loci. 
Boxes designate sites used for amplicons in ChIP and DNaseI experiments 
described in B) and C).  RNA-seq, DNase seq and ChIP seq were performed 10 
days after either control siRNA or RUNX1-EVI-1 siRNA treatment. 
B-C) Increased C/EBPα, and RUNX1 binding after RUNX1-EVI-1 knockdown is 
prevented by DNCEBP expression.  B) C/EBPα or C) RUNX1 ChIP -qPCR 
using amplicons corresponding to the MPO and SIGLEC1 enhancers and the 
TREM1 and CTSG promoters.  The position of amplicons is highlighted by 
boxes in the UCSC browser screenshots from figure 3-17C, and figure 3-21A. 
An amplicon covering the SPI1 3’ URE was used as positive control and 
chromosome 18 as negative control. qPCR enrichment relative to input and IVL.  
Chromatin was harvested from empty or DNCEBP vector transduced cells 10 
days after either control or RUNX1-EVI-1 siRNA transfection. The graph shows 
the mean of 3 independent experiments, with error bars representing SEM. 
c) Increased DNaseI hypersensitivity after RUNX1-EVI-1 knockdown is 
prevented by DNCEBP.  DNaseI and qPCR validation at MPO and SIGLEC1 
enhancer, TREM1 and CTSG promoter.  Amplicons covering the ACTB gene 
body were used as as negative control. qPCR enrichment was calculated 
relative to chromosome 18.  2 independent experiments involving 10 days of 
siRNA transfection are shown. 
 
3.8  Overexpression of an inducible version of C/EBPα 
phenocopies RUNX1-EVI-1 knockdown 
Having demonstrated that C/EBPα DNA binding capacity is critical for the 
downstream effects of RUNX1-EVI-1 knockdown, we next investigated whether 
over-expression of C/EBPα was sufficient to replicate the effects of RUNX1-
EVI-1 knockdown. To accomplish this we used a retrovirus encoding a CEBPA-
ER transgene fused to an IRES-GFP sequence.  C/EBPα –ER is a fusion of 
C/EBPα with the estrogen receptor ligand binding domain which can translocate 
into the nucleus when bound to 17β-Estradiol (Bussmann et al., 2009, Umek et 
al., 1991).  Successfully transduced SKH-1 were identifiable by the presence of 
GFP and separated by FACS. A Western blot with lysates from C/EBPα-ER 
expressing SKH-1 cells show that they express the correct protein size (76kDa) 
(figure 3-22A).  RT-PCR using C/EBPα-ER specific amplicons showed that 
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mRNA expression is specific in SKH-1 transduced with virus, as compared to 
mock treated cells (figure 3-22B).  The levels of C/EBPα-ER mRNA appeared to 
be decreased in the cells treated with 10nM 17β-Estradiol because the GFP 
positive population of cells declined following treatment as described previously 
in the methods (figure 2-3).  However, after induction of C/EBPα activity, the 
endogenous CEBPA gene showed an upregulation as a result of an “auto-
regulation” of this gene which has been seen before (Timchenko et al., 1995) 
(figure 3-22B).   
C/EBPα-ER SKH-1 cells were exposed to 10nM 17β-estradiol for 48 hrs which 
resulted in an increase of apoptotic cells (figure 3—22 C-D) and reduction in 
growth rate (figure 3-22E), when compared to ethanol treatment, or to mock 
treated SKH-1 exposed to the same treatments. This increase of apoptosis was 
similar to the effects of RUNX1-EVI-1 knockdown seen in figure 3-10.   
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Figure 3-22 Induction of C/EBPα-ER by phenocopies RUNX1-EVI-1 
knockdown 
A-B) CEBPA-ER transduction in SKH-1 cells results in expression of a fusion 
C/EBPα –ER protein.  
A) Western blot with nuclear extracts from mock treated or CEBPA-ER 
transduced SKH-1 cells treated with either vehicle (ethanol) or 10nM 17β-
Estradiol.  The membrane was probed with C/EBPα and H3 antibodies as 
indicated.  The black arrow indicates the size of band corresponding to the 
C/EBPα-ER fusion protein. 
B) Endogenous CEBPA and CEBPA-ER mRNA levels as measured by RT-
qPCR relative to GAPDH of mock treated or CEBPA-ER transduced SKH-1 
cells treated with either vehicle (ethanol) or 10nM 17β-Estradiol. The graph 
shows the mean of 3 independent experiments with SEM. 
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C-E) Induction of C/EBPα activity increases apoptosis in CEBPA-ER SKH-1 
cells.   Annexin-V APC and PI staining in mock treated or CEBPA-ER 
transduced SKH-1 cells, treated with either vehicle (ethanol) or 10nM 17 β –
Estradiol followed by flow cytometry.  C) Representative plots are shown. D) 
Relative frequencies of unstained, Annexin-V positive cells. E) Growth rate 
relative to ethanol treated mock transduced SKH-1 after 2 days of treatment of 
either ethanol or 10nM 17 β -Estradiol.  The Graph shows the mean and SEM of 
3-5 independent experiments.  * denotes p<0.05 by paired t-test. 
 
RUNX1-EVI-1 knockdown resulted in a down-regulation of CD34 and genes 
associated with stem cell function, alongside up-regulation of genes associated 
with myelopoiesis (figure 3-9).  Activation of C/EBPα-ER phenocopied RUNX1-
EVI-1 knockdown and led to the down-regulation of CD34 and genes 
associated with stem cell function (figure 3-23 A-C), despite the continued 
expression of RUNX1-EVI-1 (figure 3-23 C).  In parallel, genes associated with 
terminal myeloid differentiation were up-regulated following induction of 
C/EBPα-ER (figure 3-23C).  This was accompanied by an up-regulation of 
CD11b (figure 3-23 D-E).  Colony forming capacity was also reduced following 
C/EBPα-ER induction, in terms of both total numbers (figure 3-23 F) as well as 
morphologically in terms of size (figure 3-23 G). 
Therefore, overexpression of C/EBPα alone is sufficient to drive the changes 
seen in SKH-1 cells following RUNX1-EVI-1 knockdown.  This evidence along 
with the data provided from the DNCEBP expressing SKH-1 cell line (Chapter 
3.7), suggests that inhibition of C/EBPα by RUNX1-EVI-1 is the critical node by 
which t(3;21) cells maintain their leukaemic identity.  Our data also show that 
both RUNX1-EVI-1 and RUNX1-ETO share this C/EBPα dysfunction (Chapter 
3.6.2).   
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Figure 3-23 C/EBPα-ER activation overrides the effects of RUNX1-EVI-1 
and leads to partial differentiation of SKH-1 cells 
A-B) Induction of C/EBPα activity in CEBPA-ER SKH-1 cells results in the 
down-regulation of CD34.  Flow cytometry of mock or CEBPA-ER transduced 
SKH-1 cells treated with either vehicle (ethanol) or 10nM 17-Estradiol for 48 
hours.  A) Representative overlay of histogram of cells stained with CD34-APC.  
B) MFI (median) of CD34-APC staining.  MFI relative to ethanol treated, mock 
transduced SKH-1.  The graph shows the mean of 3 independent experiments 
with SEM.  *denotes p<0.05 by paired t-test. 
C) Changes in gene expression of key target genes after induction of C/EBPα-
ER activity mirrors the changes seen after RUNX1-EVI-1 knockdown.  mRNA 
levels relative to GAPDH of the indicated genes were measured in mock treated 
or CEBPA-ER transduced SKH-1 cells treated with either vehicle (ethanol) or 
10nM 17-Estradiol.  The graph shows the mean of 3 independent experiments 
with SEM. * denotes p<0.05 by paired t-test. 
D-E) Induction of C/EBPα activity in CEBPA-ER SKH-1 cells results in the up-
regulation of CD11b.  Flow cytometry of mock or CEBPA-ER transduced SKH-1 
cells were treated with either vehicle (ethanol) or 10nM 17-Estradiol.  A) 
Representative overlay of flow cytometry histograms of cells stained with 
CD11b-APC.  B) MFI (median) of CD11b-APC staining relative to ethanol 
treated, mock transduced SKH-1.  The graph shows the mean of 3 independent 
experiments with SEM.  *denotes p<0.05 by paired t-test. 
F-G) Induction of CEBPA-ER results in reduced colony forming capacity.  SKH-
1 cells were either mock treated or transduced with CEBPA-ER virus.  Mock 
treated or CEBPA-ER transduced SKH-1 were treated for 48 hours with either 
ethanol (vehicle control) or 17β Estradiol, prior to plating on methylcellulose 
culture.  F) Colonies of over 20 cells were counted between 7-11 days after 
plating.  The graph shows the mean of 5 experiments, with error bars 
representing S.E.M.  * signifies p<0.05 by paired t-test.  G) Representative 
photographs of colonies are shown.  The scale bar represents 400 μM. 
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Chapter 4. Discussion 
4.1 Epigenetic landscape differ between t(3;21) and t(8;21) 
leukaemias driving the use of different regulators of self-
renewal 
In this work, we demonstrated that t(3;21) leukaemia and t(8;21) leukaemia 
differ in their gene expression profiles and DHS landscape.  The samples 
cluster according to gene expression profile in a similar pattern to the clustering 
based on the pattern of DHSs (figure3-2 and 3-3).  This is not surprising, as 
these sites represent active cis-regulatory elements that control gene 
expression.  This is consistent with previous studies showing that AML can be 
classified according to gene expression and methylation profiles that segregate 
samples according to their mutational status, suggesting that AML is a disease 
of epigenetic dysfunction (Figueroa et al., 2010b, Valk et al., 2004).  This has 
been confirmed by the discovery from targeted and whole genome sequencing 
studies that mutations in AML primarily affect transcription factors and 
epigenetic regulators (Papaemmanuil et al., 2016, Cancer Genome Atlas 
Research, 2013). 
In our study, we show examples of genes which are both highly expressed in 
t(8;21) leukaemia (ROBO1  and CACNA2D2) as compared to t(3;21) 
leukaemia, and also genes which are poorly expressed in t(8;21) leukaemia as 
compared to t(3;21) leukaemia (HOXA9 and MEIS1) (figure 3-1).  t(3;21) 
leukaemia has not been studied before in this manner, but other studies have 
shown that t(8;21) AML segregate independently from other types of leukaemia 
(Valk et al., 2004).  ROBO1 and CACNA2D2 are examples of genes known to 
be upregulated in t(8;21) leukaemia in comparison to other forms of AML.  In 
contrast, HOXA9 and MEIS1 have previously been shown to be downregulated 
in t(8;21) leukaemia, as compared to other forms of AML (Lavallée et al., 2016, 
Ross et al., 2004, Valk et al., 2004, Yagi et al., 2003).  
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t(3;21) leukaemias have a poorer prognosis than t(8;21) leukaemia, with low 
remission rates of 43% and event free survival of  only 14% (Lugthart et al., 
2010).  HOXA9 and MEIS1 are both expressed in t(3;21) leukaemia but not in 
t(8;21) leukaemia.  HOXA9 expression is associated with poor prognosis in 
AML (Golub et al., 1999, Andreeff et al., 2008) and its expression is linked to a 
number of mutational subtypes including MLL and NUP98 translocations 
(Collins and Hess, 2015).  MEIS1 expression is also associated with poor 
prognosis AML as part of gene expression pattern (Eppert et al., 2011) seen in 
HSCs and LSCs.  HOXA9 and MEIS1 are often co-expressed in AML 
(Lawrence et al., 1999) and Hoxa9 requires the co-expression of Meis1 to 
transform murine bone marrow progenitor cells (Kroon et al., 1998).  This 
cooperativity can be explained by the identification of large number of cis-
regulatory elements that are co-bound by both HOXA9 and MEIS1 (Huang et 
al., 2012).  In turn, there is an association between EVI-1 (partner of RUNX1 in 
RUNX1-EVI-1) and HOXA9 and MEIS1.  HOXA9 and MEIS1 are important 
downstream targets of MLL-fusion proteins and EVI1 have been shown to be 
important in maintaining the leukaemic growth of MLL-AF9 and MLL-ENL 
transformed cells (Bindels et al., 2012, Goyama et al., 2008). Cooperation 
between HOXA9 and MEIS1 with EVI-1 is suggested by the frequency of 
retroviral insertion sites at EVI-1, in retrovirus mediated over-expression of 
HOXA9 and MEIS1 (Jin et al., 2007).   
In contrast, t(8;21) leukaemia have been shown by independent cooperative 
groups to have a significantly improved prognosis compared to other 
leukaemias (Grimwade et al., 2010, Byrd et al., 2002, Slovak et al., 2000).  
Remission rates have been reported as over 90% with 10 year overall survival 
at 61% (Grimwade et al., 2010). Interestingly, both ROBO1 and CACNA2D2 are 
associated with potential tumour suppressor function, as candidate genes in 
regions frequently deleted in solid tumours (Hesson et al., 2007) .  ROBO1 is a 
receptor that binds the SLIT2 ligand and is important in neuronal development 
by ensuring correct axonal guidance.  In MDS, loss of function mutations of 
ROBO1 and ROBO2  have been associated with progression to AML, and 
overexpression of ROBO1 in leukaemic cell lines led to increased apoptosis (Xu 
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et al., 2015).  CACNA2D2 encodes a voltage gated calcium channel, which 
when mutated in mice leads to the development of an ataxic gait and epilepsy 
(Barclay et al., 2001).  No studies on CACNA2D2  have been performed in 
AML, however, functional studies have shown both tumour suppressor activity 
in lung cancer (Carboni et al., 2003) and oncogenic properties in prostate 
cancer (Warnier et al., 2015).  Overall, CACNA2D2 is thought to be a tumour 
suppressor gene, as it is part of a 120kb region recurrently deleted in a variety 
of solid tumours (Hesson et al., 2007).   
Therefore in this work we provide evidence of differentially expressed genes, 
that helps explain the difference in prognoses between the CBF leukaemia.  
Furthermore, we describe the mechanisms that maintain this gene expression 
profile by the use of DNase-seq.  The identification of a pattern of cis-regulatory 
elements that distinguishes the t(8;21) from the t(3;21) leukaemia is further 
proof that this technology can be used for “class discovery” (Golub et al., 1999), 
enabling further refinement of AML subtyping. Here we demonstrate the 
advantage of DNase-seq over only using gene expression profiling as we are 
able to identify the cis-regulatory elements that define each leukaemia.  For 
example, DHSs which are unique to t(3;21) leukaemia as compared to t(8;21) 
leukaemia frequently contain the GATA motif.  In contrast, DHSs found in 
t(8;21) leukaemia as compared to t(3;21) leukaemia often contain the E-Box 
motif (figure 3-2D and E).  This is directly related to the different properties of 
each CBF fusion protein (Section 4.3), thereby giving insight into the 
mechanism of leukaemogenesis in each type of CBF leukaemia. 
The t(3;21) SKH-1 cell line appears to be an extremely good model for studying 
the epigenetic effects of t(3;21) leukaemia as the DHSs in the cell line and 
patient samples overlap substantially (figure 3-2B).  However, in terms of gene 
expression, the t(3;21) SKH-1 cell line shows some distinct differences with the 
t(3;21) AML patient samples, in both a PCA analysis and clustering based on 
gene expression signal (figure 3-3 B and C).  This may be due to intrinsic 
differences between autonomously growing cell lines as compared to primary 
patient samples, but also to the differences in cooperative mutations in these 
   
 161 
samples.  The SKH-1 cell line is derived from a patient with CML, who 
developed a myeloid blast crisis (Mitani et al., 1994) and therefore also 
expresses the translocation t(9;22) which produces the potent fusion protein 
BCR-ABL. 
4.1.1 Distinct and common mechanisms for self-renewal 
between t(3;21) and t(8;21) leukaemia  
In both RNA-seq and DNase-seq analyses, t(3;21) cluster with normal CD34+ 
progenitor cells, demonstrating that both cell types share a significant gene 
expression and cis-regulatory program.  Although CD34 expression is found in 
both HSCs and early progenitors, after knockdown of RUNX1-EVI-1in SKH-1 
cells, a HSC and LSC gene expression gene sets are lost (figure 3-11D), 
thereby implicating this immature stem cell expression program in the 
pathogenesis of t(3;21) leukaemia.  This may reflect shared “stemness” 
properties such as quiescence, niche dependence and self-renewal properties 
used in both HSCs and t(3;21) leukaemia.  This is consistent with previous 
studies which have shown that LSCs and HSCs share a set of genes that likely 
represent these functions (Eppert et al., 2011).  Previous literature may suggest 
that this is due to a cell of origin transformation being a normal HSC (Lapidot et 
al., 1994, Bonnet and Dick, 1997).  Contemporary views suggest that committed 
progenitors may regain aspects of stem cell properties through transformation 
into AML (Goardon et al., 2011, Quek et al., 2016, Jamieson et al., 2004).  
However, a recent study suggests that HSCs transformed by MLL-AF9 differ 
from GMP transformed by the same fusion gene, by the higher expression of 
EVI-1 and ERG, and this results in a more aggressive leukaemia (Stavropoulou 
et al., 2016). In turn, this is consistent with previous studies showing that EVI-1 
overexpression is a poor prognostic factor in AML with MLL translocations 
(Groschel et al., 2013).  Our GSEA demonstrating the loss of both HSC and 
LSC gene programs following knockdown of RUNX1-EVI-1, directly links 
RUNX1-EVI-1 to the maintenance of this gene expression profile, suggesting 
this oncogene has the potential to endow or maintain these “stem-like” 
properties.   
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A key member of this gene expression program found in both LSCs and HSCs 
(Eppert et al., 2011), and one of five genes expressed in both CD34+ and – 
LSCs (Quek et al., 2016) is MEIS1,  which also play an important role in normal 
HSC biology. Meis1 knockout mice die from haemorrhage due to a lack of 
megakaryocytes.  Although myeloerythroid lineages develop, there is a 
reduction in colony forming potential and fetal liver cells from Meis1 knockout 
mice have deficiencies in competitive repopulation assays in transplantation into 
lethally irradiated mice (Hisa et al., 2004).  We demonstrate here that RUNX1-
EVI-1 binds to the promoter of MEIS1 and upon knockdown of RUNX1-EVI-1; 
MEIS1 expression is down-regulated (figure 3-17D).    
Our finding that RUNX1-EVI-1 is directly involved in regulating this stem cell 
program is entirely consistent with our knowledge of the fusion partner of 
RUNX1.  EVI-1, also known as MECOM, is expressed in both HSCs and LSCs 
(Eppert et al., 2011).  Its role in AML is well characterised.  Over-expression of 
EVI-1 is an independent poor prognostic factor in AML as demonstrated by a 
large cooperative group (Groschel et al., 2010). When retrovirally expressed in 
murine bone marrow it causes a myelodysplastic syndrome (Buonamici et al., 
2004).  It is also a key regulator of HSC function; EVI-1 homozygous deficient 
HSCs have deficient self-renewal properties as shown by defective repopulating 
ability (Goyama et al., 2008, Kataoka et al., 2011).     
Although t(8;21) leukaemia cluster separately, both RUNX1-ETO and RUNX1-
EVI-1 target ERG (Ptasinska et al., 2014) (figure 3-12C).  In both RUNX1-ETO 
and RUNX1-EVI-1 knockdown, expression of ERG is decreased. ERG is a 
member of the ETS family of transcription factors and is another part of both 
HSC and LSC gene expression program (Eppert et al., 2011).  ERG 
overexpression in AML with normal karyotype is associated with a poor 
prognosis (Metzeler et al., 2009).  ERG function is vital for the emergence of 
definitive HSCs and the ability of adult HSCs to repopulate lethally irradiated 
recipient mice (Loughran et al., 2008). Ectopic over expression of ERG in 
human CD34+ cord blood cells results in an expansion of the progenitor pool 
(Tursky et al., 2015).   
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WT1 is another target of both RUNX1-ETO and RUNX1-EVI-1 that is highly 
expressed in primitive CD34+CD38- haematopoietic cells, which when 
overexpressed, enforces quiescence in this population  (Ellisen et al., 2001).  
WT1 expression is decreased following RUNX1-EVI-1 knockdown.   In AML, 
WT1 has both oncogenic and tumour suppressor characteristics in that, loss of 
function mutations are commonly seen, but simultaneously, overexpression of 
WT1 is associated with a poor prognosis  (Rampal and Figueroa, 2016). WT1 
encodes a zinc finger transcription factor which has been reported to direct 
TET2 to target genes. Mutations in WT1 disrupt this association with TET2 and 
leads to hypermethylation of target genes (Wang et al., 2015, Rampal et al., 
2014). 
In summary, the close association of t(3;21) leukaemia with early stem and 
progenitor cells is reflected in the expression of many genes important in 
programs important for the maintenance of the normal HSC compartment but is 
also frequently co-opted by leukaemic stem cells in order to share many 
functions associated with stem cells, such as self- renewal.  A smaller subset of 
these genes are also activated in t(8;21) leukaemia, and are likely also to be 
part of the means by which this leukaemia maintains its self-renewal properties.  
The difference in expression of these stem cell genes are likely to contribute to 
the differences in prognoses between these two forms of leukaemia.      
4.2 RUNX1-EVI-1 and RUNX1-ETO bind DNA in association with 
different transcription factor complexes 
In this study we have performed a genome wide binding study of RUNX1-EVI-1, 
which is constitutively expressed in a t(3;21) cell line and have compared this 
binding pattern to RUNX1-ETO in a t(8;21) Kasumi-1 cell line.  RUNX1-ETO 
DNA binding sites has been demonstrated previously in vivo, in both primary 
patient material and cell lines with the t(8;21) translocation (Ptasinska et al., 
2012, Martens et al., 2012).  However, DNA binding activity for RUNX1-EVI-1 
has only been previously demonstrated in in vitro studies and transfected cell 
lines in which the fusion protein has been over expressed, therefore, this is the 
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first study to be able to draw a comparison between binding sites of both CBF 
fusion proteins.   
In figure 3-5 and 3-6 we show that RUNX1-ETO and RUNX1-EVI-1 bind a 
substantial number of sites unique to each fusion protein. This difference in the 
repertoire of gene targets has important implications in terms of the 
mechanisms by which the two fusion proteins lead to leukaemia.  One possible 
reason for the difference in binding sites may be differences in DNA binding 
motifs directly bound by each CBF fusion protein.  RUNX1-ETO has only one 
DNA binding domain and thus can directly bind RUNX motifs.  The three 
potential DNA binding domains (RUNT and two zinc-finger domains from the 
EVI-1 fusion, figure 1-3) may have additional DNA specificity.  It has been 
previously shown only in in vitro studies that EVI-1 binds to either a  
GA(C/T)AAGA(T/C)AAGATAA (Delwel et al., 1993) or TGACAAGATAA 
sequence (Perkins et al., 1991).  We were unable to identify either of these 
sequences in our motif searches, even we extended the sequence length 
criteria to accommodate this long motif.  Although GATA motif containing sites 
are found in sites specifically bound by RUNX1-EVI-1 as compared to RUNX1-
ETO, the binding of the EVI-1 partner to GATA motif alone would not explain 
why sites containing these motifs are also bound by RUNX1 in the t(3;21) 
leukaemia (figure 3-6 and 3-18).  Further, in support of our argument that the 
EVI-1 part of RUNX1-EVI-1 does not bind DNA directly, others have shown that 
EVI-1 does not directly bind to DNA in a different cell line, but requires an 
interaction with GATA1 to do so.  Mutations in EVI-1 that abolish this interaction 
prevent the functional effects of EVI-1 in retroviral overexpression in murine 
bone marrow cells (Laricchia-Robbio et al., 2006). 
The differences in DNA binding sites are likely to be accounted for by the 
formation of different transcription factor complexes by each CBF fusion protein 
as a result of differing transcription factor interactions with either RUNX1-ETO 
or RUNX1-EVI-1 (figure 3-7C-D).  We used a DNase-seq footprinting algorithm 
to enable the identification of motifs directly occupied by transcription factors in 
patient AML samples.  By analysing DNA sequences bound by each CBF fusion 
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protein, as identified in ChIP-seq experiments in each cell line, in patient AML 
samples, we were able to identify which transcription factor families were 
associated with RUNX1-EVI-1 or RUNX1-ETO in purified primary, CD34+ AML 
cells.  The occupied motifs identified in the patient samples were consistent with 
the enrichment of motifs in specific sites bound by each CBF fusion protein in 
the cell line (figure 3-6).  We sampled this footprinted motif with a bootstrapping 
analysis in order to identify significantly co-localising transcription factors.  This 
identified co-localising motifs occupied by PU.1-ERG-AP1-GATA transcription 
factors in RUNX1-EVI-1 binding sites, and RUNX-ERG-E-Box occupied motifs 
in RUNX1-ETO binding sites.   
ETS transcription factor family member binding cooperativity is likely to be 
shared by the two CBF fusion proteins as this is promoted through the RUNX1 
part of the fusion protein (Wotton et al., 1994).  This may explain the presence 
of ERG occupied sites in both RUNX1-EVI-1 and RUNX1-ETO binding sites. 
The cooperativity between ERG and RUNX1-ETO binding has been previously 
shown (Martens et al., 2012). 
In contrast, RUNX1-ETO but not RUNX1-EVI-1 forms a complex with E-Box 
binding transcription factors such as HEB and E2A (Sun et al., 2013, Ptasinska 
et al., 2014).  This interaction is mediated by the NHR domain which is part of 
ETO, and the E protein (Sun et al., 2013), and hence this motif is specifically 
found at sites bound by RUNX1-ETO.   
EVI-1, the fusion partner of RUNX1-EVI-1 has been shown to directly interact 
with the AP-1 family member FOS in a number of different cell lines (Bard-
Chapeau et al., 2012). This interaction may be reinforced by the ability of EVI-1 
to directly stimulate AP-1 signalling  (Tanaka et al., 1994). In t(3;21) leukaemia, 
the most likely GATA factor to bind with RUNX1-EVI-1 is GATA2.  GATA1 and 2 
are the only GATA transcription factors expressed in both t(8;21) and t(3;21) 
leukaemia, however GATA2 is the most likely candidate in terms of expression 
patterns as GATA1 is mainly expressed in erythroid and megakaryocytic cells 
(figure3-7E)(Akashi et al., 2000).  Furthermore, GATA2 binding sites from a 
related cell line are shared with both RUNX1-EVI-1 and RUNX1 (figure 3-7F).  
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This is in keeping with the observation that GATA motifs are found in binding 
sites of both RUNX1 and RUNX1-EVI-1 (figure 3-6C).  Indeed, the loss of 
GATA2 expression (but not GATA1) is seen following RUNX1-EVI-1 knockdown 
(figure 3-9E), and this correlates with a reduction in accessibility of GATA motif 
containing DHSs (figure 3-14B) which are sites strongly bound by GATA2 in the 
related leukaemic cell line (figure 3-18 B).  This result is consistent with the 
observation that HSCs are extremely sensitive to GATA2 mRNA levels.  Gata2-
/- mice cannot survive due to a failure of haematopoiesis (Tsai et al., 1994).  
Mice with heterozygous loss of Gata2 can survive but show defects in fetal 
(Ling et al., 2004) and adult haematopoiesis (Rodrigues et al., 2005).  In 
contrast murine HSC which overexpress GATA2 by 2-fold display a block in 
their differentiation (Persons et al., 1999).  The interaction between GATA2 and 
RUNX1-EVI-1 may be mediated through its RUNX1 domain.  RUNX1 binding 
sites co-localise with the footprinted GATA motifs in t(3;21) leukaemic cells 
(figure 3-7A) and RUNX1 have been shown to physically interact with GATA2 in 
previous studies (Wilson et al., 2010). 
4.2.1 CBF fusion protein binding pattern is intrinsically linked 
to the DHS landscape  
GATA motifs are frequently found in DHSs unique to t(3;21) leukaemia, whilst, 
E-Box motifs are frequently found in DHSs unique to t(8;21) leukaemia (figure 
3-2).  This directly reflects the predominance of these motifs found in analysis of 
the CBF fusion protein binding sites (figure 3-5 and 3-6).  These unique t(3;21) 
DHSs are likely bound by a complex containing ERG/AP1/PU.1/RUNX1-EVI-
1/GATA2, whilst the unique t(8;21) DHSs are likely bound by an ERG/RUNX1-
ETO/(HEB/E2A) complex, as described above.  For example, one of these 
GATA motif containing sites unique to t(3;21) as opposed to t(8;21) leukaemia 
lies at an intragenic location within MEIS1 (figure 3-1A) and is bound by both 
RUNX1 and RUNX1-EVI-1 (Figure 3-4 F), as well as GATA2 in the TF1 cell line 
(data not shown).   
One interpretation of this observation would be that the different DHS landscape 
in each leukaemia allows a permissive environment for the binding of the 
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different transcription factor complexes.  However, evidence is also present that 
supports the interpretation that these transcription factor complexes are 
important in the maintenance of this DHS landscape specific to each leukaemia.  
Following RUNX1-EVI-1 knockdown, the reduction in GATA2 expression levels 
are associated with decrease in accessibility of a subset of GATA motif 
containing DHSs.  This subset of DHSs is of significance because it is 
associated with decreased expression of neighbouring genes (figure3-14 A-B). . 
This interaction between each CBF fusion protein complex and the DHS 
landscape is reinforced by differential cis-regulation and expression of members 
of the complex, such as GATA2.  GATA2 is more highly expressed in t(3;21) 
cells as compared to t(8;21) cells.  This is driven by differences in accessibility 
of cis-regulatory elements in this gene.  A distal GATA2 enhancer, known to 
regulate GATA2 expression, is accessible in normal CD34+ cells and t(8;21) 
patient cells but not in t(3;21) cells (Groschel et al., 2014).  The GATA2 
promoter, is accessible and bound by RUNX1 in t(3;21) but not t(8;21) cells. 
Interestingly, in murine HSC Gata2 promoter is thought to be bound by EVI-1 
(Yuasa et al., 2005), however, in our human leukaemic cells, RUNX1-EVI-1 
does not appear to bind at the promoter, but in an intragenic site. Notably, 
GATA2 expression falls following knockdown of RUNX1-EVI-1.  ERG is a 
common member of both RUNX1-EVI-1 and RUNX1-ETO complexes and is 
directly regulated by both CBF fusion proteins, as demonstrated by ChIP-seq 
and that expression of ERG decrease following knockdown of either CBF fusion 
proteins.   
In summary, both RUNX1 and the CBF fusion protein complexes bind cis-
regulatory modules, unique to each leukaemia, that through auto-regulation of 
its members, allow a stable gene regulatory network to be formed, which 
ultimately defines the behaviour of each leukaemia (Pimanda and Gottgens, 
2010, Pimanda et al., 2007).   
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4.3  Differing roles of wild-type RUNX1 in t(3;21) and t(8;21) 
leukaemia 
The untranslocated RUNX1 plays a vital role in RUNX1-ETO driven AML and 
the biological implication and mechanism for this has been carefully elucidated.  
Knockdown of the untranslocated RUNX1 leads to apoptosis of t(8;21) cells 
(Ben-Ami et al., 2013).  The untranslocated RUNX1 competes with RUNX1-
ETO for transcription factors in order to form complexes for binding to 
overlapping genomic loci.  Knockdown of RUNX1-ETO leads to increased 
binding of RUNX1 at sites previously bound by RUNX1-ETO, replacing binding 
of repressive complexes with gene activating co-factors (Ptasinska et al., 2014). 
The role of RUNX1 in the context of RUNX1-EVI-1 has not been fully examined 
before, but there is some evidence that there is also a dominant negative effect 
of RUNX1-EVI-1 towards native RUNX1, both on a direct protein-protein 
interaction and DNA binding capacity (Introduction 1.7.3).  In our study we 
demonstrate there is a 74% overlap in RUNX1 and RUNX1-EVI-1 binding sites 
(figure 3-6A).  It appears that the ability to also target genes through the RUNX1 
part is crucial to the function of the RUNX1-EVI-1 fusion protein.  When EVI-1 
has been overexpressed in RUNX1 -/- murine bone marrow cells (Takeshita et 
al., 2008) transforming properties were not detectable by colony replating 
assays.  The experiment where the full length RUNX1-EVI-1 molecule was 
transfected into RUNX1-/- cells was not performed to confirm if wild type 
RUNX1 was required for leukemogenecity of RUNX1-EVI-1.  However, we do 
not necessarily demonstrate an active competition between RUNX1-EVI-1 and 
native RUNX1 for DNA binding sites as following RUNX1-EVI-1 knockdown we 
do not observe an upregulation of RUNX1 binding at sites previously bound by 
RUNX1-EVI-1 (figure 3-17B).  The reason for this could be that at RUNX1-EVI-1 
bound sites, RUNX binding motifs are not necessarily occupied, and that 
binding at these sites by RUNX1-EVI-1 is predominantly facilitated through the 
binding of other transcription factor partners.  In keeping with this the RUNX 
footprinted motif is conspicuously absent in the core-complex at RUNX1EVI-1 
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bound sites (figure 3-7C) but is present in the complex at sites bound by 
RUNX1 (figure 3-7A). 
4.4 RUNX1-EVI-1 knockdown and overexpression provides 
functional and mechanistic insight into the t(3;21) 
leukaemia 
4.4.1 Maintenance of RUNX1-ETO, but not RUNX1-EVI-1 
expressing CD34+ PBSCs 
Although we were able to sustain RUNX1-ETO transduced CD34+ PBSCs, we 
were not able to do this for CD34+ PBSCs transduced with RUNX1-EVI-1 
(figure3-8C).  Although this could have been in part due to the poorer MOI 
achieved with this virus due to the size of the transgene, this was unlikely to be 
the sole cause, as even with equivalent MOI of virus, we obtained lower levels 
of infected CD34+ cells and cells which were transduced died early.  RUNX1-
EVI-1 is often seen as a secondary mutation, in contrast to RUNX1-ETO, either 
in CML, MDS which progresses to AML or in secondary AML following previous 
chemotherapy (Rubin et al., 1990, Rubin et al., 1987) (section 1.7.3).  
Therefore, RUNX1-EVI-1 may require co-operation with other mutations in order 
for the transformed cells to survive.  Indeed, surprisingly, knockdown of 
RUNX1-EVI-1 leads to an early upregulation of BCL2, which is a direct target of 
RUNX1-EVI-1  (figure 3-12) and this is associated with an increase, although 
not statistically significant, in growth at the day 2 post RUNX1-EVI-1 knockdown 
(figure 3-10 C). 
Although RUNX1-EVI-1 may cooperate with other mutations, it should still be 
possible to over-express RUNX1-EVI-1. This is because RUNX1-EVI-1 can be 
sustainably expressed independently in other transgenic animal models where 
either all cells express RUNX1-EVI-1 in an inducible manner (zebrafish) (Shen 
et al., 2015) or is expressed under the RUNX1 promoter (mouse) (Maki et al., 
2005) or through retroviral overexpression in murine bone marrow cells 
(Cuenco et al., PNAS, 2000).  It may be that RUNX1-EVI-1 transformation is 
dependent on the phenotype of the target cell.  For example, RUNX1-EVI-1 
transformation may require a more immature, less differentiated cell type.  
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Although we purified our apheresis material to select CD34+ PBSCs, this is 
likely to contain a heterogeneous population of LT-HSCs, ST-HSCs, MPPs, 
GMP etc.  There are indeed many examples in the literature that suggests 
transforming cells at different stages of differentiation with oncogenes lead to 
different outcomes; these include the MLL fusion proteins (Krivtsov et al., 2013, 
Stavropoulou et al., 2016) and mutant members of the cohesin complex 
(Mazumdar et al., 2015).  
Similarly, our results of transducing RUNX1-ETO into CD34+ PBSCs fail to 
maintain their CD34+ surface expression (figure 3-8G) and this is in keeping 
with another group’s attempt to transduce CD34+ PBSCs with RUNX1-ETO 
(Wichmann et al., 2015).  However, when others have transduced CD34+ cord 
blood cells with RUNX1-ETO, these cells maintain the expression of the 
immature surface marker CD34 (Mulloy et al., 2002), suggesting that the 
differences in cell population between even CD34+ PBSCs and cord blood is 
sufficient to produce a difference in phenotype following retroviral transduction 
of oncogenes.  
4.4.2 RUNX1-EVI-1 maintains an aggressive leukaemic 
phenotype in t(3;21) cells 
Our data showing that RUNX1 EVI-1 knockdown results in changes in 
differentiation of the t(3;21) cells is supported by the dysplastic phenotype of 
mice with RUNX1-EVI-1 knocked-in to the RUNX1 locus (Maki et al., 2005). In 
RUNX1-EVI-1 transgenic mice, definitive haematopoiesis fails to develop, and 
primitive haematopoietic cells in the fetal liver fail to differentiate into erythroid 
cells.  In zebrafish, the expression of RUNX1-EVI-1 under a inducible heat 
shock promoter led to an accumulation of early myeloid progenitors and blast 
like cells (Shen et al., 2015).  Similar to our results, RUNX1-EVI-1 expressing 
cells also showed increase proliferation and resistance to apoptosis.   
We have already discussed a number of mechanisms by which this stem cell 
phenotype may be maintained.  Other important RUNX1-EVI- target genes that 
are downregulated in SKH-1 following RUNX1-EVI-1 knockdown are MSI2 and 
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ZEB1.  MSI2 (also known as Musashi) is a RNA binding protein and is a direct 
target of RUNX1-EVI-1 in our cells.  MSI2 expression is high in cells with CML 
in blast crisis and associated with a poor prognosis in these patients.  MSI2 
have been shown to inhibit Numb signalling pathway by binding to the 3’UTR of 
the transcript.  Loss of Msi2 expression or overexpression of Numb abrogates 
the development of blasts crisis in a murine model of CML (Ito et al., 2010). 
ZEB1 is another gene that is directly targeted by RUNX1-EVI-1 and is 
downregulated following RUNX1-EVI-1 knockdown. The epithelial 
mesenchymal transition is the process during oncogenic transformation by 
which normal tissues lose their polarity and adhesion to neighbouring cells, 
thereby allowing metastasis to occur (Tam and Weinberg, 2013).  ZEB1 is a 
transcription factor shown to play a critical role in the epithelial-mesenchymal 
transition of solid tumours (Chaffer et al., 2013).  The role of ZEB1 has been 
recently shown in a MLL-AF9 model of leukaemia (Stavropoulou et al., 2016).  
Zeb1 expression was critical for newly transformed leukaemic cells to depart 
from its bone marrow niche and infiltrate other organs.  RUNX1-EVI-1 therefore 
targets and maintains a gene program that maintains the aggressive phenotype 
of this leukaemia.  
4.5 The down regulation of C/EBPα by both CBF fusion proteins 
is critically required to maintain their leukaemic phenotype  
Despite the differences between t(3;21) and t(8;21) leukaemia, C/EBPα is 
downregulated in both types of leukaemia (figure 3-16) suggesting that it is a 
critical node by which leukaemia is maintained.  We show that C/EBPα may be 
directly repressed by both RUNX1-EVI-1 and RUNX1-ETO through binding of a 
recently characterised upstream enhancer (figure 3-16 D) (Avellino et al., 2016).  
Given the importance of inhibiting C/EBPα, there may be multiple means by 
which this is achieved (Pabst et al., 2001, Helbling et al., 2004).  Others have 
suggested that RUNX1-EVI-1 may inhibit C/EBPα (introduction section 1.7.3) 
both through physical interaction as well as inhibition of a chaperone required to 
maintain correct mRNA levels of C/EBPα. 
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In our SKH-1 cell line, knockdown of RUNX1-EVI-1 leads to upregulation of 
C/EBPα and C/EBPδ (figure 3-15 C).  However, C/EBPα is likely to be the more 
important factor for a number of reasons.  Our RNA-seq data suggests that 
although C/EBPδ levels also increase, they are far lower than those of C/EBPα 
(figure 3-15 C).  Our experiments involving the inhibition of CEPB transcription 
factors by a dominant negative binding partner are capable of inhibiting both 
C/EBPα and C/EBPδ.  However, our ChIP-qPCR data directly show the binding 
of C/EBPα is affected by this DNCEPB peptide at key genes required for 
myeloid function (figure 3-21).  Our C/EBPα overexpression data (figure 3-22 
and 3-23) specifically show that C/EBPα overexpression phenocopies RUNX1-
EVI-1 knockdown both at a gene expression level, as well as in phenotypic 
changes.  C/EBPα but not C/EBPδ is consistently downregulated in primary 
AML patients with CBF translocations as compared to normal karyotype AML 
(figure 3-16).   Finally, C/EBPδ knockout mice have little overt phenotype 
(Tanaka et al., 1997, Sterneck et al., 1998), in contrast C/EBPα knockout mice 
fail to develop mature neutrophils and eosinophils (Zhang et al., 1997a) with a 
block at the development of GMP from CMP (Zhang et al., 2004b). 
4.5.1 C/EBPα binding leads to increase accessibility at large 
numbers of DHSs at genes required for myeloid 
differentiation 
Given the inability of C/EBPα knockout mice to develop neutrophils it is perhaps 
not surprising that in our system blocking C/EBPα DNA binding by DNCEBP, 
following RUNX1-EVI-1 knockdown, entirely abolishes the upregulation of 
genes required for terminal myeloid function  (MPO, CSF1R and CTSG)  (figure 
3-20).  These genes are also upregulated when we overexpress C/EBPα in 
these cells (figure 3-23).  We show that following knockdown of RUNX1-EVI-1, 
2510 DHS increase in accessibility, and these are sites where the CEBP motif 
is frequently found. This result is associated with the increased binding of 
C/EBPα and RUNX1 at these sites (figure 3-18) following RUNX1-EVI-
1knockdown.  We show that at a number of these genes (MPO, CTSG, TREM1 
and SIGLEC1), many of which are required for neutrophils and monocytes, the 
blocking of C/EBPα binding prevents the recruitment of RUNX1 and prevents 
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changes in the chromatin accessibility at sites which are likely to be cis-
regulatory regions for these genes.      
The ability of C/EBPα to alter chromatin accessibility is consistent with other 
studies that show that C/EBPα can interact with SWI/SNF nucleosome 
remodelling complexes (introduction 1.1.3) and that this interaction is important 
for the development of adipocytes (Pedersen et al., 2001). This ability to initiate 
the re-programming of chromatin structures may be the reason why C/EBPα is 
able to trans-differentiate cells committed to other lineages to myeloid cells 
(introduction section 1.1.3) and C/EBPα has also been shown to be important in 
the initiation of MLL-ENL leukaemia, likely to be through increasing accessibility 
of chromatin for the fusion protein to bind to target genes (Ohlsson et al., 2014).   
4.5.2 C/EBPα binding is associated with the inhibition of stem 
cell gene expression program 
We also observe that blocking C/EBPα binding prevents downregulation of 
CD34 following RUNX1-EVI-1 knockdown (figure 3-20 B) and in turn, 
overexpression of C/EBPα is sufficient to down-regulate CD34 despite the 
continued presence of RUNX1-EVI-1 (figure 3-22). 
Overexpression of C/EBPα is also sufficient to downregulate stem cell 
associated genes such as HOXA9, GATA2 and MEIS1 (figure 3-23).  The 
effects of DNCEBP on changes in stem cell associated gene expression in 
SKH-1 cells following RUNX1-EVI-1 knockdown appears to be more selective: 
although HOXA9 downregulation is completely abolished, the effects on MEIS1 
and GATA2 are relatively mild (figure 3-20D).  The difference between the 
C/EBPα overexpression and DNCEBP experiments maybe that the level of 
C/EBPα overexpression may displace other transcription factor binding in the 
cells.  For example, following RUNX1-EVI-1 knockdown we observe an 
increase in C/EBPα binding at sites previously bound by RUNX1-EVI-1 (figure 
3-17B), therefore, it maybe that with sufficient levels of C/EBPα, this may be 
able to displace other transcription factors at other sites.  In the DNCEBP 
system, the downregulation of RUNX1-EVI-1 may be sufficient to cause the 
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downregulation of some key stem cell specific genes, independently of the 
effects of C/EBPα.  In keeping with this, MEIS1 and GATA2 (figure3-4F) but not 
HOXA9 (data not shown) appears to be direct targets of RUNX1-EVI-1. 
Consistent with this idea HSCs deficient in C/EBPα have increased competitive 
repopulating capacity and self-renewal (Zhang et al., 2004b).  Although our 
demonstration that C/EBPα binding is required to “switch off” HOXA9 appears 
to be novel, this is similar to the requirement for C/EBPα to switch off mycn in 
murine HSC development (Ye et al., 2013).  In absence of C/EBPα, murine 
adult HSCs resemble fetal HSCs, in terms of a high proliferative capacity. 
C/EBPα binds mycn and represses this gene in adult HSCs which leads to 
quiescence.  In our system, MYCN is also downregulated following RUNX1-
EVI-1 knockdown, and is bound by C/EBPα (figure 3-17D).  Other examples of 
genes associated with self-renewal capacity that are directly targeted by 
C/EBPα and repressed following RUNX1-EVI-1 knockdown include SOX4 and 
BMI-1 (Zhang et al., 2004b, Zhang et al., 2013). 
4.6 Summary 
In this work, we have demonstrated that RUNX1-EVI-1 and RUNX1-ETO 
interact with a different epigenetic landscape in each type of AML through 
different transcription factor partners.  However, through knockdown of both 
RUNX1-EVI-1, and RUNX1-ETO (based on data previously published by our 
lab) we identify a core set of genes maintained by both fusion proteins.  This 
core set of genes are likely to represent genes which are commonly 
deregulated amongst many leukaemia types.  One of these genes is CEBPA 
which we demonstrate is commonly downregulated amongst all CBF 
leukaemias and is a critical node by which the transcription factor network is 
deregulated. 
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Figure 4-1 Graphical summary  
RUNX1-EVI-1 and RUNX1-ETO differentially program the epigenetic landscape 
through different DNA binding partners.  However, depletion of either CBF 
fusion proteins reliefs the inhibition of C/EBPα expression, resulting in direct 
inhibition of stem cell required genes and upregulation of genes required for 
myelopoiesis. 
4.7 Future work 
4.7.1 Ectopic expression of RUNX1-EVI-1 at varying stages of 
haematopoiesis 
We have shown that RUNX1-EVI-1 leukaemia appear to be associated with the 
expression of many genes which are characteristic of both HSCs and LSCs.  It 
is unclear to what extent this is enforced or simply maintained by RUNX1-EVI-1.  
Ectopic expression of this fusion gene in either an inducible transgenic model 
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(Stavropoulou et al., 2016) at different stages of haematopoietic development or 
through retroviral induction of different populations isolated from the 
haematopoietic hierarchy (Mazumdar et al., 2015), would decisively address 
this question. 
4.7.2 What are the shared epigenetic mechanisms between the 
two CBF fusion proteins? 
Both C-terminal fusion partners can recruit repressive complexes, albeit 
differing in identity.  Both CBF fusion proteins can recruit histone deacetylases: 
RUNX1-ETO through NCoR/Sin3A and RUNX1-EVI-1 through CtBP.  However, 
a distinguishing property of RUNX1-EVI-1 may be the formation of H3K9me3: it 
appears that CtBP and EVI-1 in its native form can recruit H3K9 
methyltransferases such as G9a (Chinnadurai, 2007, Goyama et al., 2010), and 
EVI-1 itself can methylate H3K9 to form heterochromatin (Pinheiro et al., 2012).  
This in turn can recruit DNA methyl transferases such as DNMT1 (Esteve et al., 
2006): DNA methylation is known to interact with H3K9 methyltransferases to 
re-inforce a silenced chromatin structure.  Future work could involve 
identification of these partner proteins that may explain how certain RUNX1-
EVI-1 target genes increase in expression, whilst others decrease in 
expression, following RUNX1-EVI-1 knockdown (figure3-12 A). 
4.7.3 Role of differing CEBP transcription factors following 
RUNX1-EVI-1 knockdown 
Despite the evidence that C/EBPα is the key CEBP transcription factor that is 
repressed by RUNX1-EVI-1, C/EBPδ levels also increase following RUNX1-
EVI-1 knockdown, and our DNCEBP peptide is capable of inhibiting the DNA 
binding potential of both transcription factors.  At present it is unclear as to the 
extent of the role of C/EBPδ following RUNX1-EVI-1 knockdown, begging the 
question of what would be the consequences of overexpressing this 
transcription factor.  Furthermore, it is unclear to what extent would C/EBPδ 
compensate in our system if C/EBPα was knocked down in combination with 
RUNX1-EVI-1 knockdown.  
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4.7.4 Therapeutic targeting of C/EBPα expression in CBF 
patients 
Previous groups have shown that C/EBPα trans-differentiation of lymphocytes 
lead to an irreversible switch to the myeloid lineage, even when the inducible 
C/EBPα is subsequently withdrawn (Bussmann et al., 2009).  This is in keeping 
with evidence that demonstrates that once C/EBPα mediates the transition from 
CMP to GMP it is not required thereafter (Zhang et al., 2004b).  It would be 
interesting to note how far this parallels the expression of C/EBPα in SKH-1 
cells.  In our system, although these CEBPA-ER SKH-1 cells upregulate surface 
expression of CD11b (figure 3-23D-E), they rapidly undergo apoptosis.  It is 
unclear whether these cells would otherwise be sustainable if cultured with 
cytokines, such as G-CSF.  Indeed given the vulnerability of both t(3;21) cells 
and t(8;21) cells (Pabst et al., 2001) to C/EBPα overexpression, this may 
provide an unifying therapeutic strategy for both forms of leukaemia.  
Overexpression of C/EBPα may be delivered therapeutically through a short-
activating RNA sequence that act on the promoter of C/EBPα, and this has 
shown promise in the treatment of hepatocellular carcinoma (Reebye et al., 
2014). 
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